

GenCore version 5.1.9  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: September 7, 2006, 11:54:20 ; Search time 40 Seconds  
(without alignments)  
536.408 Million cell updates/sec

Title: US-10-665-602-2

Perfect score: 1249

Sequence: 1 MTWRHHVRLFTVSLAQII.....PSVLQRRRPPCGRPLGHRL 223

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR\_80.\*

1: Pirl.\*

2: Pirl.\*

3: Pirl.\*

4: Pirl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	267	21.4	171	2	I49612
2	233	18.7	188	2	A30362
3	225	18.0	188	2	A39787
4	123	9.8	4391	2	A38096
5	121.5	9.7	1620	2	T37283
6	120.5	9.6	722	2	I48324
7	120.5	9.6	1372	2	T25933
8	119	9.5	810	2	T10756
9	118	9.4	2703	1	A24420
10	116.5	9.3	2321	2	S78549
11	115.5	9.2	2555	2	A40043
12	114.5	9.2	1574	2	T13954
13	114	9.1	1687	2	T30176
14	113.5	9.1	1964	2	T09059
15	113.5	9.1	2437	2	S42612
16	112.5	9.0	1251	2	A57293
17	112.5	9.0	2524	2	A35844
18	111	8.9	728	2	I50719
19	111	8.9	833	2	S19087
20	111	8.9	861	2	A48825
21	111	8.9	1722	2	E89753
22	111	8.9	2531	2	S18188
23	111	8.9	2531	2	A46019
24	111	8.9	3707	2	S18232
25	110	8.8	2318	2	S45306
26	109	8.7	2471	2	A49128
27	108	8.6	832	2	A31246
28	108	8.6	880	2	S00670
29	106	8.5	1810	1	A32230

30 105 8.4 615 1 KF0112  
31 104.5 8.4 387 2 B49175  
32 104 8.3 513 2 D88991  
33 103.5 8.3 835 2 JP0076  
34 103 8.2 379 2 A59180  
35 102.5 8.2 1064 2 A40136  
36 102.5 8.2 3002 2 A47221  
37 102.5 8.2 3871 2 T22812  
38 102 8.2 907 2 T15792  
39 102 8.2 1295 2 A32901  
40 101.5 8.1 477 2 JS0597  
41 101.5 8.1 1203 2 A49175  
42 101.5 8.1 2871 2 A55567  
43 101.5 8.1 2871 2 A55624  
44 101.5 8.1 5376 2 T42215  
45 101 8.1 401 2 S65138

coagulation factor  
Motch A protein -  
protein apx-1 (imp  
nel protein - chic  
Wnt inhibitory fac  
fibropellin Ia - s  
fibropellin Ia - s  
hypothetical prote  
hypothetical prote  
gip1 protein presu  
c-plasminogen acti  
Motch B protein -  
fibrillin I - bovi  
fibrillin-1 precu  
zonadhesin - mouse  
glycoprotein anti

#### ALIGNMENTS

##### RESULT 1

I49612

teratocarcinoma-derived growth factor - mouse

C/Species: Mus musculus (house mouse)

C/Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 09-Jul-2004

C/Accession: I49612

R/Donor, R.; Scalera, L.; Pacifico, F.; Simeone, A.; Persico, M.G.; Acampora, D.

Development 118, 1157-1168, 1993

A/Title: The murine cripto gene: expression during mesoderm induction and early heart m

A/Reference number: I49612; MUID:94094736; PMID:7916676

A/Accession: I49612

A/Status: preliminary; translated from GB/EMBL/DBJ

A/Molecule type: mRNA

A/Residues: 1-171 <RES>

A/Cross-references: UNIPROT:PS1865; UNIPARC:UPI00000029326; GB:M87321; NID:9402714; PIDN:

C/Genetics:

A/Gene: cripto

C/Superfamily: teratocarcinoma-derived growth factor 1; EGF homology

Query Match 21.4%; Score 267; DB 2; Length 171;  
Best Local Similarity 37.8%; Pred. No. 9.7e-16;  
Matches 56; Conservative 11; Mismatches 63; Indels 18; Gaps 3;

Qy 58 FGEVTG-----SAEGWGPEEPYPYSAF-----GEGASARPPRCRNGGTCVLGSFC 103

Db 20 FGPVAGRDLAIRDNSIWDQEPVDRSFQVPSVQNSKSLNKTCLNGGTCLIGSFC 79

Qy 104 VCPAHFTGRYCEHDORSECGALEHGAWTURACHLCRCIFGALHCLPLQTPDRCD---P 159

Db 80 ACPSPFYGRNCEHDVRKEHCGSLHGTWLPKKSCLRCWGHQQLACLQTFPLPGCDGHVMD 139

Qy 160 KDFLASHAHGFSAGGAPSLLLLPALL 187

Db 140 QDLKASRTPCQTPSVTTTTPMLAGACLF 167

##### RESULT 2

A30362

teratocarcinoma-derived growth factor 1 - human

N/Alternate names: CRIPTO protein

C/Species: Homo sapiens (man)

C/Date: 18-Oct-1989 #sequence\_revision 18-Oct-1989 #text\_change 09-Jul-2004

C/Accession: B39787; A30362

R/Donor, R.; Montuori, N.; Rocchi, M.; De Ponti-Zilli, L.; Ciccodicola, A.; Persico, M.G.

Am. J. Hum. Genet. 49, 555-565, 1991

A/Title: Isolation and characterization of the CRIPTO autosomal gene and its X-linked re

A/Reference number: A39787; MUID:91353571; PMID:1882841

A/Accession: B39787

A/Status: preliminary

A/Molecule type: DNA

A/Residues: 1-188 <DON>

A/Cross-references: UNIPROT:P13385; UNIPARC:UPI000004966D; GB:M96955; GB:M37099; NID:933



F;65,71,76/Binding site: heparan sulfate (Ser) (covalent) #status predicted  
F;89,554,1755,2121,3072,3105,3279,3780,3836,4068/Binding site: carboxylate (Asn) (coval)  
F;2995,3933,4179/Binding site: chondroitin sulfate (Ser) (covalent) #status predicted

Query Match 9.8%; Score 123; DB 2; Length 4391;  
Best Local Similarity 27.3%; Pred. No. 0.037;  
Matches 39; Conservative 4; Mismatches 42; Indels 58; Gaps 4;

QY 85 SARPCRCRNGGTC---VLGSFVCVCPAHFTGRYCEHDDRRSECCGALEHGAWTLRACHLCR 140  
DB 3847 TCDRPFQNGQCHDSESSYVVCVCPAGFTGSRCEHSQ-----3884

QY 141 CIFGALHCLPLQTPDRCDPKDFLASHAHG-----PSAGGAP 176  
DB 3885 ----ALHC-----HPEACGPDATCVNRPDGRGYTCRCHLGRSLRCBEGVTVTTPSLSGAG 3936

QY 177 SLILLPCALLHLLRLRPDAPHP 199  
DB 3937 SYLALPALTNTHRLDLDFEKP 3959

RESULT 5  
T27283  
hypothetical protein Y64G10A.f - Caenorhabditis elegans  
C;Species: Caenorhabditis elegans  
C;Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 15-Oct-1999  
C;Accession: T27283  
R;Ainscough, R.  
submitted to the EMBL Data Library, September 1999  
A;Reference number: Z20336  
A;Accession: T27283  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-1620 <NIL>  
A;Cross-references: UNIPROT:UPI000017BCB4; EMBL:AL110498; NID:e1542303; PIDN:CAB54471.1;  
A;Experimental source: clone Y64G10A  
C;Genetics:  
A;Gene: CESP:Y64G10A.f  
A;Introns: 77/1; 116/1; 198/1; 282/1; 365/1; 425/1; 466/1; 548/1; 559/1; 601/1; 625/1; 7

Query Match 9.7%; Score 121.5; DB 2; Length 1620;  
Best Local Similarity 26.6%; Pred. No. 0.02;  
Matches 47; Conservative 14; Mismatches 63; Indels 53; Gaps 8;

QY 51 LNMSTSHFGEVTSAAE-----GWGPEEPLPYSRAFEGAS-----ARPCRCRN 93  
DB 28 LNFTSIFREL-GEIEKLDLFPNFHARKYLRFARFSRRGCKCCLLRVQANCSADLCHN 86

QY 94 GGTCVLG-----SFCVCPAHFTGRYCEHDDRRSECCGALEHGAWTLRACHLCRCIF 143  
DB 87 GGTCTPSEHNDNEQVCECPVGTGAKCYD--ANECHANNNGGCEHCWNTIGTYTCRWP 144

QY 144 G-----ALHCLPLQTPDRCDPKDFLASHAHGSPAGGAPS 177  
DB 145 GFELSGDNGTCSDDIECAVNSGGSCDRVNSPGFCRDCPSDLVHLADGRTGKQVTS 201

RESULT 6  
I48324  
DELTA-like 1 - mouse  
C;Species: Mus musculus (house mouse)  
C;Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 09-Jul-2004  
C;Accession: I48324  
R;Bettenhausen, B.; de Angelis, M.H.; Simon, D.; Guenet, J.L.; Gossler, A.  
Development 121, 2407-2418, 1995  
A;Title: Transient and restricted expression during mouse embryogenesis of Dll1, a murin  
A;Reference number: I48324; MUID:95401850; PMID:7671806  
A;Accession: I48324  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: mRNA  
A;Residues: 1-722 <RES>  
A;Cross-references: UNIPROT:Q61483; UNIPARC:UPI0000028700; EMBL:X80903; NID:G806569; PID

A;Gene: Dll1  
C;Superfamily: delta-4 protein; EGF homology  
F;331-362/Domain: EGF homology <EGF2>  
F;446-477/Domain: EGF homology <EGF>  
F;484-515/Domain: EGF homology <EGF1>

Query Match 9.6%; Score 120.5; DB 2; Length 722;  
Best Local Similarity 30.0%; Pred. No. 0.012;  
Matches 45; Conservative 8; Mismatches 56; Indels 41; Gaps 8;

QY 91 CRNGGTC---VLGSFVCVCPAHFTGRYCEHDDRRSECCGALEHGAWTLRACH----LCRC 141  
DB 451 CANGGTCRDSVNDFTCTPPGYTKNCAPSVSRCEHAPCHNGA-----TCHQQRQYMCBC 506

QY 142 I--FGALHC---LPLQTPDRCDPKDFLASHAHGSPAGG-----APSLLLLLPCA 185  
DB 507 AQYGGPNCOFLPEPPP---GMVVDLSERHNSQGGPPVAVCGVVLVLLLLGCA 563

QY 186 LLHRLRLPDAPAHPRSLVPSVLRERRPCG 215  
DB 564 AVVVCVRLKLOKH-----QPPPEPCG 584

RESULT 7  
T25933  
hypothetical protein W02C12.1 - Caenorhabditis elegans  
C;Species: Caenorhabditis elegans  
C;Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004  
C;Accession: T25933  
R;Murray, J.; Wohldmann, P.  
submitted to the EMBL Data Library, December 1996  
A;Description: The sequence of C. elegans cosmid W02C12.  
A;Reference number: Z20112  
A;Accession: T25933  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-1372 <MUR>  
A;Cross-references: UNIPROT:P91536; UNIPARC:UPI0000075513; EMBL:U80815; PIDN:AAB37995.1;  
A;Experimental source: strain Bristol N2; clone W02C12  
C;Genetics:  
A;Gene: CESP:W02C12.1  
A;Map position: 4  
A;Introns: 29/1; 66/1; 774/2; 823/2; 1046/1; 1108/2; 1298/1

Query Match 9.6%; Score 120.5; DB 2; Length 1372;  
Best Local Similarity 37.1%; Pred. No. 0.021;  
Matches 36; Conservative 7; Mismatches 35; Indels 19; Gaps 6;

QY 85 SARPCRC---CRNGGTCVLGSF-----CVCVPAHFTGRYCEHDDRRSECCGALEHGAWTLRA 135  
DB 293 SAPNRICIGQPCHNGGEC--GDFGSHLECACPASFTGKGEF--KNTGCKTCENGKCAEA 348

QY 136 C-HLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPS 171  
DB 349 AGGLQKC-----ECSPGFTGCERTNIDECSTAHCPSS 380

RESULT 8  
T10756  
Nel-homolog protein - rat  
C;Species: Rattus norvegicus (Norway rat)  
C;Date: 16-Jul-1999 #sequence\_revision 16-Jul-1999 #text\_change 09-Jul-2004  
C;Accession: T10756  
R;Kuroda, S.; Tokunaga, C.; Kiyohara, Y.; Konishi, H.; Matsuhashi, S.; Kikkawa, U.  
submitted to the EMBL Data Library, November 1998  
A;Description: Protein kinase C-binding protein.  
A;Reference number: Z17122  
A;Accession: T10756  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: mRNA  
A;Residues: 1-810 <KUR>  
A;Cross-references: UNIPROT:Q62919; UNIPARC:UPI000012FF2B; EMBL:U48246; NID:g3851179; PID

Query Match 9.5%; Score 119; DB 2; Length 810;  
Best Local Similarity 39.2%; Pred. No. 0.018;  
Matches 29; Conservative 6; Mismatches 25; Indels 14; Gaps 4;  
QY 81 GEGASARPRC---CRNGGTCVLGSCFVCPAHTGTCYCEHQRSECCGALHGHAWTLRACH 137  
DB 510 GNGTICKAFCEGCRYGTCVAPNKCVCPSGFTGSHCEKIDIDCAEGFVE-----CH 561  
QY 138 -LCRCIF--GALHC 148  
DB 562 NYSRCVNLPGWYHC 575  
RESULT 9  
A24420  
notch protein - fruit fly (Drosophila melanogaster)  
N/Alternate names: neurogenic repetitive locus protein  
C/Species: Drosophila melanogaster  
C/Date: 10-Sep-1999 #sequence\_revision 10-Sep-1999 #text\_change 05-Oct-2004  
C/Accession: A24420; A24768; S093358; A05267  
R/Kidd, S.; Kelley, M.R.; Young, M.W.  
Mol. Cell. Biol. 6, 3094-3108, 1986  
A/Reference number: A24420; MUID:87064624; PMID:3097517  
A/Accession: A24420  
A/Molecule type: DNA  
A/Residues: 1-2703 <KID>  
A/Cross-references: UNIPROT:P07207; UNIPARC:UPI000016BCC6; GB:K03508; NID:gi157991; PIDN:  
R/Wharton, K.A.; Johansen, K.M.; Xu, T.; Artavanis-Tsakonas, S.  
Cell 43, 567-581, 1985  
A/Reference number: A24768; MUID:86079539; PMID:3935325  
A/Accession: A24768  
A/Molecule type: mRNA  
A/Residues: 1-48, 'I', '50-118', 'R', '120-230', 'I', '232-256', 'N', '258-266', 'A', '268-872', 'R', '874-958',  
A/Cross-references: UNIPARC:UPI0000173D1F  
A/Note: the authors translated the codon ATC for residue 49 as Thr, ATT for residue 2044  
R/Tautz, D.  
Nucleic Acids Res. 17, 6463-6471, 1989  
A/Title: Hypervariability of simple sequences as a general source for polymorphic DNA ma  
A/Reference number: S09358; MUID:89385974; PMID:2780284  
A/Accession: S09358  
A/Molecule type: DNA  
A/Residues: 2505-2551, 'QQQQ', '2552-2576', 'E', '2578-2604 <TAU>  
A/Cross-references: UNIPARC:UPI0000173D20  
R/Wharton, K.A.; Yedvobnick, B.; Finnerty, V.G.; Artavanis-Tsakonas, S.  
Cell 40, 55-62, 1985  
A/Title: opa: a novel family of transcribed repeats shared by the Notch locus and other  
A/Reference number: A05267; MUID:85099329; PMID:2981631  
A/Accession: A05267  
A/Molecule type: DNA  
A/Residues: 2504-2576, 'E', '2578-2611 <WHA2>  
A/Cross-references: UNIPARC:UPI0000173D21  
C/Genetics:  
A/Gene: notch; opa  
A/Cross-references: FlyBase:FBgn0004647  
A/Map position: 8.96-9.36  
A/Introns: 53/3; 84/3; 171/3; 240/3; 283/3; 2333/3; 2436/3; 2588/3  
C/Superfamily: notch protein; ankyrin repeat homology; EGF homology  
C/Keywords: differentiation; tandem repeat; transmembrane protein  
F/27-43/Domain: transmembrane #status predicted <TM1>  
F/297-328/Domain: EGF homology <EGX1>  
F/530-561/Domain: EGF homology <EGF1>  
F/568-599/Domain: EGF homology <EGF>  
F/988-1019/Domain: EGF homology <EGX2>  
F/1064-1095/Domain: EGF homology <EGF3>  
F/1187-1218/Domain: EGF homology <EGX3>  
F/1746-1762/Domain: transmembrane #status predicted <TMW2>  
F/1950-1982/Domain: ankyrin repeat homology <AN1>  
F/1983-2015/Domain: ankyrin repeat homology <AN2>  
F/1988-2004/Domain: transmembrane #status predicted <TMW3>  
F/2017-2049/Domain: ankyrin repeat homology <AN3>  
F/2050-2082/Domain: ankyrin repeat homology <AN4>  
F/2083-2115/Domain: ankyrin repeat homology <AN5>

F/2538-2568/Region: glutamine-rich  
F/2538-2568/Domain: neurogenic repetitive element #status predicted <OPA>  
Query Match 9.4%; Score 118; DB 1; Length 2703;  
Best Local Similarity 34.6%; Pred. No. 0.064;  
Matches 28; Conservative 13; Mismatches 24; Indels 16; Gaps 6;  
QY 91 CRNGGTCVL---GSFCVCPAHTGTCYCEHQRSECCGAL--EHGAW---TLRACH---L 138  
DB 67 CQNGGTCVTLNGKTYCADCDSHYVDYCEH---RNPENMRCONGGTCQVTFRNGHPGIS 123  
QY 139 CRCIFGALHCL-PLQTPDRCD 158  
DB 124 CKCPLGFDSELCIEIAPNACD 144  
RESULT 10  
S78549  
notch3 protein - human  
C/Species: Homo sapiens (man)  
C/Date: 24-Jul-1998 #sequence\_revision 24-Jul-1998 #text\_change 09-Jul-2004  
C/Accession: S78549; S71825  
R/Joutel, A.; Tournier-Lasserre, E.  
Submitted to the EMBL Data Library, April 1997  
A/Reference number: S78549  
A/Accession: S78549  
A/Molecule type: mRNA  
A/Residues: 1-2321 <JOUI>  
A/Cross-references: UNIPROT:Q9UMA7; UNIPARC:UPI000011D827; EMBL:U97669; NID:g2668591; PFI  
R/Joutel, A.; Corpechot, C.; Ducros, A.; Vahedi, K.; Chabrier, H.; Mouton, P.; Alamowitc  
x, M.M.; Weissenbach, J.; Bach, J.F.; Bousser, M.G.; Tournier-Lasserre, E.  
Nature 383, 707-710, 1996  
A/Title: Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke  
A/Reference number: S71825; MUID:97032728; PMID:8878478  
A/Accession: S71825  
A/Molecule type: DNA  
A/Residues: 67-113, 138-194, 268-333, 'G', '335-346, 536-613, 716-765, 1240-1279, 1815-1888 <JOUI2>  
A/Cross-references: UNIPARC:UPI0000177457; UNIPARC:UPI0000177458; UNIPARC:UPI0000177459;  
C/Genetics:  
A/Gene: notch3  
A/Map position: 19p13.1  
C/Function:  
A/Description: may be involved in pathogenesis of CADASIL, causing a type of stroke and  
C/Superfamily: notch protein; ankyrin repeat homology; EGF homology  
C/Keywords: tandem repeat; transmembrane protein  
F/123-155/Domain: EGF homology <EGX1>  
F/162-194/Domain: EGF homology <EGF1>  
F/240-271/Domain: EGF homology <EGX2>  
F/318-349/Domain: EGF homology <EGF>  
F/473-504/Domain: EGF homology <EGX3>  
F/553-884/Domain: EGF homology <EGF3>  
F/928-959/Domain: EGF homology <EGX4>  
F/1838-1870/Domain: ankyrin repeat homology <AN1>  
F/1871-1903/Domain: ankyrin repeat homology <AN2>  
F/1908-1937/Domain: ankyrin repeat homology <AN3>  
F/1938-1970/Domain: ankyrin repeat homology <AN4>  
F/1971-2003/Domain: ankyrin repeat homology <AN5>  
Query Match 9.3%; Score 116.5; DB 2; Length 2321;  
Best Local Similarity 32.3%; Pred. No. 0.075;  
Matches 43; Conservative 5; Mismatches 50; Indels 35; Gaps 9;  
QY 69 GPEELPYSRAFEGASARPCRCRNGTCV--LGSF-CVCPAHTGTCYCEHQRSECCGA 125  
DB 1165 GFGPPL-----DSGPRCLHN-GTCVDLVGGPRCTCPGTYTLRCEADINECRSGA 1213  
QY 126 LSHGAWTLRAC-----HLRCIFGALHCLPLQTPDRCDPKDFLASHANG----PSA 172  
DB 1214 C-HAART-RDCLQDFGGFRCLCHAGFSGPRCQTVLSPCESQPCQ-----HGGQCRPSP 1265  
QY 173 GGAPSLLLLLLPCA 185

Db 1266 GPGGLTFTCHCA 1278

RESULT 11  
A40043  
notch protein homolog TAN-1 precursor - human  
C/Species: Homo sapiens (man)  
C/Date: 21-Apr-1992 #sequence\_revision 21-Apr-1992 #text\_change 05-Oct-2004  
C/Accession: A40043  
R/Ellisen, L.W.; Bird, J.; West, D.C.; Soreng, A.L.; Reynolds, T.C.; Smith, S.D.; Sklar, Cell 66, 649-661, 1991  
A/Title: TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal  
A/Reference number: A40043; MUID:91347367; PMID:1831692  
A/Accession: A40043  
A/Status: preliminary; nucleic acid sequence not shown; not compared with conceptual tra  
A/Molecule type: mRNA  
A/Residues: 1-2555 <ELL>  
A/Cross-references: UNIPARC:UPI0000177455; GB:M73980  
C/Superfamily: notch protein; ankyrin repeat homology; EGF homology  
F/261-292/Domain: EGF homology <EGX1>  
F/494-525/Domain: EGF homology <EGF1>  
F/987-1018/Domain: EGF homology <EGX2>  
F/1149-1180/Domain: EGF homology <EGF>  
F/1187-1218/Domain: EGF homology <EGF3>  
F/1233-1264/Domain: EGF homology <EGX3>  
F/1927-1959/Domain: ankyrin repeat homology <AN1>  
F/1960-1992/Domain: ankyrin repeat homology <AN2>  
F/1994-2026/Domain: ankyrin repeat homology <AN3>  
F/2027-2059/Domain: ankyrin repeat homology <AN4>  
F/2060-2092/Domain: ankyrin repeat homology <AN5>

Query Match 9.2%; Score 115.5; DB 2; Length 2555;  
Best Local Similarity 35.6%; Pred. No. 0.099;  
Matches 37; Conservative 6; Mismatches 34; Indels 27; Gaps 7;

Qy 83 GASARPCRCNGTGVL-----GSFCVCPAHTGTCYCEHQRSECGALEHGAWTURAC 136  
Db 1310 GCKGKP--CKNGGTCAVASNTARGFICKPAGFEGATCENDAR--TCG-----SLRCL 1358

Qy 137 HLCRCIFG----ALHCLPLQTPDRCDPKDFLASHAGPSAGGAP 176

Db 1359 NGGTGISGPRSPTCCLIGLPGFTGPEC---QPPAS---SPCLGGNP 1396

RESULT 12  
T13954  
MEGF6 protein - rat  
C/Species: Rattus norvegicus (Norway rat)  
C/Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004  
C/Accession: T13954  
R/Nakayama, M.; Nakajima, D.; Nagase, T.; Nomura, N.; Seki, N.; Ohara, O. Genomics 51, 27-34, 1998  
A/Title: Identification of high-molecular-weight proteins with multiple EGF-like motifs  
A/Reference number: Z14126; MUID:98360089; PMID:9693030  
A/Accession: T13954  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: mRNA  
A/Residues: 1-1574 <NAK>  
A/Cross-references: UNIPROT:O88281; UNIPARC:UPI0000043BEE; EMBL:AB011532; NID:g3449293;  
A/Experimental source: strain Sprague-Dawley; brain  
C/Genetics:  
A/Gene: MEGF6

Query Match 9.2%; Score 114.5; DB 2; Length 1574;  
Best Local Similarity 34.6%; Pred. No. 0.078;  
Matches 45; Conservative 10; Mismatches 36; Indels 39; Gaps 12;

Qy 66 EGNCP---EEPLYSRAFGASARPCRCNGTGC--VLGSFCVCPAHTGTCYCE----- 115

Db 548 EGWTGIICNETCP--PDTFGKNCSS--PCTCONGGTCDPLGA--CRCPGVSGAHCEDGCPK 604

Qy 116 -----HDORSECGALEHGAWTL-----RACHLCRC---IFG---ALHCLPLQ 152

Db 605 GFYGHCKRKKCHCANRGRCHRL-YGACLCDPLGYGRFCHLA-CPPWAFPGCSEDCLCEQ 662

Qy 153 TPDR-CDPKD 161  
: | : |||

Db 663 SHTRSCNPKD 672

RESULT 13  
T30176  
EGF repeat transmembrane protein - mouse  
C/Species: Mus musculus (house mouse)  
C/Date: 22-Oct-1999 #sequence\_revision 22-Oct-1999 #text\_change 09-Jul-2004  
C/Accession: T30176  
R/Sell, C.; Hoff III, H.B.  
A/Description: Cloning of a novel mRNA regulated by the insulin like growth factor type  
A/Reference number: Z20762  
A/Accession: T30176  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: mRNA  
A/Residues: 1-1687 <SEL>  
A/Cross-references: UNIPROT:Q61204; UNIPARC:UPI00000280BB; EMBL:U57368; NID:gl336627; P1  
A/Experimental source: strain C57BL/6J; clone DBI-1; whole embryo

Query Match 9.1%; Score 114; DB 2; Length 1687;  
Best Local Similarity 34.7%; Pred. No. 0.091;  
Matches 35; Conservative 4; Mismatches 32; Indels 30; Gaps 7;

Qy 91 CRNGGTC--VLGSF-CVCPAHTGTCYCEHQRSECGALEHGAWTLRACHLCRCIFG 144  
Db 382 CENGSTCTSVASQFSCKCPAGLTGQKCEAD--INCEIPRCQHG----- 425

Qy 145 ALHCLPLQTPDRCD-PKDFLASHAGPSAGGAPSLLLLLPC 184

Db 426 --TCLNLPGSYRCQCPGFTGQHCDSFYVPCAPS-----PC 459

RESULT 14  
T09059  
notch4 - mouse  
C/Species: Mus musculus (house mouse)  
C/Date: 11-Jun-1999 #sequence\_revision 11-Jun-1999 #text\_change 09-Jul-2004  
C/Accession: T09059  
R/Rowen, L.; Mahairas, G.; Qin, S.; Ahearn, M.E.; Dankers, C.; Lasky, S.; Loretz, C.; Sci  
submitted to the EMBL Data Library, October 1997  
A/Description: Sequence of the mouse major histocompatibility locus class III region.  
A/Reference number: Z16543  
A/Accession: T09059  
A/Status: preliminary; translated from GB/EMBL/DBJ  
A/Molecule type: DNA  
A/Residues: 1-1964 <ROW>  
A/Cross-references: UNIPROT:P31695; UNIPARC:UPI000016C7F1; EMBL:AF030001; NID:g2564945;  
C/Genetics:  
A/Gene: notch4  
A/Map position: 17  
A/Introns: 22/1; 49/2; 148/1; 264/1; 305/1; 384/1; 436/1; 501/1; 539/1; 577/1; 618/1; 67  
1679/3; 1729/1; 1761/3  
C/Superfamily: notch protein; ankyrin repeat homology; EGF homology  
C/Keywords: receptor; signal transduction  
F/514-545/Domain: EGF homology <EGF>

Query Match 9.1%; Score 113.5; DB 2; Length 1964;  
Best Local Similarity 24.1%; Pred. No. 0.12;  
Matches 67; Conservative 21; Mismatches 83; Indels 107; Gaps 16;

Qy 20 INLNGSYQREKNGRGEVTKVATQKHRQSLNWTSSHFGVETG-----SAEGWGPEE 72  
: | : |||

Db 904 IDTGSSYFCRCPPGFGKLCQDNVNPCEPNPCHHGSTCVQPQSGYVCCAPGVGQNCCK 963  
: | : |||

Qy 73 PLYSRAFGASARPCRCNGTGVL---GSFCVCPAHTGTCYCEHQRSECGALEHG 129  
: | : |||

Db 964 VL-----DACQSQP--CHNHGTCTSRPGFHCACPPGFVGLRCGDV--DEC--LD-- 1008  
: | : |||

QY 130 AWTLRACH-----LCRCIFGALH--CLPLOTDRCD----- 158  
Db 1009 -----RCHPSGTAACHSLANAFYQCCLPGHTGQRCVEWMDLCOQPCSNNGSCEITGPP 1064  
QY 159 -----PKDF-----LASHAGPSAGGAPSLLLLP-----CALLHRLLRP 193  
Db 1065 PGFTCHCPKGFEGPTCSHKALSCGIIHHCHNGG-----LCLPSPKPGSPPLCACLSGFGGP 1119  
QY 194 DA---PAHPSLSVPSVLQRERRPC-----GRPGLGH 221  
Db 1120 DCLTPPAPGCGPPS-----PCLHNGTCTETPGLGN 1150  
  
RESULT 15  
S42612  
transmembrane protein precursor - zebra fish  
C:Species: Brachydanio rerio (zebra fish)  
C>Date: 20-Feb-1995 #sequence\_revision 20-Feb-1995 #text\_change 09-Jul-2004  
C:Accession: S42612  
R:Bierkamp, C.; Campos-Ortega, J.A.  
Mech. Dev. 43, 87-100, 1993  
A:Title: A zebrafish homologue of the Drosophila neurogenic gene Notch and its pattern  
A:Reference number: S42612; MUID:94128602; PMID:8297791  
A:Accession: S42612  
A>Status: preliminary  
A:Molecule type: mRNA  
A:Residues: 1-2437 <BIE>  
A:Cross-references: UNIPROT:P46530; UNIPARC:UPI0000130565; EMBL:X69088; NID:g433866; PID  
C:Superfamily: notch protein; ankyrin repeat homology; EGF homology  
P:755-786/Domain: EGF homology <EGF1>  
F:1023-1054/Domain: EGF homology <EGF>  
F:1185-1216/Domain: EGF homology <EGF2>  
F:1915-1947/Domain: ankyrin repeat homology <AN1>  
F:1948-1980/Domain: ankyrin repeat homology <AN2>  
F:1982-2014/Domain: ankyrin repeat homology <AN3>  
F:2015-2047/Domain: ankyrin repeat homology <AN4>  
F:2048-2080/Domain: ankyrin repeat homology <AN5>  
  
Query Match 9.1%; Score 113.5; DB 2; Length 2437;  
Best Local Similarity 39.5%; Pred. No. 0.14;  
Matches 32; Conservative 7; Mismatches 19; Indels 23; Gaps 7;  
  
QY 88 PRC-----CRNGGTCV--LGSF-CVCPAHFTGRYCEHDQRSECC-----GALEHGAWT 132  
Db 983 PDCTESSCFNGTCVDGIGSFCVCLPFGFTGNYCQHDV--NECDSPRCNGSCQDGYGT 1040  
  
QY 133 LRACHLCRCIFG--ALHCLPL 151  
Db 1041 YK----CTCPHGYTGLNCQSL 1057

Search completed: September 7, 2006, 11:59:50  
Job time : 42 secs

GenCore version 5.1.9  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: September 7, 2006, 11:51:00 ; Search time 297 Seconds  
(without alignments)  
694,540 Million cell updates/sec

Title: US-10-665-602-2  
Perfect score: 1249  
Sequence: 1 MTRWHVRLFTVSLALQII.....PSVLQRRRPPCRPGIGLHRL 223

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2849598 seqs, 925015592 residues

Total number of hits satisfying chosen parameters: 2849598

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Uniprot 7.2.\*

1: uniprot\_sprot.\*

2: uniprot\_trembl.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1241	99.4	223	1 CFC1_HUMAN	Q92733 homo sapien
2	488	39.1	202	1 CFC1_MOUSE	P97766 mus musculus
3	322.5	25.8	193	1 CFC1_CHICK	Q91893 gallus gall
4	286	22.9	183	2 Q504T5_BRARE	Q50415 brachydanio
5	285	22.8	183	2 Q57517_BRARE	Q57517 brachydanio
6	275.5	22.1	190	2 Q57516_BRARE	Q57516 brachydanio
7	269	21.5	179	2 Q2VU94_XENLA	Q2VU94 xenopus lae
8	267	21.4	171	1 TDGFI_MOUSE	P51865 mus musculus
9	265	21.2	171	2 Q3UZF8_MOUSE	Q3UZF8 mus musculus
10	265	21.2	171	2 Q7TQ06_MOUSE	Q7TQ06 mus musculus
11	263	21.1	191	2 Q2UZ96_XENLA	Q2UZ96 xenopus lae
12	261.5	20.9	251	2 Q2UZ94_XENLA	Q2UZ94 xenopus lae
13	261.5	20.9	251	2 Q2VU93_XENLA	Q2VU93 xenopus lae
14	261	20.9	191	2 Q2VU96_XENLA	Q2VU96 xenopus lae
15	249.5	20.0	190	2 Q2UZ97_XENLA	Q2UZ97 xenopus lae
16	248.5	19.9	190	2 Q800J2_XENLA	Q800J2 xenopus lae
17	248.5	19.9	190	2 Q91649_XENLA	Q91649 xenopus lae
18	242	19.4	181	2 Q58D57_BOVIN	Q58D57 bos taurus
19	233	18.7	188	1 TDGFI_HUMAN	P13385 homo sapien
20	233	18.7	188	2 Q8TCC1_HUMAN	Q8TCC1 homo sapien
21	225	18.0	188	1 TDGFI_HUMAN	P51864 homo sapien
22	178	14.3	66	2 Q91AT2_BRARE	Q91AT2 brachydanio
23	135	10.8	763	2 Q4VB88_HUMAN	Q4VB88 homo sapien
24	135	10.8	763	2 Q4VB91_HUMAN	Q4VB91 homo sapien
25	134.5	10.8	2061	2 Q4SRM9_TETNG	Q4SRM9 tetraodon n
26	132	10.6	164	2 Q4RQ94_TETNG	Q4RQ94 tetraodon n
27	130.5	10.4	714	1 DLLL_RAT	P97677 rattus norv
28	130.5	10.4	772	1 DLLL_BRARE	Q6148 brachydanio
29	130	10.4	737	2 Q61R63_XENLA	Q61R63 xenopus lae
30	127.5	10.2	834	2 Q52KG8_MOUSE	Q52KG8 mus musculus
31	127	10.2	566	2 Q4SPK6_TETNG	Q4SPK6 tetraodon n

32	127	10.2	780	2	Q6DJD9_XENLA	Q6dj9 xenopus lae
33	125.5	10.0	512	2	Q95RQ1_DROME	Q95rq1 drosophila
34	125	10.0	238	2	Q8QGG9_CHICK	Q8qgg9 gallus gall
35	125	10.0	738	2	Q90Z45_CHICK	Q90z45 gallus gall
36	123	9.8	351	2	Q2VPA1_HUMAN	Q2vpa1 homo sapien
37	123	9.8	810	1	NELLI_HUMAN	Q2832 homo sapien
38	123	9.8	810	2	Q4VB90_HUMAN	Q4vb90 homo sapien
39	123	9.8	810	2	Q6NSY8_HUMAN	Q6nsy8 homo sapien
40	123	9.8	2331	2	Q59EG0_HUMAN	Q59eg0 homo sapien
41	123	9.8	4391	1	PGBM_HUMAN	P98160 homo sapien
42	123	9.8	4391	2	Q5VU27_HUMAN	Q5vu27 homo sapien
43	121.5	9.7	2067	2	Q59ED8_HUMAN	Q59ed8 homo sapien
44	121.5	9.7	2555	2	Q5SXM3_HUMAN	Q5sxm3 homo sapien
45	121	9.7	1651	2	Q9TVQ2_CABEL	Q9tvq2 caenorhabdi

ALIGNMENTS

RESULT 1  
ID\_CFC1\_HUMAN STANDARD; PRT; 223 AA.  
AC Q9GZK3; Q53T05;  
DT 20-DEC-2005, integrated into UniProtKB/Swiss-Prot.  
DT 01-MAR-2001, sequence version 1.  
DT 07-MAR-2006, entry version 32.  
DE Cryptic protein precursor.  
GN Name=CFC1;  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;  
OC Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, VARIANT HTX2  
RP CYS-112, CHARACTERIZATION OF VARIANT HTX2 CYS-112, AND VARIANTS TRP-78  
RP AND CYS-189.  
RX MEDLINE=20517351; PubMed=11062482; DOI=10.1038/81695;  
RA Bamford R.N., Roesler E., Burdine R.D., Saplakoglu U., dela Cruz J.,  
RA Splitt M., Towbin J., Bowers P., Marino B., Schier A.F., Shen M.M.,  
RA Muenke M., Casey B.;  
RT "Loss-of-function mutations in the EGF-CFC gene CFC1 are associated  
RT with human left-right laterality defects.";  
RL Nat. Genet. 26:365-369(2000).  
RN [2]  
RX NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT TRP-78.  
RX PubMed=15815621; DOI=10.1038/nature03466;  
RA Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,  
RA Minx P., Wagner-McPherson C., Layman D., Wyllie K., Sekhon M.,  
RA Becker M.C., Fewell G.A., Delehaanty K.D., Miner T.L., Nash W.E.,  
RA Kremitzki C., Oddi L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,  
RA Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,  
RA Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,  
RA Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,  
RA Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,  
RA Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,  
RA Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,  
RA McCallan M.D., Meyer R., Kozlowski-Reilly A., Shan N.,  
RA Dauphin-Kohlberg S., Kozlowski-Reilly A., Strong J.T., Thompson J., Yokum M.,  
RA Swearengen-Shahid S., Snider J., Strong J., Radionenko M., Waligorski J.E.,  
RA Leonard S., Pearson C., Trani L., Radionenko M., Waligorski J.E.,  
RA Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,  
RA Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,  
RA Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabor A.,  
RA Shottland Y., Sinha P., Wohlmann P.E., Cook L.L., Hickenbotham M.T.,  
RA Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,  
RA Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,  
RA McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,  
RA Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,  
RA Miller W., Eichler E.B., Bork P., Suyama M., Torrents D.,  
RA Waterston R.H., Wilson R.K.;  
RT "Generation and annotation of the DNA sequences of human chromosomes 2  
RT and 4.";

Nature 434:724-731(2005).

[3]

RL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].

RN TISSUE=Lung;

RC MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;

RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,

RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,

RA Altshul S.F., Zseberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,

RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,

RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,

RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,

RA Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C.,

RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,

RA Boeck S.A., McSwain P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,

RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,

RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,

RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,

RA Blakesley A.C., Touchman J.W., Green E.D., Dickson M.C.,

RA Rodrigo J.C., Grimwood J., Schmutz J., Myers R.M.,

RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,

RA Schnurch A., Schein J.E., Jones S.J., Marra M.A.;

RT "Generation and initial analysis of more than 15,000 full-length human

RL and mouse cDNA sequences.";

RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

[4]

RN VARIANT TRP-78, AND INVOLVEMENT IN DTGA AND CTHM.

RC PubMed=11799476;

RA Goldmuntz E., Bamford R., Karkera J.D., dela Cruz J., Roessler E.,

RA Muenke M.;

RA "CFCl mutations in patients with transposition of the great arteries

RT and double-outlet right ventricle.";

RL Am. J. Hum. Genet. 70:776-780(2002).

CC -I- FUNCTION: Involved in the correct establishment of the left-right

CC axis. May play a role in mesoderm and/or neural patterning during

CC gastrulation.

CC -I- PTM: N-glycosylated (By similarity).

CC -I- DISEASE: Defects in CFC1 are a cause of visceral heterotaxy (HTX2)

CC [MIM:605376]. HTX2 is an autosomal form of visceral heterotaxy

CC (HTX). HTX is characterized by a variable group of congenital

CC anomalies that include complex cardiac malformations and situs

CC inversus or situs ambiguus.

CC -I- DISEASE: Defects in CFC1 are a cause of transposition of the great

CC arteries, dextro-looped (DTGA) [MIM:608808]. The more common form

CC of DTGA, consists of complete inversion of the great vessels, so

CC that the aorta incorrectly arises from the right ventricle and the

CC pulmonary artery incorrectly arises from the left ventricle. This

CC creates completely separate pulmonary and systemic circulatory

CC systems, an arrangement that is incompatible with life. Patients

CC often have atrial and/or ventricular septal defects or other types

CC of shunting that allow some mixing between the circulations in

CC order to support life minimally, but surgical intervention is

CC always required.

CC -I- DISEASE: Defects in CFC1 are a cause of conotruncal heart

CC malformations (CTHM) [MIM:217095]. CTHM consist of cardiac outflow

CC tract defects, such as tetralogy of Fallot, pulmonary atresia,

CC double-outlet right ventricle, truncus arteriosus communis, and

CC aortic arch anomalies.

CC -I- SIMILARITY: Contains 1 EGF-like domain.

CC -----

CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License

CC -----

DR ENBL; AF312769; AAC30294.1; -; mRNA.

DR ENBL; AF312925; AAG42475.1; -; Genomic DNA.

DR ENBL; AC013269; AAY14955.1; -; Genomic DNA.

DR ENBL; BC069508; AAH69508.1; -; mRNA.

DR ENBL; BC074825; AAH74825.1; -; mRNA.

DR ENBL; BC074826; AAH74826.1; -; mRNA.

DR ENBL; BC110080; AAH110081.1; -; mRNA.

DR HSSP; P00750; ITPG.

DR HGNC; HGNC:18292; CFC1.

DR MIM; 217095; phenotype.

related gene expressed in the axial and lateral mesoderm during mouse gastrulation."

Development 124:429-442(1997).

[2]

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].  
 MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
 Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Haieh F.,  
 Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 Scapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,  
 Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
 Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
 Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 Fahey J., Heiton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,  
 Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalusz D.E.,  
 Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 "Generation and initial analysis of more than 15,000 full-length human  
 and mouse cDNA sequences."

Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

[3]

NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-154.  
 MEDLINE=20480687; PubMed=11024280; DOI=10.1016/S0378-1119(00)00337-1;  
 Colas J.-F., Schoenwolf G.C.;  
 "Subtractive hybridization identifies chick-cripto, a novel EGF-CFC  
 ortholog expressed during gastrulation, neurulation and early  
 cardiogenesis."

Gene 255:205-217(2000).

[4]

FUNCTION, AND KNOCK-OUT.  
 MEDLINE=20045034; PubMed=10574770; DOI=10.1016/S0960-9822(00)80059-7;  
 Gaio U., Schweickert A., Fischer A., Garratt A.N., Mueller T.,  
 Ozcelik C., Lankes W., Strehle M., Britsch S., Blum M.,  
 Birchmeier C.;  
 "A role of the cryptic gene in the correct establishment of the left-  
 right axis."

Curr. Biol. 9:1339-1342(1999).

-1- FUNCTION: Involved in the correct establishment of the left-right  
 axis. May play a role in mesoderm and/or neural patterning during  
 gastrulation.

-1- TISSUE SPECIFICITY: No expressed in adult tissues.

-1- DEVELOPMENTAL STAGE: Expressed during gastrulation (from 6.5 dpc  
 to 11 dpc) in two spatial domains that correspond to the axial and  
 lateral mesoderm. In the first domain expression is progressively  
 localized to the anterior primitive streak, the head process, and  
 the node and notochord. In the second domain, expression is  
 initially concentrated in the lateral region of the egg cylinder,  
 and is later found circumferentially in the intermediate and  
 lateral plate mesoderm. Furthermore, the expression can also be  
 detected at the early head-fold stage in the midline  
 neuroectoderm, and consequently is an early marker for the  
 prospective floor plate of the neural tube. Expression ceases at  
 the end of gastrulation, and has not been observed in later  
 embryonic stages.

-1- PTM: N-glycosylated.

-1- MISCELLANEOUS: Mice lacking functional Cfcl1 showed positional  
 defects in internal organs. The lung presents a right pulmonary  
 isomerism. The stomach is located on either the left or the right  
 and the spleen is small and has an abnormal shape. The apex of the  
 heart pointed to the right or left. In addition malpositioning of  
 heart outflow tracts is observed, the aorta is connected to the  
 right ventricle and emerged from the heart in a ventral position  
 and to the right of the pulmonary artery. This one is connected to  
 either the left or the right ventricle.

-1- SIMILARITY: Contains 1 EGF-like domain.

-----

Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

Distributed under the Creative Commons Attribution-NoDerivs License

-----

CC EMBL; U57720; AAC53042.1; -; mRNA.  
 CC EMBL; BC100705; AA100706.1; -; mRNA.  
 DR EMBL; BC100706; AA100707.1; -; mRNA.  
 DR EMBL; BC100708; AA100709.1; -; mRNA.  
 DR EMBL; BC100711; AA100712.1; -; mRNA.  
 DR EMBL; AF242430; AAF76323.1; -; Genomic\_DNA.  
 DR HSSP; P00749; IURK.  
 DR Ensemble; ENSMUSG00000026124; Mus musculus.  
 DR MGI; MGI:109448; Cfcl1.  
 DR GO; GO:0005615; C:extracellular space; TAS.  
 DR InterPro; IPR000742; EGF\_3.  
 DR InterPro; IPR006209; EGF\_like.  
 DR InterPro; IPR013032; EGF\_like\_reg.  
 DR Pfam; PF00008; EGF\_1.  
 DR PROSITE; PS00022; EGF\_1; 1.  
 DR PROSITE; PS01186; EGF\_2; FALSE\_NEG.  
 DR PROSITE; PS50026; EGF\_3; 1.  
 DR Developmental protein; EGF-like domain; Gastrulation; Glycoprotein;  
 KW Signal.  
 FT SIGNAL 1 35 Potential  
 FT CHAIN 36 202 Cryptic protein.  
 FT DOMAIN 94 123 /FTID=PRO\_0000044631.  
 FT CARBOHYD 65 65 N-linked (GlcNAc...) (Potential).  
 FT DISULFID 98 105 By similarity.  
 FT DISULFID 99 111 By similarity.  
 FT DISULFID 113 122 By similarity.  
 FT CONFLICT 83 83 P -> T (in Ref. 2; AA100707).  
 SQ SEQUENCE 202 AA; 21792 MW; 57035AD339A16FD7 CRC64;  
 Query Match 39.1%; Score 488; DB 1; Length 202;  
 Best Local Similarity 54.6%; Pred. No. 2.4e-34;  
 Matches 100; Conservative 16; Mismatches 65; Indels 2; Gaps 1;  
 QY 5 HVRVLTFTSLALQIILNGSYQREKHNGRGVTKVATQKHRSQPLNWTSSHPGEVTGS 64  
 DB 15 HQARPLFTVTLVALQLGLGVSYQSE--GDGAREVSNILSPVPGTTLDRTLSSNRKNDI 72  
 QY 65 AEWGGEPLPYSRATGEGASAPRCRNGGTGCVLGSFCVCPAHFTGRYCEHDPORRECG 124  
 DB 73 PEGARLWDSLPSDSTLGSAPVPSRCNGGTGCVLGSFCVCPAYFTGRYCEHDPORREDCG 132  
 QY 125 ALEHGAWTLPACHLCRCIFGALHCLPOTDRCOPKDFLASHAHGSPAGSAGAPSLILLPLC 184  
 DB 133 ALGHGAWLHSCRLCRCIFGALHCLPOTDRCOPKDFLASHAHGSPAGSAGAPSLILLPLC 192  
 QY 185 ALL 187  
 DB 193 LLL 195  
 RESULT 3  
 CFCL1\_CHICK STANDARD; PRT; 193 AA.  
 AC Q31803;  
 DT 20-DEC-2005, integrated into UniProtKB/Swiss-Prot.  
 DT 01-OCT-2000, sequence version 1.  
 DT 07-MAR-2006, entry version 25.  
 DE Cryptic protein precursor (Cripto-related factor 1).  
 GN Name=CFCL1;  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;  
 RN [1]  
 RP NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, AND DEVELOPMENTAL  
 RP STAGE.  
 RX MEDLINE=20480687; PubMed=11024280; DOI=10.1016/S0378-1119(00)00337-1;  
 RA Colas J.-F., Schoenwolf G.C.;  
 RT "Subtractive hybridization identifies chick-cripto, a novel EGF-CFC

ortholog expressed during gastrulation, neurulation and early cardiogenesis.";  
Gene 255:205-217 (2000).  
[2]  
NUCLEOTIDE SEQUENCE [MRNA].  
Schlange T., Schnipkow I., Andree B., Ebert A., Zile M.H., Arnold H.-H., Brand T.;  
"Dual function of chicken cryptic in the determination of left-right asymmetry: control of midline barrier formation and lateralization of the lateral plate mesoderm.";  
Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.  
-1- FUNCTION: May play a role in mesoderm and/or neural patterning during gastrulation.  
-1- DEVELOPMENTAL STAGE: First detected in the early-streak embryo, specifically in the epiblast layer. At the late streak stage, expression is condensed in the rostral half of the primitive streak. At HH stage 4 expression appeared for the first time in the mesodermal layer of the presumptive prechordal plate rostrally and in the expanding mesoderm laterally. At HH stage 6, labeling in mesodermal progenitors underlying the future forebrain level of the neuraxis reached its maximum, whereas mesoderm expression, which was restricted to the lateral plate, was accompanied by an underlying endodermal expression at the level of the heart-forming regions. Later gastrulation (HH stage 5-7) was marked by strong expression in the notochord, beneath the future floor plate of the neural tube. Expressed in Hensen's node, within its mesenchymal core beneath the epiblast, and at a time when it is morphologically asymmetric.  
-1- SIMILARITY: Contains 1 EGF-like domain.  
Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>  
Distributed under the Creative Commons Attribution-NoDerivs License  
-----  
DR EMBL; AF228760; AAF97869.1; -; mRNA.  
DR EMBL; AF228762; AAF97869.1; -; Genomic DNA.  
DR EMBL; AF228761; AAF97869.1; JOINED; Genomic DNA.  
DR EMBL; AF228984; AAK07089.1; -; mRNA.  
DR HSSP; P00749; 10RK.  
DR Ensembl; ENSGALG0000012623; Gallus gallus.  
DR InterPro; IPRO00742; EGF 3.  
DR InterPro; IPRO06209; EGF\_Like.  
DR InterPro; IPRO13032; EGF\_Like\_reg.  
DR Pfam; PF00008; EGF, 1.  
DR PROSITE; PS00022; EGF\_1; 1.  
DR PROSITE; PS01186; EGF\_2; FALSE\_NEG.  
DR PROSITE; PS50026; EGF\_3; 1.  
KW Developmental protein; EGF-like domain; Gastrulation; Glycoprotein;  
FT SIGNAL. 1 25 Potential.  
FT CHAIN 26 193 Cryptic protein.  
FT FTIDA-PRO\_000004632.  
FT DOMAIN 91 115 EGF-like.  
FT CARBOHYD 38 38 N-linked (GLCNAC. . .) (Potential).  
FT CARBOHYD 60 60 N-linked (GLCNAC. . .) (Potential).  
FT DISULFID 91 103 By similarity.  
FT DISULFID 105 114 By similarity.  
FT SEQUENCE 193 AA; 23332 MW; B859A98F2D6325F CRC64;  
SQ  
Query Match 25.8%; Score 322.5; DB 1; Length 193;  
Best Local Similarity 34.9%; Pred. No. 5.9e-20;  
Matches 68; Conservative 34; Mismatches 76; Indels 17; Gaps 5;  
QY 1 MTRHHVRLFTVSLALQIINLNSVQREKHNGRGVEVKVATQKHQPSLNWTS----- 55  
Db 1 MFWRKHVRILFTVTIWAQIHLGKREHEK----DVKNFNFDTAQKPSKNSVTIIDAF 56  
QY 56 SHGEVTSAGNEGPPPELPYSRAFGEGASARPRCCNGGTCTVLGSCFCVCPAHTFYCE 115  
Db 57 SDMNQSYQSRKQONSREFVFT-GITESKNLNRCNQNGTCTLGAFACACPRHFSGRHCE 115  
QY 116 HDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCD---PKDFLASHAGPSA 172  
Db 116 ----LRKCSIIGHDWMKGCWLCRLCYGLTKLCSQNTQDGCBLRREERIIRLYSNGRL 171

QY 173 GGAPSLLLLLPCALL 187  
Db 172 QQTMSALICLLTFL 186  
RESULT 4  
Q50415 BRARE PRELIMINARY; PRT; 183 AA.  
AC Q50415;  
DT 07-JUN-2005, integrated into UniProtKB/TrEMBL.  
DT 07-JUN-2005, sequence version 1.  
DT 07-FEB-2006, entry version 4.  
DE Oep protein.  
GN Name=oeop;  
OS Brachydanio rerio (Zebrafish) (Danio rerio).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;  
OC Cyprinidae; Danio.  
OX NCBI\_TaxID=7955;  
RN [1]  
RP NUCLEOTIDE SEQUENCE.  
RC TISSUE=Embryo;  
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;  
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Klausner R.D., Collins F.S., Wagner J., Shenmen C.M., Schuler G.D., Altshuler S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K., Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F., Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L., Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E., Brownstein M.J., Ustin T.B., Toshiyuki S., Carninci P., Prange C., Roha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J., Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H., Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W., Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A., Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A., Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.N., Krzyzanski M.I., Skalska U., Smalick D.E., Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).  
RN [2]  
RP TISSUE=Embryo;  
RG NIH MGC Project;  
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.  
CC -----  
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>  
CC Distributed under the Creative Commons Attribution-NoDerivs License  
-----  
CC EMBL; BC095007; AAH95007.1; -; mRNA.  
DR Ensembl; ENSDARG0000035095; Danio rerio.  
DR ZFIN; ZDB-GENE-990415-198; oep.  
DR InterPro; IPRO13032; EGF\_Like\_reg.  
DR PROSITE; PS00022; EGF\_1; UNKNOWN 1.  
SQ SEQUENCE 183 AA; 20374 MW; 5571447894E18507 CRC64;  
Query Match 22.9%; Score 286; DB 2; Length 183;  
Best Local Similarity 43.0%; Pred. No. 8.4e-17;  
Matches 52; Conservative 16; Mismatches 51; Indels 2; Gaps 2;  
QY 71 EEPLPYSAFGEGASARPRCCNGGTCTVLGSCFCVCPAHTFYCEHQRSECGALEHGA 130  
Db 65 EAALPFVGLTVAKQSR-TCCXNGGTCTILGSCFCACPKYFGRSCYEDLRDCGVPHGE 123  
QY 131 WTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAGPSAGGASLLLLPCALLHRL 190  
Db 124 WYQKGSYCRGCGYGLLHCFPHVFSKDCDDSQEVRHRSQ-SLRTLSSTIVMFAAFILHRL 182  
QY 191 L<sub>1</sub>191

```
Db 183 L 183
RESULT 5
O57517 BRARE PRELIMINARY; PRT; 183 AA.
ID O57517;
AC O57517;
DT 01-JUN-1998, integrated into UniProtKB/TrEMBL.
DT 01-JUN-1998, sequence version 1.
DT 07-FEB-2006, entry version 24.
DE One-eyed pinhead short form protein.
GN Name=oeep;
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98117252; PubMed=9458048; DOI=10.1016/S0092-8674(00)80918-6;
RA Zhang J., Talbot W.S., Schier A.F.;
RT "Positional cloning identifies zebrafish one-eyed pinhead as a
RT permissive EGF-related ligand required during gastrulation.";
RL Cell 92:241-251(1998).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
Db 183 L 183
RESULT 6
O57516 BRARE PRELIMINARY; PRT; 190 AA.
ID O57516;
AC O57516;
DT 01-JUN-1998, integrated into UniProtKB/TrEMBL.
DT 01-JUN-1998, sequence version 1.
DT 07-FEB-2006, entry version 23.
DE One-eyed pinhead long form protein.
GN Name=oeep;
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98117252; PubMed=9458048; DOI=10.1016/S0092-8674(00)80918-6;
RA Zhang J., Talbot W.S., Schier A.F.;
RT "Positional cloning identifies zebrafish one-eyed pinhead as a
RT permissive EGF-related ligand required during gastrulation.";
RL Cell 92:241-251(1998).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
Db 183 L 183
RESULT 7
O2VU94 XENLA PRELIMINARY; PRT; 179 AA.
ID O2VU94;
AC O2VU94;
DT 10-JAN-2006, integrated into UniProtKB/TrEMBL.
DT 10-JAN-2006, sequence version 1.
DT 07-MAR-2006, entry version 4.
DE CR3 short transcript variant (Cripto-3 short).
GN Name=CR3;
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidae; Pipidae;
OC Xenopodinae; Xenopus; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=16339189; DOI=10.1242/dev.02188;
RA Onuma Y., Yeo C.Y., Whitman M.;
RT "XCR2, one of three Xenopus EGF-CFC genes, has a distinct role in the
RT regulation of left-right patterning.";
RL Development 133:237-250(2006).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
Db 183 L 183
Query Match 22.8%; Score 285; DB 2; Length 183;
Best Local Similarity 43.0%; Pred. No. 1e-16;
Matches 52; Conservative 16; Mismatches 51; Indels 2; Gaps 2;
QY 71 EEPLPYSRAFEGASARPCRCNGTGVLCGFCVCPAHTGTYCEHQRSECGALEHGA 130
Db 65 EAALPFVGLTGVAQKSR-TCCKNGGTCLGSCFACPKYFTGRSCYDELRDCGVIPHGE 123
QY 131 WTLRACHLCRCIFGALHCLPQTDPKDFLASHAHGSPSAGAGSLLLLPCALLHRL 190
Db 124 WVQKGCYCRGCGYLLHCFPHVFSKDCDDSQEVRWHRSG-SLRTLSTIWMFATFILHRL 182
QY 191 L 191
Db 183 L 183
RESULT 8
O57515 BRARE PRELIMINARY; PRT; 190 AA.
ID O57515;
AC O57515;
DT 01-JUN-1998, integrated into UniProtKB/TrEMBL.
DT 01-JUN-1998, sequence version 1.
DT 07-FEB-2006, entry version 23.
DE One-eyed pinhead long form protein.
GN Name=oeep;
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98117252; PubMed=9458048; DOI=10.1016/S0092-8674(00)80918-6;
RA Zhang J., Talbot W.S., Schier A.F.;
RT "Positional cloning identifies zebrafish one-eyed pinhead as a
RT permissive EGF-related ligand required during gastrulation.";
RL Cell 92:241-251(1998).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
Db 183 L 183
Query Match 22.1%; Score 275.5; DB 2; Length 190;
Best Local Similarity 41.1%; Pred. No. 7.2e-16;
Matches 53; Conservative 18; Mismatches 47; Indels 11; Gaps 4;
QY 71 EEPLPYSRAFEGASARPCRCNGTGVLCGFCVCPAHTGTYCEHQRSECGALEHGA 130
Db 65 EAALPFVGLTGVAQKSR-TCCKNGGTCLGSCFACPKYFTGRSCYDELRDCGVIPHGE 123
QY 131 WTLRACHLCRCIFGALHCLP-----LQTPRCDPKDFLASHAHGSPSAGAGSLLLL 182
Db 124 WVQKGCYCRGCGYLLHCFPHVFSKDCDFVSKD-CDDSQEVRWHRSG-SLRTLSTIWMF 181
QY 183 PCALLHRL 191
Db 182 ATFILHRL 190
RESULT 9
O2VU94 XENLA PRELIMINARY; PRT; 179 AA.
ID O2VU94;
AC O2VU94;
DT 10-JAN-2006, integrated into UniProtKB/TrEMBL.
DT 10-JAN-2006, sequence version 1.
DT 07-MAR-2006, entry version 4.
DE CR3 short transcript variant (Cripto-3 short).
GN Name=CR3;
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipoidae; Pipidae;
OC Xenopodinae; Xenopus; Xenopus.
OX NCBI_TaxID=8355;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=16339189; DOI=10.1242/dev.02188;
RA Onuma Y., Yeo C.Y., Whitman M.;
RT "XCR2, one of three Xenopus EGF-CFC genes, has a distinct role in the
RT regulation of left-right patterning.";
RL Development 133:237-250(2006).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
Db 183 L 183
Query Match 21.5%; Score 269; DB 2; Length 179;
Best Local Similarity 35.1%; Pred. No. 2.5e-15;
Matches 60; Conservative 21; Mismatches 58; Indels 32; Gaps 8;
QY 1 MTRRHVRLFTVSLALQ-IILGNYSQREKINGGR-----GEVTKVATQKHROSPLN 52
```



RA Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,  
RA Hill D., Huninick L., Tacconi M., Ikeo K., Iwama A., Ishikawa T.,  
RA Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelson J., Kitamura H.,  
RA Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,  
RA Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,  
RA Liuni S., McWilliam S., Madan Babu M., Mader M., Marchionni L.,  
RA Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,  
RA Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,  
RA Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,  
RA Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavese G., Pesole G.,  
RA Petrovsky N., Piazza S., Reed J.C., Reid J.F., Ring B.Z., Ringwald M.,  
RA Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,  
RA Schonbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,  
RA Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,  
RA Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,  
RA Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,  
RA Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,  
RA Yamashita H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,  
RA Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,  
RA Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,  
RA Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,  
RA Iida J., Imamura K., Itoh M., Kondo S., Konno H., Nakano K., Ninomiya N.,  
RA Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,  
RA Nishio T., Okada M., Plessey C., Shibata K., Shiraki T., Suzuki S.,  
RA Tagami T., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,  
RA Hayashizaki Y.;  
RT "The transcriptional landscape of the mammalian genome.";  
RL Science 309:1559-1563(2005).  
RN [3]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RX PubMed=16141073; DOI=10.1126/science.1112009;  
RG RIKEN Genome Exploration Research Group, and Genome Science Group  
RG (Genome Network Core team) and the FANTOM Consortium;  
RT "Antisense Transcription in the Mammalian Transcriptome.";  
RL Science 309:1564-1566(2005).  
RN [4]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RX MEDLINE=22354683; PubMed=12466851; DOI=10.1038/nature01266;  
RA Okazaki Y., Furuno M., Kasukawa T., Adachi J., Bono H., Kondo S.,  
RA Nikaide I., Osato N., Saïto R., Suzuki H., Yamanaka I., Kiyosawa H.,  
RA Yagi K., Tomaru Y., Hasegawa Y., Nogami A., Schonbach C., Gojobori T.,  
RA Baldarelli R., Hill D.P., Bult C., Hume D.A., Quackenbush J.,  
RA Schriml L.M., Kanapin A., Matsuda H., Batalov S., Beisel K.W.,  
RA Blake J.A., Bradt D., Brusic V., Chothia C., Corbani L.E., Cousins S.,  
RA Dalla E., Dragani T.A., Fletcher C.F., Forrest A., Frazer K.S.,  
RA Gaasterland T., Gariboldi M., Gissi C., Godzik A., Gough J.,  
RA Grimmond S., Gustincich S., Hirokawa N., Jackson I.J., Jarvis E.D.,  
RA Kanai A., Kawai H., Kawasawa Y., Kedzierski R.M., King B.L.,  
RA Konagaya A., Kurochkin I.V., Lee Y., Lenhard B., Lyons F.A.,  
RA Maglott D.R., Maltais L., Marchionni L., McKenzie L., Miki H.,  
RA Nagashima T., Numata K., Okido T., Pavan W.J., Pertea G., Pesole G.,  
RA Petrovsky N., Pillai R., Pontius J.U., Qi D., Ramchandran S.,  
RA Ravasi T., Reed J.C., Reed D.J., Reid J., Ring B.Z., Ringwald M.,  
RA Sandelin A., Schneider C., Semple C.A., Setou M., Shimada K.,  
RA Sultana R., Takenaka Y., Taylor M.S., Teasdale R.D., Tomita M.,  
RA Verardo R., Wagner L., Wahlestedt C., Wang Y., Watanabe Y., Wells C.,  
RA Wilming L.G., Wynshaw-Boris A., Yanagisawa M., Yang I., Yang L.,  
RA Yuan Z., Zavolan M., Zhu Y., Zimmer A., Carninci P., Hayatsu N.,  
RA Hirozane-Kishikawa T., Konno H., Nakamura M., Sakazume N., Sato K.,  
RA Shiraki T., Waki K., Kawai J., Aizawa K., Arakawa T., Fukuda S.,  
RA Hara A., Hashizume W., Imotani K., Ishii Y., Itoh M., Kagawa I.,  
RA Miyazaki A., Sakai K., Sasaki D., Shibata K., Shinagawa A.,  
RA Yashunishi A., Yoshino M., Waterston R., Lander E.S., Rogers J.,  
RA Barney E., Hayashizaki Y.;  
RT "Analysis of the mouse transcriptome based on functional annotation of  
RT 60,770 full-length cDNAs.";  
RL Nature 420:563-573(2002).  
RN [5]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;  
RN [6]

RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,  
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,  
RA Aizawa K., Iizawa M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,  
RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,  
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,  
RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,  
RA Kuehl P., Lewis S., Matsuo Y., Nikaide I., Pesole G., Quackenbush J.,  
RA Schriml L.M., Staubli F., Suzuki R., Tomita M., Wagner L., Washio T.,  
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,  
RA Blake J., Boffelli D., Bojunga N., Carninci P., de Bonaldo M.F.,  
RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,  
RA Gustincich S., Hill D., Hofmann M., Hume D.A., Kamly M., Lee N.H.,  
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,  
RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,  
RA Sasaki H., Sato K., Schoenbach C., Seya T., Shibata Y., Storch K.-F.,  
RA Suzuki H., Toyo-oka K., Wang K.H., Weitz C., Whittaker C., Wilming L.,  
RA Wynshaw-Boris A., Yoshida K., Hasegawa Y., Kawai H., Kohtauki S.,  
RA Hayashizaki Y.;  
RT "Functional annotation of a full-length mouse cDNA collection.";  
RL Nature 409:685-690(2001).  
RN [6]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;  
RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,  
RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;  
RT "Normalization and subtraction of cap-trapper-selected cDNAs to  
RT prepare full-length cDNA libraries for rapid discovery of new genes.";  
RL Genome Res. 10:1617-1630(2000).  
RN [7]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;  
RA Shibata K., Itoh M., Aizawa K., Nagaoaka S., Sasaki N., Carninci P.,  
RA Konno H., Katsunai T., Tashiro H., Itoh M.,  
RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,  
RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,  
RA Fujiwara S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,  
RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsura S., Kawai J.,  
RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;  
RT "RIKEN integrated sequence analysis (RISA) system-384-format  
RT sequencing pipeline with 384 multicapillary sequencer.";  
RL Genome Res. 10:1757-1771(2000).  
RN [8]  
RP NUCLEOTIDE SEQUENCE.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RA Arakawa T., Carninci P., Fukuda S., Hashizume W., Hayashida K.,  
RA Hori F., Iida J., Imamura K., Imotani K., Itoh M., Kanagawa S.,  
RA Kawai J., Kojima M., Konno H., Murata M., Nakamura M., Ninomiya N.,  
RA Nishiyori H., Nomura K., Ohno M., Sakazume N., Sano H., Sasaki D.,  
RA Shibata K., Shiraki T., Tagami M., Tagami Y., Waki K., Watahiki A.,  
RA Muramatsu M., Hayashizaki Y.;  
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.  
CC Copyrighted by the Uniprot Consortium, see <http://www.uniprot.org/terms>  
CC Distributed under the Creative Commons Attribution-NoDerivs License  
CC -----  
CC EMBL; AK133730; BA521807.1; -; mRNA.  
DR MGI; MGI:98658; Tdglf1.  
DR GO; GO:0005615; C:extracellular space; RCA.  
DR GO; GO:0019897; C:extrinsic to plasma membrane; IDA.  
DR GO; GO:0008595; P:determination of anterior/posterior axis, e. . .; IMP.  
DR InterPro; IPR007042; EGF\_3.  
DR InterPro; IPR013032; EGF\_like\_reg.  
DR PROSITE; PS00022; EGF\_1; UNKNOW\_1.  
DR PROSITE; PS00026; EGF\_3; 1.  
DR Cell adhesion; EGF-like domain.  
KW SEQUENCE 171 AA; 18646 MW; C53400FDEBFB6380 CRC64;  
SQ

Query Match 21.2%; Score 265; DB 2; Length 171;  
Best Local Similarity 37.8%; Pred. No. 5.3e-15;  
Matches 56; Conservative 11; Mismatches 63; Indels 18; Gaps 3;

Qy	58	FGVVTG-----SAGWGPEEPPLVYSRAF-----GEGASAPRCRNGGTGCVLGSFC 103
Db	20	FGPVAGRDIAIRDNSIMWDQIEAPVADRDRSFGQVPSVGTQNSKSLNKTCLNGGTGCVLGSFC 79
Qy	104	VCPAHTFTGVCYCHDORRSCGALRGAWTLRACHLCRCICFGLHCLPLQTPDRCD---P 159
Db	80	ACPPSYGRNCCHDVREKHCGSILGHTWLPKKCSLCRCWHGQLHCLPQTFPLPGDQGVMD 139
Qy	160	KDFLASHAHGPSAGGAPSLLLLLPCALL 187
Db	140	QDLKASGTQCQTPSVTTTFLMAGACLF 167
RESULT 10		
Q7TQ06 MOUSE		
ID	Q7TQ06	PRELIMINARY; PRT; 171 AA.
AC	Q7TQ06	
DT	01-OCT-2003	integrated into UniProtKB/TrEMBL.
DT	01-OCT-2003	sequence version 1.
DT	07-MAR-2006	entry version 23.
DE	Tdgl1 protein.	
GN	Names=Tdgl1	
OS	Mus musculus (Mouse)	
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
OC	Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;	
OC	Muridea; Muridae; Murinae; Mus.	
NCBI_TaxID	10090;	
[1]		
RP	NUCLEOTIDE SEQUENCE	
RP	STRAIN=C57BL/6J; TISSUE=Blasctocyst; DOI=10.1073/pnas.2426038999;	
RX	MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.2426038999;	
RA	Straussberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,	
RA	Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,	
RA	Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,	
RA	Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,	
RA	Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,	
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,	
RA	Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,	
RA	Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaby S.J.,	
RA	Boeak S.A., McSwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,	
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,	
RA	Villalón D.K., Muny D.M., Sodergren E.J., Lu X., Gibbs R.A.,	
RA	Fahey J., Helton E., Kettner M., Madan A.C., Rodrigues S., Sanchez A.,	
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,	
RA	Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,	
RA	Rodriguez A.C., Girmwood J., Schmutz J., Myers R.M.,	
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smallos D.E.,	
RA	Schnerch A., Schein J.E., Jones S.J.W., Marra M.A.;	
RT	"Generation and initial analysis of more than 15,000 full-length human	
RT	and mouse cDNA sequences."	
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).	
RN	[2]	
RP	NUCLEOTIDE SEQUENCE	
RP	STRAIN=C57BL/6J; TISSUE=Blasctocyst;	
RA	Straussberg R.;	
RL	Submitted (May-2003) to the EMBL/GenBank/DBJ databases.	
CC	Copyrighted by the UniProt Consortium, see <a href="http://www.uniprot.org/terms">http://www.uniprot.org/terms</a>	
CC	Distributed under the Creative Commons Attribution-NoDerivs License	
CC	-----	
CC	EMBL; BC052646; AAHS2646.1; -; mRNA.	
DR	HSSP; P00740; LEDM.	
DR	Ensembl; ENSMUSG00000032494; Mus musculus.	
DR	MGI; MGI:98658; Tdgl1.	
DR	GO; GO:0008615; C:extracellular space; RCA.	
DR	GO; GO:0009897; C:extrinsic to plasma membrane; IDA.	
DR	GO; GO:0008595; P:determination of anterior/posterior axis, e. . .; IMP.	
DR	InterPro; IPR000742; EGF 3.	
DR	InterPro; IPR006209; EGF_like.	
DR	InterPro; IPR013032; EGF_like_reg.	
DR	Pfam; PF00008; EGF; 1.	
DR	PROSITE; PS00022; EGF 1; UNKNOWN_1.	
DR	PROSITE; PS00026; EGF 3; 1.	

[illegible]



GenCore version 5.1.9  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: September 7, 2006, 12:11:27 ; Search time 174 Seconds  
(without alignments)  
593.660 Million cell updates/sec

Title: US-10-665-602-2

Perfect score: 1249

Sequence: 1 MTRHHVRLFTVSLALQII.....PSVLQRERRPCGRPLGHRL 223

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 2097797 seqs, 463214858 residues

Total number of hits satisfying chosen parameters: 2097797

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications\_AA\_Main:\*

- 1: /EMC\_Celestra\_SID33/ptodata/2/pubpaa/US07\_PUBCOMB.pep:\*
- 2: /EMC\_Celestra\_SID33/ptodata/2/pubpaa/US08\_PUBCOMB.pep:\*
- 3: /EMC\_Celestra\_SID33/ptodata/2/pubpaa/US09\_PUBCOMB.pep:\*
- 4: /EMC\_Celestra\_SID33/ptodata/2/pubpaa/US10A\_PUBCOMB.pep:\*
- 5: /EMC\_Celestra\_SID33/ptodata/2/pubpaa/US10B\_PUBCOMB.pep:\*
- 6: /EMC\_Celestra\_SID33/ptodata/2/pubpaa/US11\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1249	100.0	223	4	US-10-665-602-2
2	1249	100.0	229	3	US-09-764-893-98
3	1249	100.0	229	3	US-09-764-881-101
4	1249	100.0	229	3	US-09-764-853-608
5	1249	100.0	229	3	US-09-764-898-269
6	1249	100.0	229	3	US-09-764-881-101
7	1249	100.0	229	4	US-10-073-865-98
8	1249	100.0	229	4	US-10-242-747-101
9	1242	99.4	231	3	US-09-764-898-198
10	1241	99.4	223	4	US-10-295-027-422
11	1241	99.4	223	4	US-10-295-027-1293
12	1241	99.4	223	4	US-10-264-237-2712
13	1241	99.4	223	5	US-10-940-431-4
14	1238	98.7	223	4	US-10-257-113-2
15	488	39.1	202	5	US-10-940-431-3
16	275.5	22.1	190	5	US-10-940-431-6
17	264	21.1	160	4	US-10-016-447-7
18	264	21.1	166	4	US-10-424-599-231675
19	256	20.5	171	5	US-10-940-431-1
20	249.5	20.0	190	5	US-10-940-431-5
21	248.5	19.9	190	4	US-10-016-447-4
22	238	19.1	360	4	US-10-390-566-7
23	238	19.1	367	4	US-10-390-566-6
24	233	18.7	139	4	US-10-390-566-4
25	233	18.7	139	4	US-10-390-566-3
26	233	18.7	174	4	US-10-665-602-7
27	233	18.7	188	4	US-10-241-220-58

28	233	18.7	188	4	US-10-388-578-6	Sequence 6, Appli
29	233	18.7	188	4	US-10-390-566-1	Sequence 1, Appli
30	233	18.7	188	4	US-10-362-597A-3	Sequence 3, Appli
31	233	18.7	188	4	US-10-362-597A-6	Sequence 6, Appli
32	233	18.7	188	4	US-10-362-597A-96	Sequence 96, Appli
33	233	18.7	188	4	US-10-407-481-3	Sequence 3, Appli
34	233	18.7	188	4	US-10-407-481-6	Sequence 6, Appli
35	233	18.7	188	4	US-10-407-481-96	Sequence 96, Appli
36	233	18.7	188	4	US-10-712-124-58	Sequence 58, Appli
37	233	18.7	188	4	US-10-593-538-1	Sequence 1, Appli
38	233	18.7	188	4	US-10-389-431-6	Sequence 6, Appli
39	233	18.7	188	4	US-10-816-476-3	Sequence 3, Appli
40	233	18.7	188	4	US-10-816-476-6	Sequence 6, Appli
41	233	18.7	188	4	US-10-816-476-96	Sequence 96, Appli
42	233	18.7	188	5	US-10-872-972-58	Sequence 58, Appli
43	233	18.7	188	5	US-10-872-991-58	Sequence 58, Appli
44	233	18.7	188	5	US-10-491-997-28	Sequence 28, Appli
45	233	18.7	188	5	US-10-940-431-2	Sequence 2, Appli

#### ALIGNMENTS

RESULT 1  
US-10-665-602-2  
; Sequence 2, Application US/10665602  
; Publication No. US20040086967A1  
; GENERAL INFORMATION:  
; APPLICANT: Melesner, Paul S.  
; TITLE OF INVENTION: Human Criptin Growth Factor  
; NUMBER OF INVENTIONS: 7  
; NUMBER OF SEQUENCES: 7  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Human Genome Sciences, Inc.  
; STREET: 9410 Key West Avenue  
; CITY: Rockville  
; STATE: MD  
; COUNTRY: USA  
; ZIP: 20850  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/665,602  
; FILING DATE: 22-Sep-2003  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/09/393,023A  
; FILING DATE: 09-SEP-1999  
; APPLICATION NUMBER: US 08/471,371  
; FILING DATE: 06-JUN-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Marks, Michelle S.  
; REGISTRATION NUMBER: 41,971  
; REFERENCE/DOCKET NUMBER: PF2000D1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 301-309-8504  
; TELEFAX: 301-309-8439  
; INFORMATION FOR SEQ ID NO: 2:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 223 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
US-10-665-602-2

Query Match 100.0%; Score 1249; DB 4; Length 223;  
Best Local Similarity 100.0%; Pred. No. 1.2e-103;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTRHHVRLFTVSLALQIINLNGSYQREKHNGRGEVTKVATQKHQSPLNWTSHFGE 60  
DB 1 MTRHHVRLFTVSLALQIINLNGSYQREKHNGRGEVTKVATQKHQSPLNWTSHFGE 60  
QY 61 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCVCPAHTGTRYCEHDQRR 120  
DB 61 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCVCPAHTGTRYCEHDQRR 120  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
DB 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPCGRPLGHLR 223  
DB 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPCGRPLGHLR 223

## RESULT 2

US-09-764-893-98  
; Sequence 98, Application US/09764893  
; Publication No. US20020086330A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: P209  
; CURRENT APPLICATION NUMBER: US/09/764,893  
; Prior application data removed - consult PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 154  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 98  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-893-98

Query Match 100.0%; Score 1249; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.2e-103;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLNGSYQREKHNGRGEVTKVATQKHQSPLNWTSHFGE 60  
DB 7 MTRHHVRLFTVSLALQIINLNGSYQREKHNGRGEVTKVATQKHQSPLNWTSHFGE 66  
QY 61 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCVCPAHTGTRYCEHDQRR 120  
DB 67 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCVCPAHTGTRYCEHDQRR 126  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPCGRPLGHLR 223  
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPCGRPLGHLR 229

## RESULT 3

US-09-764-881-101  
; Sequence 101, Application US/09764881  
; Publication No. US20020086821A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: PT207  
; CURRENT APPLICATION NUMBER: US/09/764,881

; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - refer to PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 192  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 101  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-881-101

Query Match 100.0%; Score 1249; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.2e-103;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLNGSYQREKHNGRGEVTKVATQKHQSPLNWTSHFGE 60  
DB 7 MTRHHVRLFTVSLALQIINLNGSYQREKHNGRGEVTKVATQKHQSPLNWTSHFGE 66  
QY 61 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCVCPAHTGTRYCEHDQRR 120  
DB 67 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCVCPAHTGTRYCEHDQRR 126  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPCGRPLGHLR 223  
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPCGRPLGHLR 229

## RESULT 4

US-09-764-853-608  
; Sequence 608, Application US/09764853  
; Patent No. US20020090672A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: P206  
; CURRENT APPLICATION NUMBER: US/09/764,853  
; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - consult PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 939  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 608  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-853-608

Query Match 100.0%; Score 1249; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.2e-103;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLNGSYQREKHNGRGEVTKVATQKHQSPLNWTSHFGE 60  
DB 7 MTRHHVRLFTVSLALQIINLNGSYQREKHNGRGEVTKVATQKHQSPLNWTSHFGE 66  
QY 61 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCVCPAHTGTRYCEHDQRR 120

Db 67 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126  
Qy 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
Db 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186  
Qy 181 LLPCALLHRLLRDPADAPAHPSLPSVLQRRRRCGRPGLGHRL 223  
Db 187 LLPCALLHRLLRDPADAPAHPSLPSVLQRRRRCGRPGLGHRL 229

## RESULT 5

US-09-764-898-269  
; Sequence 269, Application US/09764898  
; Patent No. US2002090673A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: P201  
; CURRENT APPLICATION NUMBER: US/09/764,898  
; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - consult PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 311  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 269  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-898-269

Query Match 100.0%; Score 1249; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.2e-103;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MTRWHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKIQRSPLNWTSSHFG 60  
Db 7 MTRWHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKIQRSPLNWTSSHFG 66  
Qy 61 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
Db 67 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126  
Qy 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
Db 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186  
Qy 181 LLPCALLHRLLRDPADAPAHPSLPSVLQRRRRCGRPGLGHRL 223  
Db 187 LLPCALLHRLLRDPADAPAHPSLPSVLQRRRRCGRPGLGHRL 229

## RESULT 6

US-09-764-881-101  
; Sequence 101, Application US/09764881  
; Publication No. US20030125246A9  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: P207  
; CURRENT APPLICATION NUMBER: US/09/764,881  
; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - refer to PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 192  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 101

; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-881-101

Query Match 100.0%; Score 1249; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.2e-103;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MTRWHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKIQRSPLNWTSSHFG 60  
Db 7 MTRWHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKIQRSPLNWTSSHFG 66  
Qy 61 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
Db 67 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126  
Qy 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
Db 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186  
Qy 181 LLPCALLHRLLRDPADAPAHPSLPSVLQRRRRCGRPGLGHRL 223  
Db 187 LLPCALLHRLLRDPADAPAHPSLPSVLQRRRRCGRPGLGHRL 229

## RESULT 7

US-10-073-865-98  
; Sequence 98, Application US/10073865  
; Publication No. US20030044904A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: P209C1  
; CURRENT APPLICATION NUMBER: US/10/073,865  
; CURRENT FILING DATE: 2002-02-14  
; Prior Application removed - See file wrapper or Palm  
; NUMBER OF SEQ ID NOS: 154  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 98  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: misc\_feature  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-10-073-865-98

Query Match 100.0%; Score 1249; DB 4; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.2e-103;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MTRWHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKIQRSPLNWTSSHFG 60  
Db 7 MTRWHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKIQRSPLNWTSSHFG 66  
Qy 61 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
Db 67 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126  
Qy 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180



```

; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: US 60/347,211
; PRIOR FILING DATE: 2002-01-08
; PRIOR APPLICATION NUMBER: US 60/347,349
; PRIOR FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/355,250
; PRIOR FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/356,714
; PRIOR FILING DATE: 2002-02-13
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1386
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1293
; LENGTH: 223
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-295-027-1293

Query Match          99.4%; Score 1241; DB 4; Length 223;
Best Local Similarity 99.6%; Pred. No. 6.1e-103;
Matches 222; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1  MTRHHVRLLFTVSLALQIINLGNVYQREKHNGRGREVTKVATQKHQSPLNWTSSTHFG 60
Db      1  MTRHHVRLLFTVSLALQIINLGNVYQREKHNGRGREVTKVATQKHQSPLNWTSSTHFG 60

Qy      61  VTGSAGWGPEEPPLPSYRAFGEASAPRCRRNGGTCVLGSCFVCPAHFTGRYCEHDORR 120
Db      61  VTGSAGWGPEEPPLPSYRAFGEASAPRCRRNGGTCVLGSCFVCPAHFTGRYCEHDORR 120

Qy      121  SECGALEHGAWTURACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAGPSLLL 180
Db      121  SECGALEHGAWTURACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAGPSLLL 180

Qy      181  LLPCELLHLLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGHRLL 223
Db      181  LLPCELLHLLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGHRLL 223

RESULT 12

```

```

; Sequence 27121, Application 057102674237
; Publication No. US20040009491A1
; GENERAL INFORMATION:
; APPLICANT: Birse et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PA131P1
; CURRENT APPLICATION NUMBER: US/10/264,237
; CURRENT FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/16450
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/205,515
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 2876
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 2712
; LENGTH: 223
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-264-237-2712

Query Match          99.4%; Score 1241; DB 4; Length 223;
Best Local Similarity 99.6%; Pred. No. 6.1e-103;
Matches 222; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1  MTRWRHVRLLFTVSLALQIINLGNYSQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGE 60
DB      1  MTRWRHVRLLFTVSLALQIINLGNYSQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGE 60

QY      61  VTGSASGWGPEEPLPYSRAFEGEGASARPRCCRNNGTCTVLGSCFVCPAHFTGRCYCEHDQRR 120
DB      61  VTGSASGWGPEEPLPYSRAFEGEGASARPRCCRNNGTCTVLGSCFVCPAHFTGRCYCEHDQRR 120

```

QY 121 SEC GALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLL 180  
DB 121 SEC GALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLL 180  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223  
DB 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223

## RESULT 13

US-10-940-431-4  
; Sequence 4, Application US/10940431  
; Publication No. US20050208045A1  
; GENERAL INFORMATION:  
; APPLICANT: Vale, Wylie  
; APPLICANT: Harrison, Craig A.  
; APPLICANT: Gray, Peter C.  
; TITLE OF INVENTION: CRYPTO Antagonism of Activin and TGF-  
; TITLE OF INVENTION: Signaling  
; FILE REFERENCE: D6525  
; CURRENT APPLICATION NUMBER: US/10/940,431  
; PRIOR FILING DATE: 2004-09-14  
; PRIOR APPLICATION NUMBER: 60/503,046  
; PRIOR FILING DATE: 2003-09-15  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: Macintosh OS 10  
; SEQ ID NO 4  
; LENGTH: 223  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: amino acid sequence of human Criptic protein  
US-10-940-431-4

Query Match 99.4%; Score 1241; DB 5; Length 223;  
Best Local Similarity 99.6%; Pred. No. 6.1e-103; Mismatches 1; Indels 0; Gaps 0;  
Matches 22; Conservative 0;  
QY 1 MTRHHVRLFTVSLALQIINLGNYSYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGE 60  
DB 1 MTRHHVRLFTVSLALQIINLGNYSYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGE 60  
QY 61 VTGSAEGWGPEEPLPYSRAFEGASAPRCRCNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 61 VTGSAEGWGPEEPLPYSRAFEGASAPRCRCNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
QY 121 SEC GALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLL 180  
DB 121 SEC GALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLL 180  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223  
DB 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223

## RESULT 14

US-10-257-113-2  
; Sequence 2, Application US/10257113  
; Publication No. US20030207293A1  
; GENERAL INFORMATION:  
; APPLICANT: DUCKER, KLAUS  
; TITLE OF INVENTION: CRYPTIC-LIKE SECRETED PROTEIN  
; FILE REFERENCE: MERCK-2519  
; CURRENT APPLICATION NUMBER: US/10/257,113  
; CURRENT FILING DATE: 2001-04-06  
; PRIOR APPLICATION NUMBER: EP 00107142.2  
; PRIOR FILING DATE: 2000-04-10  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 223  
; TYPE: PRT

; ORGANISM: Homo sapiens  
US-10-257-113-2

Query Match 98.7%; Score 1233; DB 4; Length 223;  
Best Local Similarity 99.1%; Pred. No. 3.2e-102;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLGNYSYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGE 60  
DB 1 MTRHHVRLFTVSLALQIINLGNYSYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGE 60  
QY 61 VTGSAEGWGPEEPLPYSRAFEGASAPRCRCNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 61 VTGSAEGWGPEEPLPYSRAFEGASAPRCRCNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
QY 121 SEC GALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLL 180  
DB 121 SEC GALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLL 180  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223  
DB 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223

## RESULT 15

US-10-940-431-3  
; Sequence 3, Application US/10940431  
; Publication No. US20050208045A1  
; GENERAL INFORMATION:  
; APPLICANT: Vale, Wylie  
; APPLICANT: Harrison, Craig A.  
; APPLICANT: Gray, Peter C.  
; TITLE OF INVENTION: CRYPTO Antagonism of Activin and TGF-  
; TITLE OF INVENTION: Signaling  
; FILE REFERENCE: D6525  
; CURRENT APPLICATION NUMBER: US/10/940,431  
; CURRENT FILING DATE: 2004-09-14  
; PRIOR APPLICATION NUMBER: 60/503,046  
; PRIOR FILING DATE: 2003-09-15  
; NUMBER OF SEQ ID NOS: 6  
; SOFTWARE: Macintosh OS 10  
; SEQ ID NO 3  
; LENGTH: 202  
; TYPE: PRT  
; ORGANISM: Mus musculus  
; FEATURE:  
; OTHER INFORMATION: amino acid sequence of mouse Criptic protein  
US-10-940-431-3

Query Match 39.1%; Score 488; DB 5; Length 202;  
Best Local Similarity 54.6%; Pred. No. 1.6e-35; Mismatches 65; Indels 2; Gaps 1;  
Matches 100; Conservative 16;  
QY 5 HVRLLFTVSLALQIINLGNYSYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGEVTGS 64  
DB 15 HQARPLFTVVALQLGLGYSQSE--GDGAREVSNILSPVPGTTLDRTLSNRRKNDI 72  
QY 65 AEGWGPEEPLPYSRAFEGASAPRCRCNGGTCVLGSCFVCPAHFTGRYCEHDQRRSEC 124  
DB 73 PEGARLWDSLPSSTLGESAVPSRCCHNGGTCVLGSCFVCPAYFTGRYCEHDQRRDCG 132  
QY 125 ALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLL 184  
DB 133 ALHGAWTLHSCRLCRLCIFSALYCLPHQTFSHCDLKSFLUSSGARGSRCSIFSLLLLVLC 192  
QY 185 ALL 187  
DB 193 LLL 195

Search completed: September 7, 2006, 12:14:55  
Job time : 175 secs

GenCore version 5.1.9  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: September 7, 2006, 12:12:11 ; Search time 33 Seconds  
(without alignments)  
474.718 Million cell updates/sec

Title: US-10-665-602-2

Perfect score: 1249

Sequence: 1 MTRHHVRLFTVSLALQII.....PSVLQRRRRCGRPLGHLRL 223

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 254368 seqs, 70249769 residues

Total number of hits satisfying chosen parameters: 254368

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Published Applications AA New:  
1: /EMC\_Celerra\_SID33/ptodata/1/pubpaa/US09\_NEW\_PUB.pep.\*  
2: /EMC\_Celerra\_SID33/ptodata/1/pubpaa/US06\_NEW\_PUB.pep.\*  
3: /EMC\_Celerra\_SID33/ptodata/1/pubpaa/US07\_NEW\_PUB.pep.\*  
4: /EMC\_Celerra\_SID33/ptodata/1/pubpaa/US08\_NEW\_PUB.pep.\*  
5: /EMC\_Celerra\_SID33/ptodata/1/pubpaa/PCT\_NEW\_PUB.pep.\*  
6: /EMC\_Celerra\_SID33/ptodata/1/pubpaa/US10\_NEW\_PUB.pep.\*  
7: /EMC\_Celerra\_SID33/ptodata/1/pubpaa/US11\_NEW\_PUB.pep.\*  
8: /EMC\_Celerra\_SID33/ptodata/1/pubpaa/US60\_NEW\_PUB.pep.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	127.5	10.2	713	7	US-11-175-714-5
2	123	9.8	810	6	US-10-781-841-34
3	123	9.8	4391	7	US-11-183-325-56
4	121.5	9.7	2556	7	US-11-264-243-6
5	121	9.7	1198	7	US-11-217-997-14
6	120.5	9.6	720	7	US-11-175-714-4
7	120.5	9.6	2494	6	US-10-669-920-22
8	117.5	9.4	2505	6	US-10-669-920-15
9	117.5	9.4	5738	6	US-10-505-828-150
10	116	9.3	162	7	US-11-217-997-10
11	116	9.3	173	7	US-11-217-997-36
12	115.5	9.2	2556	7	US-11-071-796A-22
13	115	9.2	170	7	US-11-217-997-8
14	114.5	9.2	587	7	US-11-030-653-32
15	114.5	9.2	618	7	US-11-178-724-19
16	114.5	9.2	618	7	US-11-071-796A-18
17	114	9.1	324	6	US-10-669-920-906
18	114	9.1	2451	6	US-10-669-920-908
19	114	9.1	2503	6	US-10-539-328-723
20	111	8.9	723	7	US-11-178-724-18
21	111	8.9	723	7	US-11-071-796A-17
22	111	8.9	729	7	US-11-175-714-8
23	111	8.9	830	7	US-11-175-714-11
24	111	8.9	1953	7	US-11-264-243-16
25	110.5	8.8	1398	7	US-11-217-997-4

Sequence 6, Appli  
Sequence 5, Appli  
Sequence 22, Appli  
Sequence 21, Appli  
Sequence 38, Appli  
Sequence 30, Appli  
Sequence 27, Appli  
Sequence 12, Appli  
Sequence 2, Appli  
Sequence 22, Appli  
Sequence 16, Appli  
Sequence 20, Appli  
Sequence 18, Appli  
Sequence 42, Appli  
Sequence 40, Appli  
Sequence 3263, Ap  
Sequence 37, Appli  
Sequence 8, Appli  
Sequence 7, Appli  
Sequence 12, Appli

## ALIGNMENTS

### RESULT 1

US-11-175-714-5  
; Sequence 5, Application US/11175714  
; Publication No. US20060122373A1  
; GENERAL INFORMATION:  
; APPLICANT: Millennium Pharmaceuticals, Inc.  
; APPLICANT: McCarthy, Sean A.  
; APPLICANT: Gearing, David  
; APPLICANT: Holtzman, Douglas A.  
; APPLICANT: Pan, Yang  
; APPLICANT: Busfield, Samantha J.  
; APPLICANT: Barnes, Thomas M.  
; APPLICANT: Mackay, Charles  
; APPLICANT: Lora, Jose M.  
; TITLE OF INVENTION: DELTA3, FTHMA-070, TANGO85, TANGO77,  
; TITLE OF INVENTION: SPOIL, NEOKINE, TANGO129 AND INTEGRIN ALPHA SUBUNIT PROTEIN  
; TITLE OF INVENTION: AND NUCLEIC ACID MOLECULES AND USES THEREOF  
; FILE REFERENCE: MPI05-0100NMIM  
; CURRENT APPLICATION NUMBER: US/11/175,714  
; CURRENT FILING DATE: 2005-07-05  
; PRIOR APPLICATION NUMBER: US 10/417,719  
; PRIOR FILING DATE: 2003-04-17  
; PRIOR APPLICATION NUMBER: US 09/568,218  
; PRIOR FILING DATE: 2000-05-09  
; PRIOR APPLICATION NUMBER: US 09/872,855  
; PRIOR FILING DATE: 1997-06-11  
; PRIOR APPLICATION NUMBER: US 09/832,633  
; PRIOR FILING DATE: 1997-04-04  
; PRIOR APPLICATION NUMBER: US 10/895,676  
; PRIOR FILING DATE: 2004-07-21  
; PRIOR APPLICATION NUMBER: US 10/105,934  
; PRIOR FILING DATE: 2002-03-25  
; PRIOR APPLICATION NUMBER: US 09/862,972  
; PRIOR FILING DATE: 2001-05-22  
; PRIOR APPLICATION NUMBER: US 09/062,389  
; PRIOR FILING DATE: 1998-04-17  
; PRIOR APPLICATION NUMBER: US 60/062,017  
; PRIOR FILING DATE: 1997-10-10  
; PRIOR APPLICATION NUMBER: US 60/044,746  
; PRIOR FILING DATE: 1997-04-18  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 195  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 5  
; LENGTH: 713  
; TYPE: PRT  
; ORGANISM: Rattus Norvegicus  
; US-11-175-714-5

Query Match	10.2%	Score 127.5;	DB 7;	Length 713;
Best Local Similarity	25.3%	Pred. NO. 0.00074;		
Matches 55; Conservative 11; Mismatches 70; Indels 81; Gaps 9				
Qy	20	INLGNVQREKHNGRGVEVTKATQIKRQSPLNLTSSHFGEVTGSAEGWGPEELPYSTRA	79	
		: :       :		
Dd	419	VDLGNVLCRCQTGFSGRYCEDNVDDCASP-----	449	
Qy	80	FGEASARPRCCRRGGTC---VLGSFCVCPAHFTGRYCEHDQRSECGALBHGAWTLRAC	136	
		::  :: :: : :		
Dd	450	-----CANGGTCRDSVNDFSCTCPPGYTCKNCSPVRCEHAHPCHNGA----TC	494	
Qy	137	H-----LCRCI--FGALHC--LPLOTPTDRCDPKDFLASHAGPS-----AGGAPSL	178	
		::  :: :: : :		
Dd	495	HQRQRYWCECAQGYGGANCQFLDEPPPD-----LIVAAQGSFFVAACGVVLVL	547	
Qy	179	LLLLPCCALLHLRLRPDAPAHPRSILVPSVLQERRPCG	215	
		:: :		
Dd	548	LLLLGCAAVVVCRLLKLOKH-----OPPPP	575	

```

; Publication No. US20060104898A1
;
; GENERAL INFORMATION:
; APPLICANT: Vanderbilt University
; APPLICANT: Hallahan, Dennis E
; APPLICANT: Ou, Shimlan
;
; TITLE OF INVENTION: IN VIVO PANNING FOR LIGANDS TO RADIATION-INDUCED MOLECULES
;
; FILE REFERENCE: 1242/47/2/2 CIP
;
; CURRENT APPLICATION NUMBER: US/11/183,325
;
; CURRENT FILING DATE: 2005-07-15
;
; PRIOR APPLICATION NUMBER: US 60/328123
;
; PRIOR FILING DATE: 2001-10-03
;
; PRIOR APPLICATION NUMBER: US 10/259,087
;
; PRIOR FILING DATE: 2002-09-27
;
; NUMBER OF SEQ ID NOS: 56
;
; SOFTWARE: PatentIn version 3.3
;
; SEQ ID NO 56
;
; LENGTH: 4391
;
; TYPE: prt
;
; ORGANISM: Homo sapiens
;
; PUBLICATION INFORMATION:
;
; DATABASE ACCESSION NUMBER: P98160
;
; DATABASE ENTRY DATE: 2003-02-28
;
; RELEVANT RESIDUES: (1) .. (4391)
;
; US-11-183-325-56

```

US-11-183-323-36  
; Sequence 56, Application US/111833325

Qy 141 CIGFALHCLPLQTPDRCDPKDFLASHAHGSPSAGGASLLLLLPALLHRLRLPDAPAPHR 200  
 Db 1046 CT-----CPQYTGPN-C-QNLVHWCDSPPCKNGG-----KCWQHTQVRCPCPSGT 1091  
 Qy 201 SL-----VPSV-----LQRE-----RPPCGRPGL 219  
 Db 1092 GLYCDVPSVSEVAARQGVQDVVARLQCQHGGL 1122

RESULT 5  
 US-11-217-997-14  
 ; Sequence 14, Application US/11217997  
 ; Publication No. US20060111561A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Valerie L. Gerlach  
 ; APPLICANT: Elma R. Fernandes  
 ; APPLICANT: Richard A. Shimkets  
 ; APPLICANT: Meera Patturajan  
 ; APPLICANT: Vladimir Y. Gusev  
 ; APPLICANT: Stacie (Casman) Navara  
 ; APPLICANT: Velizar T. Tchernev  
 ; APPLICANT: David W. Anderson  
 ; APPLICANT: Xiaojia (Sasha) Guo  
 ; APPLICANT: Luca Rastelli  
 ; APPLICANT: Mei Zhong  
 ; APPLICANT: Muralidhara Padigaru  
 ; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODED THEREBY  
 ; FILE REFERENCE: Cura 551 CIP  
 ; CURRENT APPLICATION NUMBER: US/11/217,997  
 ; CURRENT FILING DATE: 2005-08-31  
 ; PRIOR APPLICATION NUMBER: 10/453,372  
 ; PRIOR FILING DATE: 2003-06-03  
 ; PRIOR APPLICATION NUMBER: 10/055,877  
 ; PRIOR FILING DATE: 2002-01-22  
 ; PRIOR APPLICATION NUMBER: 60/262,892  
 ; PRIOR FILING DATE: 2001-01-19  
 ; PRIOR APPLICATION NUMBER: 60/263,598  
 ; PRIOR FILING DATE: 2001-01-23  
 ; PRIOR APPLICATION NUMBER: 60/263,799  
 ; PRIOR FILING DATE: 2001-01-24  
 ; PRIOR APPLICATION NUMBER: 60/264,117  
 ; PRIOR FILING DATE: 2001-01-25  
 ; PRIOR APPLICATION NUMBER: 60/264,139  
 ; PRIOR FILING DATE: 2001-01-25  
 ; PRIOR APPLICATION NUMBER: 60/264,478  
 ; PRIOR FILING DATE: 2001-01-26  
 ; PRIOR APPLICATION NUMBER: 60/263,351  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: 60/272,870  
 ; PRIOR FILING DATE: 2001-03-02  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 62  
 ; SOFTWARE: Curaseq1 version 0.1  
 ; SEQ ID NO 14  
 ; LENGTH: 1198  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-11-217-997-14

Query Match 9.7%; Score 121; DB 7; Length 1198;  
 Best Local Similarity 30.0%; Pred. No. 0.005;  
 Matches 48; Conservative 14; Mismatches 56; Indels 42; Gaps 10;  
 Qy 83 GASARPC-CRNGTCC-VLGSFVCVCPAHFTGRYCEHD-----QRRSEC-----GALEHGAWT 132  
 Db 992 GDNCRHSCLCQNGCTDPVSGHCACPEGWAGLACECPRDVRAGRHSGGCLNGG--- 1048  
 Qy 133 LRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGGASLLLL----- 181  
 Db 1049 LCDPHTGRCL-----CPAGTGDCKQ-----SHPHGLLEASAAIFLPACGAGLERP 1097  
 Qy 182 LPCALLHRLRLP-----DAPAPHRSLVPSVLQRRRPPCG 215

Db 1098 VPSAAAAARLPLPATTSLGPAAPVPLASLAPAA-SRDVRPGG 1136  
 RESULT 6  
 US-11-175-714-4  
 ; Sequence 4, Application US/11175714  
 ; Publication No. US20060122373A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Millennium Pharmaceuticals, Inc.  
 ; APPLICANT: McCarthy, Sean A.  
 ; APPLICANT: Gearing, David  
 ; APPLICANT: Holtzman, Douglas A.  
 ; APPLICANT: Pan, Yang  
 ; APPLICANT: Busfield, Samantha J.  
 ; APPLICANT: Barnes, Thomas M.  
 ; APPLICANT: Mackay, Charles  
 ; APPLICANT: Lora, Jose M.  
 ; TITLE OF INVENTION: DELTA3, FTMA-070, TANGO85, TANGO77,  
 ; TITLE OF INVENTION: SPOIL, NEOKINE, TANGO129 AND INTEGRIN ALPHA SUBUNIT PROTEIN  
 ; FILE REFERENCE: MPI05-0100NMIM  
 ; CURRENT APPLICATION NUMBER: US/11/175,714  
 ; CURRENT FILING DATE: 2005-07-05  
 ; PRIOR APPLICATION NUMBER: US 10/417,719  
 ; PRIOR FILING DATE: 2003-04-17  
 ; PRIOR APPLICATION NUMBER: US 09/568,218  
 ; PRIOR FILING DATE: 2000-05-09  
 ; PRIOR APPLICATION NUMBER: US 09/872,855  
 ; PRIOR FILING DATE: 1997-06-11  
 ; PRIOR APPLICATION NUMBER: US 09/832,633  
 ; PRIOR FILING DATE: 1997-04-04  
 ; PRIOR APPLICATION NUMBER: US 10/895,676  
 ; PRIOR FILING DATE: 2004-07-21  
 ; PRIOR APPLICATION NUMBER: US 10/105,934  
 ; PRIOR FILING DATE: 2002-03-25  
 ; PRIOR APPLICATION NUMBER: US 09/862,972  
 ; PRIOR FILING DATE: 2001-05-22  
 ; PRIOR APPLICATION NUMBER: US 09/062,389  
 ; PRIOR FILING DATE: 1998-04-17  
 ; PRIOR APPLICATION NUMBER: US 60/062,017  
 ; PRIOR FILING DATE: 1997-10-10  
 ; PRIOR APPLICATION NUMBER: US 60/044,746  
 ; PRIOR FILING DATE: 1997-04-18  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 195  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 4  
 ; LENGTH: 720  
 ; TYPE: PRT  
 ; ORGANISM: Mus Musculus  
 US-11-175-714-4

Query Match 9.6%; Score 120.5; DB 7; Length 720;  
 Best Local Similarity 30.0%; Pred. No. 0.0033;  
 Matches 45; Conservative 8; Mismatches 56; Indels 41; Gaps 8;  
 Qy 91 CRNGTCC---VLGSFVCVCPAHFTGRYCEHDORSECCALEHGAWTLRACH-----LCRC 141  
 Db 449 CANGGTCRDSVNDFTCTCPGYTKNCSAPVSRCEHAPCHNGA-----TCHQGRQRYMCEC 504  
 Qy 142 I--FGALHC---LPLQTPDRCDPKDFLASHAHGSPSAGG-----APSLLLLLPCCA 185  
 Db 505 AQQYGGPNCQFLPEPPP---GPMVVDLSERHMSQGGPPFWAVACAGVVLVLLLLGCA 561  
 Qy 186 LHLRLRDPAPAPHRSLVPSVLQRRRPPCG 215  
 Db 562 AVVVCVRLKLQKH-----QPPPEPCG 582

RESULT 7  
 US-10-669-920-22  
 ; Sequence 22, Application US/10669920  
 ; Publication No. US20060194265A1

```
; SEQ ID NO 15
; LENGTH: 2505
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-669-920-15

Query Match          9.4%; Score 117.5; DB 6; Length 2505;
Best Local Similarity 29.4%; Pred. No. 0.023;
Matches 40; Conservative 12; Mismatches 57; Indels 27; Gaps 8;

QY      87 RPRCCRNGTGVLG---SFCVCPAHTGRCYCEHDDRRSECGALEHGAWTLRAC---HLCLR 140
       |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db      900 RENPCHNGSGCTDGTINTAFCDCLPGFQGFAPCEED--INECNPCQNGA-NCTDCVDSTYCT 956

QY     141 CI--FGALHCLPLQTTPDRCDPKDFLASHAHGPSAGGAPSLLLLLPCALLHRLRPDPDAH 198
       |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db     957 CPVGFGIHC-ENNTPDCTESSCFNG----GTCVDGINSFTCLCPPGFTGSYCQYD--- 1007

QY     199 PRSLVPSVLQRERRPC 214
       |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db    1008 -----VNECDSRPC 1016

RESULT 9
US-10-505-928-150
; Sequence 150, Application US/10505928
; Publication No. US20060088532A1
; GENERAL INFORMATION:
; APPLICANT: Ludwig Institute for Cancer Research et al.
; TITLE OF INVENTION: LYMPHATIC ENDOTHELIAL GENES
; FILE REFERENCE: 28967/39178
; CURRENT APPLICATION NUMBER: US/10/505.928
; CURRENT FILING DATE: 2004-08-27
; PRIOR APPLICATION NUMBER: US 60/363,019
; PRIOR FILING DATE: 2002-03-07
; NUMBER OF SEQ ID NOS: 866
; SOFTWARE: PatentIn 3.2
; SEQ ID NO 150
; LENGTH: 5738
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-505-928-150

Query Match          9.4%; Score 117.5; DB 6; Length 5738;
Best Local Similarity 26.6%; Pred. No. 0.053;
Matches 55; Conservative 6; Mismatches 65; Indels 81; Gaps 11;

QY     59 GEVTGSAGWGPEEPLPY-SPAFGEASARPRCCRNGTGTVLGSFC-----VC---P 106
       |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db    3629 GSVPG-AGGWGPWGPWSHCSRSCGGGLRSRTRACDPPPOGLGDYCSGPRAQGEVCOALP 3697

QY     107 AHFTGRYCEHDDRSECGA-----LEHGAWTLRACHLCRCIFGALHCLPLQT----- 153
       |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db    3688 CPVTNCTAIEGAEYSPCGPFRSCDDLHVCM-----RCQPGC-YCPGGQVLSNSG 3738

QY     154 -----PDRCDPKDFLASHAHGPSAGGAPSLLLLLPCALLHRLRPDPDAHPRSILVPSVLQ 208
       |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db    3739 AICVQPQHCSCLDLLLTGORHHPGA-----RLARPDCGNHCTCL----- 3776

QY     209 RERR-----PCGRP 217
       |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db    3777 -EGRLNCTDLPCPCGGGQSLLHPCCQP 3802

RESULT 10
US-11-217-997-10
; Sequence 10, Application US/11217997
; Publication No. US20060111561A1
; GENERAL INFORMATION:
; APPLICANT: Valerie L. Gerlach
; APPLICANT: Elma R. Fernandes
; APPLICANT: Richard A. Shimkets
; APPLICANT: Meera Patturajan
```

```
; APPLICANT: Vladimir Y. Gusev
; APPLICANT: Stacie (Casman) Navara
; APPLICANT: Velizar T. Tchernev
; APPLICANT: David W. Anderson
; APPLICANT: Xiaojia (Sasha) Guo
; APPLICANT: Luca Rastelli
; APPLICANT: Mei Zhong
; APPLICANT: Muralidhara Padigaru
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODED THEREBY
; CURRENT APPLICATION NUMBER: US/11/217,997
; CURRENT FILING DATE: 2005-08-31
; PRIOR APPLICATION NUMBER: 10/453,372
; PRIOR FILING DATE: 2003-06-03
; PRIOR APPLICATION NUMBER: 10/055,877
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: 60/262,892
; PRIOR FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: 60/263,598
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/263,799
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/264,117
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 60/264,139
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 60/263,799
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/264,478
; PRIOR FILING DATE: 2001-01-26
; PRIOR APPLICATION NUMBER: 60/263,351
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 60/264,139
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 60/272,870
; PRIOR FILING DATE: 2001-03-02
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: Curaseqlist version 0.1
; SEQ ID NO 10
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-217-997-10

Query Match          9.3%; Score 116; DB 7; Length 162;
Best Local Similarity 28.6%; Pred. No. 0.0018;
Matches 42; Conservative 14; Mismatches 41; Indels 50; Gaps 10;

QY 61 VTGSAEGWGP-----EEPLPYSRAPGEGASARPRC-CRNGGTC-VLGSFCVCPAHFTG 111
Db 30 IPASARTEGPVTLSQLACEHPGPPG---FHGAGCGGLCWCHGAPCDPISGRCLCPAGFHG 86
QY 112 RYCEHDORSECCGALEHGAWTLRACHL-CRC-----IFGALHCL-----P 150
Db 87 HFCERDCRQGQGP-----SCTLHDCGGGADCDPVSGQCHCVDGVMGTCTREGGP 137
QY 151 LOTPDRCDPKDFLASHAHGPSAGGAPS 177
Db 138 LRLPEN-----PSLAQG-SAGTLPA 156

RESULT 11
US-11-217-997-36
; Sequence 36, Application US/11217997
; Publication No. US20060111561A1
; GENERAL INFORMATION:
; APPLICANT: Valerie L. Gerlach
; APPLICANT: Elma R. Fernandes
; APPLICANT: Richard A. Shimkets
; APPLICANT: Meera Patturajan
; APPLICANT: Vladimir Y. Gusev
; APPLICANT: Stacie (Casman) Navara
; APPLICANT: Velizar T. Tchernev
; APPLICANT: David W. Anderson
; APPLICANT: Xiaojia (Sasha) Guo
; APPLICANT: Luca Rastelli
```

```
; APPLICANT: Mei Zhong
; APPLICANT: Muralidhara Padigaru
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODED THEREBY
; FILE REFERENCE: Cura 551 CIP
; CURRENT APPLICATION NUMBER: US/11/217,997
; CURRENT FILING DATE: 2005-08-31
; PRIOR APPLICATION NUMBER: 10/453,372
; PRIOR FILING DATE: 2003-06-03
; PRIOR APPLICATION NUMBER: 10/055,877
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: 60/262,892
; PRIOR FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: 60/263,598
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/263,799
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/264,117
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 60/264,139
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 60/264,478
; PRIOR FILING DATE: 2001-01-26
; PRIOR APPLICATION NUMBER: 60/263,351
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 60/272,870
; PRIOR FILING DATE: 2001-03-02
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: Curaseqlist version 0.1
; SEQ ID NO 36
; LENGTH: 173
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-217-997-36

Query Match          9.3%; Score 116; DB 7; Length 173;
Best Local Similarity 28.6%; Pred. No. 0.0019;
Matches 42; Conservative 14; Mismatches 41; Indels 50; Gaps 10;

QY 61 VTGSAEGWGP-----EEPLPYSRAPGEGASARPRC-CRNGGTC-VLGSFCVCPAHFTG 111
Db 39 IPASARTEGPVTLSQLACEHPGPPG---FHGAGCGGLCWCHGAPCDPISGRCLCPAGFHG 95
QY 112 RYCEHDORSECCGALEHGAWTLRACHL-CRC-----IFGALHCL-----P 150
Db 96 HFCERDCRQGQGP-----SCTLHDCGGGADCDPVSGQCHCVDGVMGTCTREGGP 146
QY 151 LOTPDRCDPKDFLASHAHGPSAGGAPS 177
Db 147 LRLPEN-----PSLAQG-SAGTLPA 165

RESULT 12
US-11-071-796A-22
; Sequence 22, Application US/11071796A
; Publication No. US20060140943A1
; GENERAL INFORMATION:
; APPLICANT: CHAMPION, BRIAN ROBERT
; APPLICANT: SOLARI, ROBERTO CELESTE ERCOLE
; APPLICANT: DALLMAN, MARGARET JANE
; APPLICANT: LAMB, JONATHAN ROBERT
; APPLICANT: HOYNE, GERARD FRANCIS
; APPLICANT: BRIEND, EMMANUEL CYRILLE PASCAL
; TITLE OF INVENTION: IMMUNOTHERAPY USING MODULATORS OF NOTCH SIGNALING
; FILE REFERENCE: 674525-2018
; CURRENT APPLICATION NUMBER: US/11/071,796A
; CURRENT FILING DATE: 2005-03-03
; PRIOR APPLICATION NUMBER: PCT/GB03/03874
; PRIOR FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: GB 0220658.9
; PRIOR FILING DATE: 2002-09-05
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 3.3
```

```
; SEQ ID NO 22
; LENGTH: 2556
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: MOD RES
; LOCATION: (891)
; OTHER INFORMATION: Variable amino acid
; US-11-071-796A-22

Query Match          9.2%; Score 115.5; DB 7; Length 2556;
Best Local Similarity 35.6%; Pred. No. 0.035;
Matches 37; Conservative 6; Mismatches 34; Indels 27; Gaps 7;

QY 83 GASARPRCCRGTCVL-----GSCFCVCPAHTGTRYCEHQRSSCGALEHGAWTLRAC 136
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1311 GCKGKP--CKNGGTCVAVSNTARGTCKCPAGFEGATCENDAR--TCG-----SLRCL 1359

QY 137 HLCRCIFG----ALHCLPLQTPDRCDPKDFLASHAHGPSAGGAP 176
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 1360 NGGTCISGRSPSTCLCLGPGTGPPEC---QPPAS---SPCLGGNP 1397

RESULT 13
US-11-217-997-8
; Sequence 8, Application US/11217997
; Publication No. US2006011561A1
; GENERAL INFORMATION:
; APPLICANT: Valerie L. Gerlach
; APPLICANT: Elma R. Fernandes
; APPLICANT: Richard A. Shinkets
; APPLICANT: Meera Patturajan
; APPLICANT: Vladimir Y. Gusev
; APPLICANT: Stacie (Casman) Navara
; APPLICANT: Velizar T. Tchernev
; APPLICANT: David W. Anderson
; APPLICANT: Xiaojia (Sasha) Guo
; APPLICANT: Luca Rastelli
; APPLICANT: Mei Zhong
; APPLICANT: Muralidhara Padigaru
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODED THEREBY
; FILE REFERENCE: Cura 551 CIP
; CURRENT APPLICATION NUMBER: US/11/217,997
; CURRENT FILING DATE: 2005-08-31
; PRIOR APPLICATION NUMBER: 10/453,372
; PRIOR FILING DATE: 2003-06-03
; PRIOR APPLICATION NUMBER: 10/055,877
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: 60/262,892
; PRIOR FILING DATE: 2001-01-19
; PRIOR APPLICATION NUMBER: 60/263,598
; PRIOR FILING DATE: 2001-01-23
; PRIOR APPLICATION NUMBER: 60/263,799
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: 60/264,117
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 60/264,139
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 60/264,478
; PRIOR FILING DATE: 2001-01-26
; PRIOR APPLICATION NUMBER: 60/263,351
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 60/272,870
; PRIOR FILING DATE: 2001-03-02
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: CuraSequelist version 0.1
; SEQ ID NO 8
; LENGTH: 170
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-217-997-8
```

```
Query Match          9.2%; Score 115; DB 7; Length 170;
Best Local Similarity 28.6%; Pred. No. 0.0024;
Matches 42; Conservative 14; Mismatches 41; Indels 50; Gaps 10;

QY 61 VTGSAEGWGP-----EEPLPYSAFEGEGASARPRC--CRNGGTC--VLGSFCVCPAHTG 111
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 30 IPASARTEGVTLSQACEHPGPG---PHGAGRQGLCWCQHGAPCDPISGRCLCPAGFHG 86

QY 112 RYCEHQRSSCGALEHGAWTLRACHL--CRC-----IFGALHCL-----P 150
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 87 HFCRDCRRGQFGP-----SCTLHCDCGGGADCDPVSQGCCHCVDMGPTCREGGP 137

QY 151 LQTPDRCDPKDFLASHAHGPSAGGAPS 177
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 138 LRLPEN-----PSLAQG--SAGTLPA 156

RESULT 14
US-11-030-653-32
; Sequence 32, Application US/11030653
; Publication No. US20060147945A1
; GENERAL INFORMATION:
; APPLICANT: Edmonds, Brian
; APPLICANT: Micanovic, Radmila
; APPLICANT: Ou, Weijia
; APPLICANT: Su, Eric
; APPLICANT: Tschang, Sheng-Hung
; APPLICANT: Wang, He
; TITLE OF INVENTION: Novel secreted proteins and their uses
; FILE REFERENCE: X-14001
; CURRENT APPLICATION NUMBER: US/11/030,653
; CURRENT FILING DATE: 2005-01-06
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 32
; LENGTH: 587
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-030-653-32

Query Match          9.2%; Score 114.5; DB 7; Length 587;
Best Local Similarity 31.6%; Pred. No. 0.0095;
Matches 50; Conservative 8; Mismatches 45; Indels 55; Gaps 13;

QY 89 RC-----CRNGGTCV--LGSP--CVCPAHTGTRYCEHQRSSCGALEHGAWTLRAC----- 136
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 356 RGSLOPCRNGGLCLDLGHALRCRCRAGFAGPRCEHD--LDDCAG-----RACANGGT 405

QY 137 -----HLCRCI--FGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSL--LLLP 183
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 406 CVEGGGNAHRCSCALGFGGRDC-----RERADP-----CAARPCAGGRCYAHFSLVCA 454

QY 184 CALLHRLRLRPDAPHP--RSLVPSVLQRRRPGC--RPG 218
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 455 CAPGYMGARCEFPVHPDGSALPAA-----PPGLRPG 486

RESULT 15
US-11-178-724-19
; Sequence 19, Application US/11178724
; Publication No. US20060128619A1
; GENERAL INFORMATION:
; APPLICANT: CHAMPION, BRIAN R.
; APPLICANT: YOUNG, LESLEY L.
; APPLICANT: MCKENZIE, GRAHAME J.
; TITLE OF INVENTION: THERAPEUTIC USE OF MODULATORS OF NOTCH
; FILE REFERENCE: 674525-2021
; CURRENT APPLICATION NUMBER: US/11/178,724
; CURRENT FILING DATE: 2005-07-11
; PRIOR APPLICATION NUMBER: PCT/GB04/00021
; PRIOR FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: GB 0300428.0
; PRIOR FILING DATE: 2003-01-09
```



**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.9  
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: September 7, 2006, 12:15:10 ; Search time 191 Seconds  
(without alignments)  
533.818 Million cell updates/sec

Title: US-10-665-602-2  
Perfect score: 223  
Sequence: 1 MTRHHVRLFTVSLALQII.....PSVLQRRPCGRPGLGHL 223

Scoring table: OLIGO  
Gapop 60.0 , Gapext 60.0

Searched: 2589679 seqs, 45716429 residues

Word size : 30

Total number of hits satisfying chosen parameters: 15

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

- Database : A\_Geneseq\_8.\*
- 1: Genesecp1980s.\*
  - 2: Genesecp1990s.\*
  - 3: Genesecp2000s.\*
  - 4: Genesecp2001s.\*
  - 5: Genesecp2002s.\*
  - 6: Genesecp2003as.\*
  - 7: Genesecp2003bs.\*
  - 8: Genesecp2004s.\*
  - 9: Genesecp2005s.\*
  - 10: Genesecp2006s.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	223	100.0	223	8	ADO05060 Human cri
2	223	100.0	229	4	AAU18122 Novel hum
3	223	100.0	229	4	AAU17028 Human nov
4	223	100.0	229	4	ABB10300 Human cdn
5	223	100.0	229	4	AAU19904 Novel hum
6	223	100.0	229	5	ABJ05749 Novel hum
7	223	100.0	229	5	ABP66887 Human pol
8	187	83.9	223	5	ABB90336 Human pol
9	187	83.9	223	6	ABU56711 Lung canc
10	187	83.9	223	7	ADN39104 Cancer/an
11	187	83.9	223	7	ADN39975 Cancer/an
12	187	83.9	223	9	ADY85963 Human Cri
13	187	83.9	231	4	AAU16957 Human nov
14	149	66.8	230	2	AAW09111 Human cri
15	145	65.0	223	5	AAG77914 Human cry

ALIGNMENTS

RESULT 1  
ADO05060  
ID ADO05060 standard; protein; 223 AA.

XX ADO05060;  
AC AC  
DT 29-JUL-2004 (first entry)  
XX Human criptin growth factor (CGF) protein.  
XX  
KW Criptin growth factor; CGF; wound healing; tissue regeneration;  
KW Implant fixation; angiogenesis; neoplasia; tumour; gene therapy; human.  
XX  
OS Homo sapiens.  
XX  
PN US2004086967-A1.  
XX  
PD 06-MAY-2004.  
XX  
PF 22-SEP-2003; 2003US-00665602.  
XX  
PR 06-JUN-1995; 95US-00471371.  
PR 09-SEP-1999; 99US-00393023.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Meissner PS, Coleman TA;  
XX  
DR WPI; 2004-356201/33.  
DR N-PSDB; ADO05059.  
XX  
PT New human polynucleotides encoding human criptin growth factor  
PT polypeptides, useful for wound healing or tissue regeneration,  
PT stimulating implant fixation and angiogenesis, and for treating and/or  
PT preventing tumor.  
XX  
PS Claim 12; SEQ ID NO 2; 19pp; English.  
XX  
CC The invention provides criptin growth factor (CGF) polypeptides and their  
CC encoding polynucleotides. The invention is useful for wound healing and  
CC tissue regeneration, stimulating implant fixation, angiogenesis and for  
CC treating and preventing neoplasia such as tumour. The invention is also  
CC useful in gene therapy. The present sequence is human criptin growth  
CC factor (CGF) protein.  
XX  
SQ Sequence 223 AA;  
Query Match 100.0%; Score 223; DB 8; Length 223;  
Best Local Similarity 100.0%; Pred. No. 1.4e-195; Indels 0; Gaps 0;  
Matches 223; Conservative 0; Mismatches 0;  
QY 1 MTRHHVRLFTVSLALQIIINLGNSTYQREKHNGRGVTKVATQKHRSPLNWTSSHFG 60  
DB 1 MTRHHVRLFTVSLALQIIINLGNSTYQREKHNGRGVTKVATQKHRSPLNWTSSHFG 60  
QY 61 VTGSAGWGPEEPPLYSRAFGEASARPCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 61 VTGSAGWGPEEPPLYSRAFGEASARPCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
QY 121 SECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
DB 121 SECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
QY 181 LIPCALLHRLLRDPADAPHRPSLVPSVLQRRRRCGRPGLGHL 223  
DB 181 LIPCALLHRLLRDPADAPHRPSLVPSVLQRRRRCGRPGLGHL 223  
RESULT 2  
AAU18122  
ID AAU18122 standard; protein; 229 AA.  
XX  
AC AAU18122;  
XX  
DT 21-NOV-2001 (first entry)  
XX

DE Novel human uterine motility-association polypeptide #29.  
XX  
KW Human; uterine motility-association disorder; uterus; pregnancy; labour;  
KM menstrual cycle; gene therapy.  
OS  
XX Homo sapiens.  
XX W020015201-A1.  
PN  
XX  
XX 02-AUG-2001.  
XX  
XX 17-JAN-2001; 2001WO-US001317.  
XX  
XX 31-JAN-2000; 2000US-0179065P.  
PR 04-FEB-2000; 2000US-0180628P.  
PR 24-FEB-2000; 2000US-0184664P.  
PR 02-MAR-2000; 2000US-0186350P.  
PR 16-MAR-2000; 2000US-0189874P.  
PR 17-MAR-2000; 2000US-0190076P.  
PR 18-APR-2000; 2000US-0198123P.  
PR 19-MAY-2000; 2000US-0205515P.  
PR 07-JUN-2000; 2000US-0209467P.  
PR 28-JUN-2000; 2000US-0214886P.  
PR 30-JUN-2000; 2000US-0215135P.  
PR 07-JUL-2000; 2000US-0216647P.  
PR 07-JUL-2000; 2000US-0216880P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218290P.  
PR 26-JUL-2000; 2000US-0220963P.  
PR 26-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225213P.  
PR 14-AUG-2000; 2000US-0225214P.  
PR 14-AUG-2000; 2000US-0225366P.  
PR 14-AUG-2000; 2000US-0225467P.  
PR 14-AUG-2000; 2000US-0225468P.  
PR 14-AUG-2000; 2000US-0225270P.  
PR 14-AUG-2000; 2000US-0225447P.  
PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 14-AUG-2000; 2000US-0225759P.  
PR 18-AUG-2000; 2000US-0226279P.  
PR 22-AUG-2000; 2000US-0226681P.  
PR 22-AUG-2000; 2000US-0226868P.  
PR 23-AUG-2000; 2000US-0227182P.  
PR 23-AUG-2000; 2000US-0227009P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 06-SEP-2000; 2000US-0230437P.  
PR 06-SEP-2000; 2000US-0230438P.  
PR 08-SEP-2000; 2000US-0231242P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231244P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 08-SEP-2000; 2000US-0231414P.  
PR 08-SEP-2000; 2000US-0232080P.  
PR 08-SEP-2000; 2000US-0232081P.  
PR 14-SEP-2000; 2000US-0231968P.  
PR 14-SEP-2000; 2000US-0232397P.  
PR 14-SEP-2000; 2000US-0232398P.  
PR 14-SEP-2000; 2000US-0232399P.  
PR 14-SEP-2000; 2000US-0232400P.  
PR 14-SEP-2000; 2000US-0232401P.  
PR 14-SEP-2000; 2000US-0233063P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 14-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 25-SEP-2000; 2000US-0234998P.  
PR 26-SEP-2000; 2000US-0235484P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241787P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.  
PR 08-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.  
PR 17-NOV-2000; 2000US-0249244P.  
PR 17-NOV-2000; 2000US-0249245P.  
PR 17-NOV-2000; 2000US-0249246P.  
PR 17-NOV-2000; 2000US-0249247P.  
PR 17-NOV-2000; 2000US-0249297P.  
PR 17-NOV-2000; 2000US-0249299P.  
PR 17-NOV-2000; 2000US-0249300P.  
PR 01-DEC-2000; 2000US-0250160P.  
PR 05-DEC-2000; 2000US-0250391P.  
PR 05-DEC-2000; 2000US-0251030P.  
PR 05-DEC-2000; 2000US-0251988P.  
PR 05-DEC-2000; 2000US-0256719P.  
PR 06-DEC-2000; 2000US-0251479P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
PR 08-DEC-2000; 2000US-0251989P.

```
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Barash SC, Ruben SM;
XX
XX WPI; 2001-488777/53.
XX
XX N-PSDB; AAS28964.
XX
XX New nucleic acid molecules encoding 49 human secreted proteins for
PT diagnosing, preventing, treating or ameliorating medical conditions and
PT used as food additives or preservatives.
XX
XX Claim 11; SEQ ID NO 98; 524pp; English.
XX
XX The present invention relates to the isolation of novel human uterine
CC motility-association polypeptides, and cDNA (AAS28936-AAS28994) and
CC genomic sequences encoding for these polypeptides. The sequences of the
CC invention are useful in the diagnosis, treatment, prevention and/or
CC prognosis of diseases associated with uterine motility such as pregnancy
CC and labour, and menstrual disorders. The polynucleotide sequences of the
CC invention are also useful in gene therapy. AAU18094-AAU18152 represent
CC novel human uterine motility-association polypeptides. Note: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 229 AA;
SQ
Query Match 100.0%; Score 223; DB 4; Length 229;
Best Local Similarity 100.0%; Pred. No. 1.5e-195;
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTRWHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKRPQLNWTSSHFE 60
DB 7 MTRWHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKRPQLNWTSSHFE 66
QY 61 VTGSAEGWGPEEPLPYSRAGEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQR 120
DB 67 VTGSAEGWGPEEPLPYSRAGEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQR 126
QY 121 SECCALHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGGAPSLLL 180
DB 127 SECCALHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGGAPSLLL 186
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRPPCGRPLGLHRL 223
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRPPCGRPLGLHRL 229
RESULT 3
AAU17028
ID AAU17028 standard; protein; 229 AA.
XX
XX AAU17028;
AC
XX
XX 07-NOV-2001 (first entry)
DT
XX
XX Human novel secreted protein, SEQ ID 269.
DE
XX
XX Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;
KW cardiant; vasotropic; cerebroprotective; neurotropic; neuroprotective;
KW antibacterial; virucide; fungicide; ophthalmologic; vulnerary;
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW cerebral ischaemia; angiogenesis; nervous system disorder;
KW Alzheimer's disease; infection; ocular disorder; corneal infection;
KW wound healing; epithelial cell proliferation; skin ageing; food additive;
KW preservative; antiproliferative.
XX
XX Homo sapiens.
OS
```

```
XX
PN WO200155441-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US001320.
XX
XX 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214866P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
```

```

PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239355P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249257P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 06-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251889P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0255967P.
(PHUMA-) HUMAN GENOME SCI INC.
XX

PI Rosen CA, Barash SC, Ruben SM;
XX WPI; 2001-476222/51.
DR N-PSDB; AAS26933.
XX
XX Novel polypeptides and polynucleotides useful as diagnostic reagents to
PT diagnose diseases or disorders associated with aberrant expression or
PT activity of polypeptides, for treating blood clotting disorder,
PT hemophilia.
XX
XX Claim 11; SEQ ID NO 269; 601pp; English.
XX
XX The invention relates to isolated nucleic acid molecules and their
CC encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbant assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC to prevent skin aging due to sunburn, to maintain organs tissues, to
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
CC

Query Match 100.0%; Score 223; DB 4; Length 229;
Best Local Similarity 100.0%; Pred. No. 1.5e-195;
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MTWRHHVRLFTVSLALQIINLNSYQREKHNGRGGEVTKVATQKHQSPLNWTSHFGE 60
DB 7 MTWRHHVRLFTVSLALQIINLNSYQREKHNGRGGEVTKVATQKHQSPLNWTSHFGE 66
QY 61 VTGSAEGWGPEBPLPYSRAFEGGASAPRCCRNNGTCTVLGSCFCVCPAHFTGTYCEHDQRR 120
DB 67 VTGSAEGWGPEBPLPYSRAFEGGASAPRCCRNNGTCTVLGSCFCVCPAHFTGTYCEHDQRR 126
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLOTDPDRCDPKDFLASHAHGPSAGAPSLLL 180
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLOTDPDRCDPKDFLASHAHGPSAGAPSLLL 186
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPFCGRPGLGHLR 223
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPFCGRPGLGHLR 229

RESULT 4
ABB10300
ID ABB10300 standard; protein; 229 AA.
XX
XX ABB10300;
AC
XX
DT 10-JAN-2002 (first entry)
XX
DE Human cDNA SEQ ID NO: 608.
XX
XX Human; gene therapy; neural disorder; immune system disorder;
KW muscular disorder; reproductive disorder; gastrointestinal disorder;
KW pulmonary disorder; cardiovascular disorder; renal disorder;
KW proliferative disorder; inflammation.
XX
XX Homo sapiens.
OS
```

XX WO200154474-A2.  
PN 27-SEP-2000; 2000US-0235836P.  
XX 29-SEP-2000; 2000US-0236327P.  
XX 29-SEP-2000; 2000US-0236367P.  
PD 29-SEP-2000; 2000US-0236368P.  
XX 29-SEP-2000; 2000US-0236369P.  
XX 29-SEP-2000; 2000US-0236370P.  
XX 02-OCT-2000; 2000US-0236802P.  
XX 02-OCT-2000; 2000US-0237037P.  
XX 02-OCT-2000; 2000US-0237038P.  
XX 02-OCT-2000; 2000US-0237039P.  
XX 02-OCT-2000; 2000US-0237040P.  
XX 13-OCT-2000; 2000US-0239935P.  
XX 13-OCT-2000; 2000US-0239937P.  
XX 20-OCT-2000; 2000US-0240960P.  
XX 20-OCT-2000; 2000US-0241221P.  
XX 20-OCT-2000; 2000US-0241785P.  
XX 20-OCT-2000; 2000US-0241786P.  
XX 20-OCT-2000; 2000US-0241787P.  
XX 20-OCT-2000; 2000US-0241808P.  
XX 20-OCT-2000; 2000US-0241809P.  
XX 20-OCT-2000; 2000US-0241826P.  
XX 01-NOV-2000; 2000US-024617P.  
XX 08-NOV-2000; 2000US-0246474P.  
XX 08-NOV-2000; 2000US-0246475P.  
XX 08-NOV-2000; 2000US-0246476P.  
XX 08-NOV-2000; 2000US-0246477P.  
XX 08-NOV-2000; 2000US-0246478P.  
XX 08-NOV-2000; 2000US-0246523P.  
XX 08-NOV-2000; 2000US-0246524P.  
XX 08-NOV-2000; 2000US-0246525P.  
XX 08-NOV-2000; 2000US-0246526P.  
XX 08-NOV-2000; 2000US-0246527P.  
XX 08-NOV-2000; 2000US-0246528P.  
XX 08-NOV-2000; 2000US-0246532P.  
XX 08-NOV-2000; 2000US-0246609P.  
XX 08-NOV-2000; 2000US-0246610P.  
XX 08-NOV-2000; 2000US-0246611P.  
XX 08-NOV-2000; 2000US-0246613P.  
XX 17-NOV-2000; 2000US-0249207P.  
XX 17-NOV-2000; 2000US-0249208P.  
XX 17-NOV-2000; 2000US-0249209P.  
XX 17-NOV-2000; 2000US-0249210P.  
XX 17-NOV-2000; 2000US-0249211P.  
XX 17-NOV-2000; 2000US-0249212P.  
XX 17-NOV-2000; 2000US-0249213P.  
XX 17-NOV-2000; 2000US-0249214P.  
XX 17-NOV-2000; 2000US-0249215P.  
XX 17-NOV-2000; 2000US-0249216P.  
XX 17-NOV-2000; 2000US-0249217P.  
XX 17-NOV-2000; 2000US-0249218P.  
XX 17-NOV-2000; 2000US-0249244P.  
XX 17-NOV-2000; 2000US-0249245P.  
XX 17-NOV-2000; 2000US-0249264P.  
XX 17-NOV-2000; 2000US-0249265P.  
XX 17-NOV-2000; 2000US-0249297P.  
XX 17-NOV-2000; 2000US-0249299P.  
XX 17-NOV-2000; 2000US-0249300P.  
XX 01-DEC-2000; 2000US-0250160P.  
XX 01-DEC-2000; 2000US-0250391P.  
XX 05-DEC-2000; 2000US-0251030P.  
XX 05-DEC-2000; 2000US-0251988P.  
XX 05-DEC-2000; 2000US-0256719P.  
XX 08-DEC-2000; 2000US-0251479P.  
XX 08-DEC-2000; 2000US-0251856P.  
XX 08-DEC-2000; 2000US-0251868P.  
XX 08-DEC-2000; 2000US-0251869P.  
XX 08-DEC-2000; 2000US-0251989P.  
XX 08-DEC-2000; 2000US-0251990P.  
XX 11-DEC-2000; 2000US-0254097P.  
XX 05-JAN-2001; 2001US-0259678P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA  
XX

```
PI Rosen CA, Barash SC, Ruben SM;
XX WPI; 2001-476161/51.
DR N-PSDB; ABA06522.
XX
PT Isolated nucleic acid molecule encoding an inflammation-associated
PT polypeptide is used in preventing, treating or ameliorating a medical
PT condition.
XX
XX Claim 11; SEQ ID NO 608; 859pp + Sequence Listing; English.
PS
PS The present invention provides human cDNAs, proteins and related genomic
CC DNAs. These can be used in the treatment of neural, immune system,
CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
CC renal and proliferative disorders and inflammation. The present sequence
CC is a protein of the invention
XX
SQ Sequence 229 AA;

Query Match 100.0%; Score 223; DB 4; Length 229;
Best Local Similarity 100.0%; Pred. No. 1.5e-195;
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTRHRVRLFTVSLALQIINLNSYQREKHNGRGVTKVATQKHQSPLNWTSHFGE 60
Db 7 MTRHRVRLFTVSLALQIINLNSYQREKHNGRGVTKVATQKHQSPLNWTSHFGE 66

Qy 61 VTGSAEGWGPEEPLPYSRAFGEASARPCRCRNGGTCVLGSCFVCPAFTGRYCEHDQRR 120
Db 67 VTGSAEGWGPEEPLPYSRAFGEASARPCRCRNGGTCVLGSCFVCPAFTGRYCEHDQRR 126

Qy 121 SECGALEHGAWTURACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGAPSLLL 180
Db 127 SECGALEHGAWTURACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGAPSLLL 186

Qy 181 LLPCALLHRLRPDAPAHPSRLVPSVLQRRRRCRPGGLGHLR 223
Db 187 LLPCALLHRLRPDAPAHPSRLVPSVLQRRRRCRPGGLGHLR 229

RESULT 5
AAU19904
ID AAU19904 standard; protein; 229 AA.
XX
AC AAU19904;
DT
DT 06-DEC-2001 (first entry)
XX
DE Novel human calcium-binding protein #13.
XX
KW Human; calcium-binding protein; calcium flux; neurological disease;
KW immune dysfunction; digestive disorder; neoplastic disease;
KW blood disorder; infectious disease; gene therapy; immunosuppressive;
KW antiarthritic; cytostatic; vasotropic; antibacterial; nootropic;
KW virucide.
XX
XX Homo sapiens.
XX
XX WO200155304-A2.
XX
PD 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US001302.
XX
XX 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235634P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
```

20-OCT-2000; 2000US-0241786P.  
20-OCT-2000; 2000US-0241787P.  
20-OCT-2000; 2000US-0241808P.  
20-OCT-2000; 2000US-0241809P.  
20-OCT-2000; 2000US-0241826P.  
01-NOV-2000; 2000US-0244617P.  
08-NOV-2000; 2000US-0246474P.  
08-NOV-2000; 2000US-0246475P.  
08-NOV-2000; 2000US-0246476P.  
08-NOV-2000; 2000US-0246477P.  
08-NOV-2000; 2000US-0246478P.  
08-NOV-2000; 2000US-0246523P.  
08-NOV-2000; 2000US-0246524P.  
08-NOV-2000; 2000US-0246525P.  
08-NOV-2000; 2000US-0246526P.  
08-NOV-2000; 2000US-0246527P.  
08-NOV-2000; 2000US-0246528P.  
08-NOV-2000; 2000US-0246532P.  
08-NOV-2000; 2000US-0246609P.  
08-NOV-2000; 2000US-0246610P.  
08-NOV-2000; 2000US-0246611P.  
08-NOV-2000; 2000US-0246613P.  
17-NOV-2000; 2000US-0249207P.  
17-NOV-2000; 2000US-0249208P.  
17-NOV-2000; 2000US-0249209P.  
17-NOV-2000; 2000US-0249210P.  
17-NOV-2000; 2000US-0249211P.  
17-NOV-2000; 2000US-0249212P.  
17-NOV-2000; 2000US-0249213P.  
17-NOV-2000; 2000US-0249214P.  
17-NOV-2000; 2000US-0249215P.  
17-NOV-2000; 2000US-0249216P.  
17-NOV-2000; 2000US-0249217P.  
17-NOV-2000; 2000US-0249218P.  
17-NOV-2000; 2000US-0249244P.  
17-NOV-2000; 2000US-0249245P.  
17-NOV-2000; 2000US-0249264P.  
17-NOV-2000; 2000US-0249265P.  
17-NOV-2000; 2000US-0249297P.  
17-NOV-2000; 2000US-0249299P.  
17-NOV-2000; 2000US-0249300P.  
01-DEC-2000; 2000US-0250160P.  
01-DEC-2000; 2000US-0250391P.  
05-DEC-2000; 2000US-0251030P.  
05-DEC-2000; 2000US-0251988P.  
05-DEC-2000; 2000US-0256719P.  
06-DEC-2000; 2000US-0251479P.  
08-DEC-2000; 2000US-0251856P.  
08-DEC-2000; 2000US-0251858P.  
08-DEC-2000; 2000US-0251859P.  
08-DEC-2000; 2000US-0251869P.  
08-DEC-2000; 2000US-0251989P.  
08-DEC-2000; 2000US-0251990P.  
11-DEC-2000; 2000US-0254037P.  
05-JAN-2001; 2001US-02559678P.  
(HUMA-) HUMAN GENOME SCI INC.  
Rosen CA, Barash SC, Ruben SM;  
WPI; 2001-465568/50.  
N-PSDB; AAS31589.  
Isolated nucleic acid molecule encoding a calcium-binding protein is used in preventing, treating or ameliorating a medical condition.  
Claim 11; SEQ ID NO 101; 542pp; English.  
The present invention relates to the isolation of novel human calcium-binding proteins, and cDNA (AAS31577-AAS31654) and genomic sequences encoding for these proteins. The sequences of the invention are useful in the diagnosis, prevention and/or prognosis of diseases associated with aberrant calcium flux. Such disorders include neurological diseases (e.g. amyotrophic lateral sclerosis, ALS), immune dysfunction (e.g. severe combined immunodeficiency, SCID), digestive disorders (e.g. irritable bowel syndrome, IBS), neoplastic disease (e.g. cancer), blood disorders (e.g. haemophilia), and/or infectious disease (e.g. acquired immunodeficiency syndrome, AIDS). The novel calcium-binding proteins are also useful as screening tools to identify antagonists and/or agonists that may enhance or inhibit activities mediated by calcium-binding proteins. The polynucleotides of the invention are also useful in gene therapy. AAU19892-AAU19969 represent the novel human calcium-binding proteins. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pat\_sequences  
XX Sequence 229 AA;  
SQ  
Query Match 100.0%; Score 223; DB 4; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-195;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTWRHVRLLFTVSLALQIINLGNISYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGE 60  
DB 7 MTWRHVRLLFTVSLALQIINLGNISYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFGE 66  
QY 61 VTGSAEGWGPEEPLPYSRAFEGEGASAPRCRCRNGGTCVLGSCVCPAHFTGRYCEHDORR 120  
DB 67 VTGSAEGWGPEEPLPYSRAFEGEGASAPRCRCRNGGTCVLGSCVCPAHFTGRYCEHDORR 126  
QY 121 SEGGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180  
DB 127 SEGGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 186  
QY 181 LLPCALLHRLLRDPAPAHPRSLVPSVLQRRRRCGRPGLGHLRL 223  
DB 187 LLPCALLHRLLRDPAPAHPRSLVPSVLQRRRRCGRPGLGHLRL 229  
RESULT 6  
ABJ05749  
ID ABJ05749 standard; protein; 229 AA.  
XX  
AC ABJ05749;  
XX  
DT 14-NOV-2002 (first entry)  
XX  
DE Novel human protein SEQ ID No 98.  
XX  
KW Immunostimulant; antirheumatic; antiarthritic; neuroprotective;  
KW antiallergic; antidiabetic; antiaschmatic; antiinflammatory; nootropic;  
KW immunosuppressive; anticoagulant; thrombolytic; antiatherosclerotic;  
KW cytostatic; nephrotropic; antiparkinsonian; gynecological; virucide;  
KW antibacterial; antiarrhythmic; fungicide; HCFAT05; HWAAB95; HTNBM01;  
KW immunodeficiency; autoimmune disorder; allergic reaction; cardiovascular;  
KW inflammatory condition; graft-versus-host disease; reproductive system;  
KW blood-related disorder; hyperproliferative; endocrine; neurological;  
KW respiratory; renal; infectious disease; gastrointestinal; gene therapy;  
KW neuronal growth; neuronal disorder; neuro-degenerative condition;  
KW keratinocyte growth; human.  
XX  
OS Homo sapiens.  
XX  
PN US2002086330-A1.  
XX  
PD 04-JUL-2002.  
XX  
PF 17-JAN-2001; 2001US-00764893.  
XX  
PR 31-JAN-2000; 2000US-0179065P.  
PR 04-FEB-2000; 2000US-0180628P.  
PR 26-JUN-2000; 2000US-0214886P.  
PR 07-JUL-2000; 2000US-0216647P.  
PR 07-JUL-2000; 2000US-0216880P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218290P.

PR 26-JUL-2000; 2000US-0220963P.  
PR 28-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225267P.  
PR 14-AUG-2000; 2000US-0225268P.  
PR 14-AUG-2000; 2000US-0225270P.  
PR 14-AUG-2000; 2000US-0225477P.  
PR 14-AUG-2000; 2000US-0225575P.  
PR 22-AUG-2000; 2000US-0225758P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 23-SEP-2000; 2000US-0234997P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239335P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 17-NOV-2000; 2000US-0249299P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
XX  
PA (ROSE/) ROSEN C A.  
PA (RUBE/) RUBEN S M.  
PA (BARA/) BARASH S C.  
XX  
PI Rosen CA, Ruben SM, Barash SC;  
XX  
XX WPI; 2002-665432/71.  
DR  
XX  
XX Novel polypeptide useful for diagnosis, prognosis, prevention, and  
PT treatment of immune, hyperproliferative, renal, respiratory,  
PT cardiovascular, reproductive, endocrine, gastrointestinal and  
PT neurological disorders.  
XX  
PS Disclosure; Page 268-269; 335pp; English.  
XX  
XX The invention relates to an isolated polypeptide comprising a sequence at  
CC least 90% identical to a full length protein sequence selected from 55  
CC sequences given in the specification such as a sequence of 163, 74 or 140  
CC amino acids fully defined in the specification, or the encoding sequence  
CC contained in 49 cDNA clones given in specification e.g. HCFAR05, HMAAE95  
CC or HTNBM01. The protein and its encoding nucleic acid are useful for  
CC diagnosing a pathological condition or susceptibility to a pathological  
CC condition in a subject and for preventing, treating or ameliorating a  
CC medical condition. The protein, its encoding nucleic acid and an isolated  
CC antibody that can bind to the protein are useful in treating, preventing,  
CC diagnosing and/or prognosing immunodeficiencies, autoimmune disorders,  
CC allergic reactions and conditions, inflammatory conditions, graft-versus-  
CC host disease, blood-related disorders, hyperproliferative disorders,  
CC renal disorders, cardiovascular disorders, respiratory disorders,  
CC neurological disorders, endocrine disorders, reproductive system

CC disorders, infectious diseases, and gastrointestinal disorders. The  
CC protein of the invention is useful to stimulate neuronal growth and to  
CC treat, prevent, and/or diagnose neuronal damage which occurs in certain  
CC neuronal disorders or neuro-degenerative conditions, for stimulating  
CC keratinocyte growth, to prevent hair loss, to modulate mammalian  
CC characteristics such as body height, weight, hair color, and to increase  
CC or decrease storage capabilities, fat content, lipid, protein,  
CC carbohydrate, vitamins, minerals, cofactors or other nutritional  
CC components. The nucleic acid of the invention can be used in gene  
CC therapy. This sequence represents a novel human protein of the invention  
XX  
SQ Sequence 229 AA;  
Query Match 100.0%; Score 223; DB 5; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-195; Indels 0; Gaps 0;  
Matches 223; Conservative 0; Mismatches 0;  
QY 1 MTRRHVRLFTVSLALQIINLNSYQREKHNGRGGEVTKVATQKHQSPLNWTSHHFGE 60  
DB 7 MTRRHVRLFTVSLALQIINLNSYQREKHNGRGGEVTKVATQKHQSPLNWTSHHFGE 66  
QY 61 VTGSAEGWGPEEPLPYSRAPFGGASARPRCCRNNGGTCVLGSCVCVPAHFTGRYCEHDQRR 120  
DB 67 VTGSAEGWGPEEPLPYSRAPFGGASARPRCCRNNGGTCVLGSCVCVPAHFTGRYCEHDQRR 126  
QY 121 SECGALEHGCAWTIRACHLCRCIFGALHCLPLOTPOKCDPKDFLASHAHGSPSAGAPSLLL 180  
DB 127 SECGALEHGCAWTIRACHLCRCIFGALHCLPLOTPOKCDPKDFLASHAHGSPSAGAPSLLL 186  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPRPCGRPGLGHRL 223  
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPRPCGRPGLGHRL 229  
RESULT 7  
ABP66887  
ID ABP66887 standard; protein; 229 AA.  
XX  
AC ABP66887;  
XX  
XX 09-DEC-2002 (first entry)  
XX  
XX Human polypeptide SEQ ID NO 608.  
XX  
XX Human; nootropic; neuroprotective; cytostatic; dermatological; virucide;  
KW immunosuppressive; antiinflammatory; anti-HIV; antibacterial; vulnerary;  
KW antiparkinsonian; antisickling; antianemic; antiarthritic; cancer;  
KW antirheumatic; hepatotropic; cerebroprotective; antiinflammatory;  
KW antiallergic; antidiabetic; antitumor; anticonvulsant; antifungal;  
KW antiparasitic; cardiant; immune disorder; cardiovascular disorder;  
KW neurological disease; infection; nephrotropic; gene therapy; vaccine.  
XX  
XX Homo sapiens.  
OS  
XX  
PN US2002090672-A1.  
XX  
XX 11-JUL-2002.  
PD  
XX 17-JAN-2001; 2001US-00764853.  
XX  
XX 31-JAN-2000; 2000US-0179065P.  
PR 04-FEB-2000; 2000US-0180628P.  
PR 28-JUN-2000; 2000US-0214886P.  
PR 07-JUL-2000; 2000US-0216647P.  
PR 07-JUL-2000; 2000US-0216880P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218290P.  
PR 26-JUL-2000; 2000US-0220963P.  
PR 26-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225267P.

PR 14-AUG-2000; 2000US-0225268P.  
PR 14-AUG-2000; 2000US-0225270P.  
PR 14-AUG-2000; 2000US-0225447P.  
PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 22-AUG-2000; 2000US-0226868P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 17-NOV-2000; 2000US-0249259P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
XX (ROSE/) ROSEN C A.  
PA (RUBE/) RUBEN S M.  
PA (BARA/) BARASH S C.  
XX  
XX Rosen CA, Ruben SM, Barash SC;  
XX  
XX WPI: 2002-681727/73.  
DR N-PSDB; ABV83859.  
XX  
XX Novel polypeptide useful for diagnosis, prognosis, prevention, and  
PT treatment of immune, hyperproliferative, renal, respiratory,  
PT cardiovascular, reproductive, endocrine, gastrointestinal and  
PT neurological disorders.  
XX  
XX Claim 11; SEQ ID NO 608; 369pp + Sequence Listing; English.  
PS  
XX The invention relates to novel genes (ABV83682-ABV84101) and proteins  
CC (ASP66710-ABP67129) useful for preventing, treating or ameliorating  
CC medical conditions e.g. by protein or gene therapy. The genes are  
CC isolated from a range of human tissues disclosed in the specification.  
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in  
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and  
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,  
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune  
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic  
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,  
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)  
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing  
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)  
CC infectious diseases such as viral, bacterial, fungal and parasitic  
CC infections. Note: The sequence data for this patent did not form part of  
CC the printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
XX Sequence 229 AA;

Query Match 100.0%; Score 223; DB 5; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-195;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 MTWRHHVRLFTVSLALQIINLGNYSYQREKHNGRGEVTKVATOKHQPSPLNWTSSHFGE 60  
Db 7 MTWRHHVRLFTVSLALQIINLGNYSYQREKHNGRGEVTKVATOKHQPSPLNWTSSHFGE 66  
Qy 61 VTSAEGWGPEEPLPYSRAFEGASARPCRCNGTCTVLGSCFVCVCPAHFTGRYCEHDORR 120  
Db 67 VTSAEGWGPEEPLPYSRAFEGASARPCRCNGTCTVLGSCFVCVCPAHFTGRYCEHDORR 126  
Qy 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDFKFLASHAHGSPAGAPSLLL 180  
Db 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDFKFLASHAHGSPAGAPSLLL 186  
Qy 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPCGRPLGHLRL 223  
Db 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRPCGRPLGHLRL 229  
RESULT 8  
ABB90336  
ID ABB90336 standard; protein; 223 AA.  
XX AC ABB90336;  
XX  
XX 24-MAY-2002 (first entry)  
XX Human polypeptide SEQ ID NO 2712.  
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;  
XX antiallergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;  
XX vulnary; anticonvulsant; antibacterial; antifungal; antiparasitic;  
XX cardiact; gene therapy; cancer; immune disorder; cardiovascular disorder;  
XX neurological disease; infection; human; secreted protein.  
XX Homo sapiens.  
XX WO200190304-A2.  
XX 29-NOV-2001.  
XX 18-MAY-2001; 2001WO-US016450.  
XX 19-MAY-2000; 2000US-0205515P.  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX Birse CE, Rosen CA;  
XX  
XX WPI: 2002-122018/16.  
DR N-PSDB; ABL90745.  
XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and  
PT prevention of neural, immune system, muscular, reproductive,  
PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative  
PT disorders.  
XX  
XX Claim 11; SEQ ID NO 2712; 2081pp + Sequence Listing; English.  
XX  
XX The invention relates to novel genes (ABL90449-ABL90853) and proteins  
CC (ABB9040-ABB90444) useful for preventing, treating or ameliorating  
CC medical conditions e.g. by protein or gene therapy. The genes are  
CC isolated from a range of human tissues disclosed in the specification.  
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in  
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and  
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,  
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune  
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic  
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,  
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)

CC	cardiovascular disorders such as myocardial ischaemias; (d) wound healing
CC	; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC	infectious diseases such as viral, bacterial, fungal and parasitic
CC	infections. Note: The sequence data for this patent did not form part of
CC	the printed specification, but was obtained in electronic format directly
CC	from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 223 AA;
	Query Match 83.9%; Score 187; DB 5; Length 223;
	Best Local Similarity 100.0%; Pred. No. 1.3e-162; Indels 0; Gaps 0;
	Matches 187; Conservative 0; Mismatches 0;
Qy	37 EVTKVATQKHKRQSPLNMTSSHFGEVTVTSAGWGPEEPLPYSRAFGEGASARPCRCNGGT 96
Db	37 EVTKVATQKHKRQSPLNMTSSHFGEVTVTSAGWGPEEPLPYSRAFGEGASARPCRCNGGT 96
Qy	97 CVLGSCFCVCPAHFTGRVCEHQRSECCGALSHGAWTLRACHLCRCIFGALHCLPLQTPDR 156
Db	97 CVLGSCFCVCPAHFTGRVCEHQRSECCGALSHGAWTLRACHLCRCIFGALHCLPLQTPDR 156
Qy	157 CDPKDFLASHAHGPSAGAPSLLLLLPCALLHRLLRDPAPAHPRSLVPSVLQRRRPPCGR 216
Db	157 CDPKDFLASHAHGPSAGAPSLLLLLPCALLHRLLRDPAPAHPRSLVPSVLQRRRPPCGR 216
Qy	217 PGLGHRL 223
Db	217 PGLGHRL 223
RESULT 9	
ABU56711	ID ABU56711 standard; protein; 223 AA.
XX	AC ABU56711;
XX	DT DT
XX	DE DE
XX	Lung cancer-associated polypeptide #304.
KW	Lung cancer-associated polypeptide; cytostatic; emphysema;
KW	antiinflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;
KW	small cell lung cancer; benign lesion; precancerous lesion; bronchitis;
KW	chronic obstructive pulmonary disease; hypersensitivity pneumonitis;
KW	interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis.
XX	Unidentified.
XX	WO200286443-A2.
XX	31-OCT-2002.
XX	18-APR-2002; 2002WO-US012476.
XX	18-APR-2001; 2001US-0284770P.
PR	10-MAY-2001; 2001US-0290492P.
PR	09-NOV-2001; 2001US-0339245P.
PR	13-NOV-2001; 2001US-0350666P.
PR	29-NOV-2001; 2001US-0334370P.
PR	12-APR-2002; 2002US-0372246P.
XX	(EOSB-) EOS BIOTECHNOLOGY INC.
XX	Aziz N, Murray R;
XX	WPI; 2003-093161/08.
DR	N-PSDB; ABX76440.
XX	
PT	Detecting a lung cancer-associated transcript in a cell from a patient
PT	for treating lung cancer, by contacting a biological sample from the
PT	patient with a polynucleotide that exhibits increased or decreased
PT	expression in lung cancer.
XX	

```

PR 29-NOV-2001; 2001US-0334393P.
PR 03-DEC-2001; 2001US-0335394P.
PR 14-DEC-2001; 2001US-0340376P.
PR 08-JAN-2002; 2002US-0347211P.
PR 10-JAN-2002; 2002US-0347349P.
PR 08-FEB-2002; 2002US-0355250P.
PR 13-FEB-2002; 2002US-0356714P.
PR 20-FEB-2002; 2002US-0359077P.
PR 29-MAR-2002; 2002US-0368809P.
PR 04-APR-2002; 2002US-0370110P.
PR 12-APR-2002; 2002US-0372246P.
PR 05-JUN-2002; 2002US-0386614P.
PR 16-JUL-2002; 2002US-0396839P.
PR 22-JUL-2002; 2002US-0397775P.
PR 22-JUL-2002; 2002US-0397845P.
PR 09-SEP-2002; 2002US-0409450P.
XX
XX (EOSB-) EOS BIOTECHNOLOGY INC.
XX
XX Afar D, Aziz N, Ginsburg WM, Gish KC, Glynne R, Hevezi PA;
XX Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;
XX
XX WPI; 2003-468649/44.
XX N-PSDB; ADN39103.
XX
XX Determining the presence or absence of a pathological cell in a patient,
XX useful for diagnosing, prognosing or treating cancer, comprises detecting
XX a nucleic acid in a biological sample.
XX
XX Claim 12; SEQ ID NO 422; 1385pp; English.
XX
XX The invention relates to nucleic acids and proteins (ADN38683-ADN40064)
XX whose expression is upregulated or downregulated in specific cancers or
XX other diseases such as angiogenic or fibrotic disorders, and to methods
XX of determining the presence or absence of a pathological cell in a
XX patient by detecting a nucleic acid at least 80% identical to those of
XX the invention or by detecting a polypeptide of the invention. The
XX invention also relates to expression vectors and host cells comprising a
XX nucleic acid of the invention; antibodies which specifically bind a
XX polypeptide of the invention; use of such antibodies for drug targeting;
XX and methods of screening for modulators of activity or expression of the
XX polypeptides and nucleic acids. The nucleic acids, polypeptides,
XX antibodies and methods are useful for diagnosing, prognosing and treating
XX cancer and other conditions such as psoriasis, ischaemia, heart disease,
XX atherosclerosis, inflammatory diseases, autoimmune diseases, retinal
XX neovascularisation syndromes, scarring and uterine fibroids. The present
XX sequence represents a polypeptide of the invention.
XX
XX Sequence 223 AA;
XX
XX Query Match 83.9%; Score 187; DB 7; Length 223;
XX Best Local Similarity 100.0%; Pred. No. 1.3e-162;
XX Matches 187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 37 EVTKVATQKHRSQPLNWTSHFGVETGSAEGWGPEEPLPYSRAPFGEGASARPCCRNGGT 96
DB 37 EVTKVATQKHRSQPLNWTSHFGVETGSAEGWGPEEPLPYSRAPFGEGASARPCCRNGGT 96
QY 97 CVLGSFVCVCPAHTFGYCEHDDRRSECCALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156
DB 97 CVLGSFVCVCPAHTFGYCEHDDRRSECCALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156
QY 157 CDPKDFLASHAHGPSAGAGPSLLLLPCALLHLLRLRPDPAHPRSLVPSVLOERRPCGR 216
DB 157 CDPKDFLASHAHGPSAGAGPSLLLLPCALLHLLRLRPDPAHPRSLVPSVLOERRPCGR 216
QY 217 PGLGHRL 223
DB 217 PGLGHRL 223

```

RESULT 11

```

ADN39975
ID ADN39975 standard; protein; 223 AA.
XX
XX AC ADN39975;
XX
XX DT 17-JUN-2004 (first entry)
XX
XX DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:C345.
XX
XX KW Human; differential expression; cancer; angiogenic disorder;
XX fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;
XX inflammatory disease; autoimmune disease;
XX retinal neovascularisation syndrome; scarring; uterine fibroid;
XX detection; diagnosis; prognosis; drug screening; drug targeting;
XX wound healing; contraception; cytostatic; cardiac; immunomodulatory;
XX vulnery; gene therapy; vaccine.
XX
XX OS Homo sapiens.
XX
XX PN WO2003042661-A2.
XX
XX PD 22-MAY-2003.
XX
XX PF 13-NOV-2002; 2002WO-US036810.
XX
XX PR 13-NOV-2001; 2001US-0350666P.
XX PR 21-NOV-2001; 2001US-0332464P.
XX PR 29-NOV-2001; 2001US-0334393P.
XX PR 03-DEC-2001; 2001US-035394P.
XX PR 14-DEC-2001; 2001US-0340376P.
XX PR 08-JAN-2002; 2002US-0347211P.
XX PR 10-JAN-2002; 2002US-0347349P.
XX PR 08-FEB-2002; 2002US-0355250P.
XX PR 13-FEB-2002; 2002US-0356714P.
XX PR 20-FEB-2002; 2002US-0359077P.
XX PR 29-MAR-2002; 2002US-0368809P.
XX PR 04-APR-2002; 2002US-0370110P.
XX PR 12-APR-2002; 2002US-0372246P.
XX PR 05-JUN-2002; 2002US-0386614P.
XX PR 16-JUL-2002; 2002US-0396839P.
XX PR 22-JUL-2002; 2002US-0397775P.
XX PR 22-JUL-2002; 2002US-0397845P.
XX PR 09-SEP-2002; 2002US-0409450P.
XX
XX (EOSB-) EOS BIOTECHNOLOGY INC.
XX
XX Afar D, Aziz N, Ginsburg WM, Gish KC, Glynne R, Hevezi PA;
XX Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;
XX
XX WPI; 2003-468649/44.
XX N-PSDB; ADN39758.
XX
XX Determining the presence or absence of a pathological cell in a patient,
XX useful for diagnosing, prognosing or treating cancer, comprises detecting
XX a nucleic acid in a biological sample.
XX
XX Claim 12; SEQ ID NO C345; 1385pp; English.
XX
XX The invention relates to nucleic acids and proteins (ADN38683-ADN40064)
XX whose expression is upregulated or downregulated in specific cancers or
XX other diseases such as angiogenic or fibrotic disorders, and to methods
XX of determining the presence or absence of a pathological cell in a
XX patient by detecting a nucleic acid at least 80% identical to those of
XX the invention or by detecting a polypeptide of the invention. The
XX invention also relates to expression vectors and host cells comprising a
XX nucleic acid of the invention; antibodies which specifically bind a
XX polypeptide of the invention; use of such antibodies for drug targeting;
XX and methods of screening for modulators of activity or expression of the
XX polypeptides and nucleic acids. The nucleic acids, polypeptides,
XX antibodies and methods are useful for diagnosing, prognosing and treating
XX cancer and other conditions such as psoriasis, ischaemia, heart disease,
XX atherosclerosis, inflammatory diseases, autoimmune diseases, retinal
XX neovascularisation syndromes, scarring and uterine fibroids. They may

```



PR 07-JUL-2000; 2000US-0216880P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218290P.  
PR 26-JUL-2000; 2000US-0220933P.  
PR 26-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225213P.  
PR 14-AUG-2000; 2000US-0225214P.  
PR 14-AUG-2000; 2000US-0225266P.  
PR 14-AUG-2000; 2000US-0225267P.  
PR 14-AUG-2000; 2000US-0225268P.  
PR 14-AUG-2000; 2000US-0225270P.  
PR 14-AUG-2000; 2000US-0225447P.  
PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 14-AUG-2000; 2000US-0225759P.  
PR 18-AUG-2000; 2000US-0226279P.  
PR 22-AUG-2000; 2000US-0226681P.  
PR 22-AUG-2000; 2000US-0226688P.  
PR 22-AUG-2000; 2000US-0227182P.  
PR 23-AUG-2000; 2000US-0227009P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 03-SEP-2000; 2000US-0229509P.  
PR 03-SEP-2000; 2000US-0229513P.  
PR 06-SEP-2000; 2000US-0230437P.  
PR 06-SEP-2000; 2000US-0230438P.  
PR 08-SEP-2000; 2000US-0231242P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231244P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 08-SEP-2000; 2000US-0231414P.  
PR 08-SEP-2000; 2000US-0232080P.  
PR 08-SEP-2000; 2000US-0232081P.  
PR 13-SEP-2000; 2000US-0231968P.  
PR 14-SEP-2000; 2000US-0232397P.  
PR 14-SEP-2000; 2000US-0232398P.  
PR 14-SEP-2000; 2000US-0232399P.  
PR 14-SEP-2000; 2000US-0232400P.  
PR 14-SEP-2000; 2000US-0232401P.  
PR 14-SEP-2000; 2000US-0233033P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 14-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 23-SEP-2000; 2000US-0234997P.  
PR 23-SEP-2000; 2000US-0234998P.  
PR 26-SEP-2000; 2000US-0235484P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241787P.  
PR 20-OCT-2000; 2000US-0241808P.

PR 20-OCT-2000; 2000US-0241809P.  
PR 20-OCT-2000; 2000US-0241826P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.  
PR 08-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.  
PR 17-NOV-2000; 2000US-0249244P.  
PR 17-NOV-2000; 2000US-0249245P.  
PR 17-NOV-2000; 2000US-0249246P.  
PR 17-NOV-2000; 2000US-0249265P.  
PR 17-NOV-2000; 2000US-0249266P.  
PR 17-NOV-2000; 2000US-0249297P.  
PR 17-NOV-2000; 2000US-0249299P.  
PR 17-NOV-2000; 2000US-0249300P.  
PR 01-DEC-2000; 2000US-0250160P.  
PR 01-DEC-2000; 2000US-0250391P.  
PR 05-DEC-2000; 2000US-0251030P.  
PR 05-DEC-2000; 2000US-0251988P.  
PR 05-DEC-2000; 2000US-0256719P.  
PR 06-DEC-2000; 2000US-0251479P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
PR 08-DEC-2000; 2000US-0251989P.  
PR 08-DEC-2000; 2000US-0251990P.  
PR 11-DEC-2000; 2000US-0254097P.  
PR 05-JAN-2001; 2001US-0259678P.  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA Rosen CA, Barash SC, Ruben SM;  
PI  
PI  
XX  
XX  
DR WPI; 2001-476222/51.  
N-PSDB; AAS26862.  
XX  
XX Novel polypeptides and polynucleotides useful as diagnostic reagents to  
PT diagnose diseases or disorders associated with aberrant expression or  
PT activity of polypeptides, for treating blood clotting disorder,  
PT hemophilia.  
XX  
XX Claim 11; SEQ ID NO 198; 601pp; English.  
PS  
XX  
XX The invention relates to isolated nucleic acid molecules and their  
CC encoded secreted proteins. The nucleic acids and proteins are used to  
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,  
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used  
CC in diagnosing a pathological condition or susceptibility to a  
CC pathological condition. Antibodies to the proteins can also be used in  
CC alleviating symptoms associated with the disorders and in diagnostic

immunoassays e.g. radioimmunoassays or enzyme linked immunosorbant assays (ELISA). Disorders which are diagnosed or treated include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g. neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiodenests, nervous system disorders e.g. Alzheimer's disease, infections caused by bacteria, viruses and fungi and ocular disorders e.g. corneal infection, and many other disorders listed in the specification. The polypeptides can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues and in chemotaxis. The polypeptides can also be used as a food additive or preservative to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors and other nutritional components. The present sequence represents a novel secreted protein of the invention. Note: The

Query March	83.9%;	Score 187;	DB 4;	Length 231;
Best Local Similarity	100.0%;	Pred. No. 1.3e-162;		
Matches 187;	Conservative	0;	Mismatches 0;	Indels 0; Gaps 0
Qy	37	EVTKVATQKHRQSP	LNLTSSHFGEVTS	AEAGWGPEEPLPYSRAFGEGASAPRCRCNGGT 96
Db	45	EVTKVATQKHRQSP	LNLTSSHFGEVTS	AEAGWGPEEPLPYSRAFGEGASAPRCRCNGGT 104
Qy	97	CVLGSCFVCPAHFT	GRYCEHQRORSE	ECGALBHGAWTLRACHLCRCIFGALHCLPLQTDPDR 156
Db	105	CVLGSCFVCPAHFT	GRYCEHQRORSE	ECGALBHGAWTLRACHLCRCIFGALHCLPLQTDPDR 164
Qy	157	CDPKDFLASHAHGFS	SAGGAPSLLLLL	PCALLHRLLRDPAPAHPRSLVPSVLQRRRRPCGR 216
Db	165	CDPKDFLASHAHGFS	SAGGAPSLLLLL	PCALLHRLLRDPAPAHPRSLVPSVLQRRRRPCGR 224
Qy	217	PGLGHRL	223	
Db	225	PGLGHRL	231	

RESULT 14  
AAW09111  
ID AAW09111 standard: protein: 230 AA.

XX	
DT	16-APR-1997 (first entry)
XX	
XX	Human criptin growth factor.
DE	
XX	
XX	Criptin growth factor; CGF; angiogenesis; wound healing; vulnery;
KW	muscle wastage; osteoporosis; implant fixation.
KW	pancreas cancer; diagnosis; gene therapy.
KW	

XX	Key	Location/Qualifiers
FH	peptide	1..23
FT		/label= siq peptide
FT		

AA	W09639420-A1.	
PN		
XX		
PD	12-DEC-1996.	
XX		
PF	05-JUN-1995;	95WO-US007087.
XX		
PR	05-JUN-1995;	95WO-US007087.
XX		
PA	(HUMA-) HUMAN GENOME SCI INC.	

Meissner PS, Coleman TA;  
WPI; 1997-043055/04.  
N-PSDB; AAT51058.

PT New isolated human Cripin Growth Factor polypeptide - which can be used  
PT to stimulate angiogenesis and develop products for use in diagnosis and  
PT therapy.

PS Claim 12; Fig 1; 52pp; English.

Human criptin growth factor (CGF) (AAW09111) is a novel polypeptide structurally related to human cripto growth factor. It is overexpressed and secreted by certain types of cancer cells, e.g. pancreatic cancers. Recombinant CGF can be produced in host cells utilising vectors incorporating a CGF cDNA clone (AAW51058) isolated from a human pancreatic cancer tissue cDNA library. CGF can be used to treat e.g. muscle wasting diseases, osteoporosis, to aid implant fixation, to stimulate tissue regeneration and wound healing, to promote angiogenesis and to stimulate proliferation of vascular smooth muscle and endothelial cell prodn. It can also be used as a marker for cancer diagnosis

Sequence 230 AA;

Query Match 66.8%; Score 149; DB 2; Length 230;  
Best Local Similarity 100.0%; Pred. No. 8.1e-128;  
Matches 149; Conservative 0; Mismatches 0; Indels

RESULT 15  
AAG77914  
ID AAG77914 standard; protein: 223 AA.

23-JAN-2002 (first entry)

Cryptic; human; cytostatic; cardiac; nootropic; neuroleptic; cancer;  
 antiasthmatic; anti-angiogenic; gene therapy; lung cancer; asthma;  
 respiratory disease; epilepsy; schizophrenia; depression; hyperactivity;  
 heart hypertrophy; heart failure; cardiomyopathy; angiogenesis;  
 vasculogenesis.

OS Homo sapiens.

WO200177322-A1.

18-OCT-2001.

06-APR-2001: 2001WO-EP003965.

10-APR-2000: 2000EP-00107142.

PA (MERE ) MERCK PATENT GMBH.

PI Duecker K:

WPI; 2002-017462/02.

DR N-PSDB; AAH77168.

Novel cryptic-like secreted polypeptide found in various tumors and organs is useful to treat diseases including cancer, particularly lung cancer, asthma and heart disease.

PS Claim 1; Page 33-34; 37pp; English.  
XX  
CC The sequence represents the novel human cryptic-like secreted protein of  
CC the invention. The polypeptide of the invention has cytostatic, cardiant,  
CC neurotropic, neuroleptic, antiasthmatic, and anti-angiogenic activity, and  
CC has a use in gene therapy. The polypeptide and polynucleotide of the  
CC invention may be used to treat cancer, particularly lung cancer,  
CC respiratory diseases, asthma, epilepsy, schizophrenia, depression,  
CC hyperactivity, heart hypertrophy, heart failure, cardiomyopathies,  
CC aberrant angiogenesis and vasculogenesis  
XX  
SQ Sequence 223 AA;  
Query Match 65.0%; Score 145; DB 5; Length 223;  
Best Local Similarity 100.0%; Pred. No. 3.6e-124;  
Matches 145; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 79 AFGEGASARPRCCRNCGTCVLGSCVCPAHTGTYCEHDQRRSECGALEHGAWTLRACHL 138  
Db 79 AFGEGASARPRCCRNCGTCVLGSCVCPAHTGTYCEHDQRRSECGALEHGAWTLRACHL 138  
Qy 139 CRCIFGALHCLPLOTDPDRCDPKDFLASHAGPSAGGAPSLLLLPALLHRLLRPDAPAH 198  
Db 139 CRCIFGALHCLPLOTDPDRCDPKDFLASHAGPSAGGAPSLLLLPALLHRLLRPDAPAH 198  
Qy 199 PRSLVPSVLQRRERPCGRPGLGHRL 223  
Db 199 PRSLVPSVLQRRERPCGRPGLGHRL 223

Search completed: September 7, 2006, 12:18:51  
Job time : 192 secs

**THIS PAGE BLANK (USPTO)**

~~THIS PAGE BLANK (USPTO)~~

GenCore version 5.1.9  
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: September 7, 2006, 11:44:20 ; Search time 196 Seconds  
(without alignments)  
520.200 Million cell updates/sec

Title: US-10-665-602-2  
Perfect score: 1249  
Sequence: 1 MTRHVRLLFTVSLALQII.....PSVLQRRPFCRPGILGRL 223

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 2589679 seqs, 457216429 residues

Total number of hits satisfying chosen parameters: 2589679

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A Geneseq 8:\*

- 1: Geneseqp1980s:\*
- 2: Geneseqp1950s:\*
- 3: Geneseqp2000s:\*
- 4: Geneseqp2001s:\*
- 5: Geneseqp2002s:\*
- 6: Geneseqp2003as:\*
- 7: Geneseqp2003bs:\*
- 8: Geneseqp2004s:\*
- 9: Geneseqp2005s:\*
- 10: Geneseqp2006s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1249	100.0	223	8 ADO05060	Ado05060 Human cri
2	1249	100.0	229	4 AAU18122	Aau18122 Novel hum
3	1249	100.0	229	4 AAU17028	Aau17028 Human nov
4	1249	100.0	229	4 ABB10300	Abb10300 Human cdn
5	1249	100.0	229	4 AAU19904	Aau19904 Novel hum
6	1249	100.0	229	5 ABJ05749	Abj05749 Novel hum
7	1249	100.0	229	5 ABP66887	Abp66887 Human pol
8	1242	99.4	231	4 AAU16957	Aau16957 Human nov
9	1241	99.4	223	5 ABB90336	Abb90336 Human pol
10	1241	99.4	223	6 ABU56711	Abu56711 Lung canc
11	1241	99.4	223	7 ADN39104	Adn39104 Cancer/an
12	1241	99.4	223	7 ADN39975	Adn39975 Cancer/an
13	1241	99.4	223	9 ADY85963	Ady85963 Human cri
14	1233	98.7	223	5 AAG77914	Aag77914 Human cry
15	1044	83.6	230	2 AAW09111	Aaw09111 Human cri
16	488	39.1	202	9 ADY85962	Ady85962 Murine Cr
17	275.5	22.1	190	9 ADY85965	Ady85965 Zebrafish
18	267	21.4	171	8 ADS88690	Ads88690 Amino aci
19	267	21.4	171	9 ADZ42246	Adz42246 Mouse Cri
20	264	21.1	156	8 ADS88691	Ads88691 Amino aci
21	264	21.1	166	8 ADS88692	Ads88692 Murine Cr
22	256	20.5	171	9 ADY85960	Ady85960 Murine Cr
23	255.5	20.5	129	8 ADS88693	Ads88693 Amino aci

24	255.5	20.5	139	8	ADS88694	AdS88694 Sequence
25	249.5	20.0	190	9	ADY85964	Ady85964 African c
26	248.5	19.9	190	2	AAR90768	Aar90768 FGF recep
27	238	19.1	360	5	ABB77107	Abb77107 Human Cri
28	238	19.1	367	5	ABB77106	Abb77106 Human Cri
29	237.5	19.0	188	2	AAW29735	Aaw29735 Homo sapi
30	233.5	18.7	188	8	ADS88697	AdS88697 Amino aci
31	233	18.7	129	5	ABB77104	Abb77104 Human Cri
32	233	18.7	139	5	ABB77103	Abb77103 Human Cri
33	233 <sup>a</sup>	18.7	173	8	ADS88698	AdS88698 Amino aci
34	233	18.7	174	2	AAR13326	Aar13326 Recombina
35	233	18.7	174	2	AAW32107	Aaw32107 Recombina
36	233	18.7	174	8	ADO05065	AdO05065 Human cri
37	233	18.7	183	8	ADS88699	AdS88699 Amino aci
38	233	18.7	188	2	AAR22548	Aar22548 Human CRI
39	233	18.7	188	2	AAW87630	Aaw87630 Human CRI
40	233	18.7	188	5	ABB77101	Abb77101 Human Cri
41	233	18.7	188	5	AAO14638	Aao14638 Human cri
42	233	18.7	188	5	AAO14636	Aao14636 Human cri
43	233	18.7	188	5	AAO14727	Aao14727 Human var
44	233	18.7	188	6	ABP97176	Abp97176 Tumour-as
45	233	18.7	188	6	ABP58131	Abp58131 Human Cri

ALIGNMENTS

RESULT 1  
ADO05060  
ID ADO05060 standard; protein; 223 AA.  
XX  
AC ADO05060;  
XX  
DT 29-JUL-2004 (first entry)  
XX

DE Human criptin growth factor (CGF) protein.  
DE  
KW Criptin growth factor; CGF; wound healing; tissue regeneration;  
KW Implant fixation; angiogenesis; neoplasia; tumour; gene therapy; human.  
XX Homo sapiens.  
OS  
XX  
PN US2004086967-A1.  
XX  
PD 06-MAY-2004.  
XX

PF 22-SEP-2003; 2003US-00665602.  
XX  
PR 06-JUN-1995; 95US-00471371.  
PR 09-SEP-1999; 99US-00393023.  
XX

XX (HUMA-) HUMAN GENOME SCI INC.  
XX  
PA Meissner PS, Coleman TA;  
XX  
PI  
XX  
DR WPI: 2004-356201/33.  
DR N-PSDB; ADO05059.  
XX

XX New human polynucleotides encoding human criptin growth factor  
PT polypeptides, useful for wound healing or tissue regeneration,  
PT stimulating implant fixation and angiogenesis, and for treating and/or  
PT preventing tumor.  
XX

PS Claim 12; SEQ ID NO 2; 19pp; English.  
XX

XX The invention provides criptin growth factor (CGF) polypeptides and their  
CC encoding polynucleotides. The invention is useful for wound healing and  
CC tissue regeneration, stimulating implant fixation, angiogenesis and for  
CC treating and preventing neoplasia such as tumour. The invention is also  
CC useful in gene therapy. The present sequence is human criptin growth  
CC factor (CGF) protein.  
XX  
SQ Sequence 223 AA;

Query Match 100.0%; Score 1249; DB 8; Length 223;  
Best Local Similarity 100.0%; Pred. No. 2e-95;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVTKVATQKHQSPLNWTS SHFG 60  
Db 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVTKVATQKHQSPLNWTS SHFG 60

Qy 61 VTGSAECGWPEELPYSGRAFEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
Db 61 VTGSAECGWPEELPYSGRAFEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120

Qy 121 SEGCALEHGWATLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
Db 121 SEGCALEHGWATLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180

Qy 181 LLPCALLHRLRPDAPAHPSLVPSVLQRRPCGRPLGHLR 223  
Db 181 LLPCALLHRLRPDAPAHPSLVPSVLQRRPCGRPLGHLR 223

RESULT 2  
AAU18122  
ID AAU18122 standard; protein; 229 AA.  
XX AAU18122;  
AC  
XX  
XX  
DT 21-NOV-2001 (first entry)  
XX  
DE Novel human uterine motility-association polypeptide #29.  
XX  
KW Human; uterine motility-association disorder; uterus; pregnancy; labour;  
KW menstrual cycle; gene therapy.  
XX  
XX Homo sapiens.  
XX  
PN W0200155201-A1.  
XX  
PD 02-AUG-2001.  
XX  
XX 17-JAN-2001; 2001WO-US001317.  
XX  
PR 31-JAN-2000; 2000US-0179065P.  
PR 04-FEB-2000; 2000US-0180628P.  
PR 24-FEB-2000; 2000US-0184664P.  
PR 02-MAR-2000; 2000US-0186350P.  
PR 16-MAR-2000; 2000US-0189874P.  
PR 17-MAR-2000; 2000US-0190076P.  
PR 18-APR-2000; 2000US-0198123P.  
PR 19-MAY-2000; 2000US-0205515P.  
PR 07-JUN-2000; 2000US-0209467P.  
PR 30-JUN-2000; 2000US-0214886P.  
PR 06-JUL-2000; 2000US-0215135P.  
PR 07-JUL-2000; 2000US-0216647P.  
PR 07-JUL-2000; 2000US-0216880P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218290P.  
PR 26-JUL-2000; 2000US-0220963P.  
PR 26-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225213P.  
PR 14-AUG-2000; 2000US-0225214P.  
PR 14-AUG-2000; 2000US-0225266P.  
PR 14-AUG-2000; 2000US-0225267P.  
PR 14-AUG-2000; 2000US-0225268P.  
PR 14-AUG-2000; 2000US-0225270P.  
PR 14-AUG-2000; 2000US-0225447P.  
PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 14-AUG-2000; 2000US-0225759P.  
PR 18-AUG-2000; 2000US-0226279P.  
PR 22-AUG-2000; 2000US-0226681P.  
PR 22-AUG-2000; 2000US-0226868P.  
PR 22-AUG-2000; 2000US-0227182P.  
PR 23-AUG-2000; 2000US-0227009P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 06-SEP-2000; 2000US-0230437P.  
PR 06-SEP-2000; 2000US-0230438P.  
PR 08-SEP-2000; 2000US-0231242P.  
PR 08-SEP-2000; 2000US-0231243P.  
PR 08-SEP-2000; 2000US-0231244P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 08-SEP-2000; 2000US-0231414P.  
PR 08-SEP-2000; 2000US-0232080P.  
PR 08-SEP-2000; 2000US-0232081P.  
PR 12-SEP-2000; 2000US-0231968P.  
PR 14-SEP-2000; 2000US-0232397P.  
PR 14-SEP-2000; 2000US-0232398P.  
PR 14-SEP-2000; 2000US-0232399P.  
PR 14-SEP-2000; 2000US-0232400P.  
PR 14-SEP-2000; 2000US-0232401P.  
PR 14-SEP-2000; 2000US-0233063P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 14-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 25-SEP-2000; 2000US-0234998P.  
PR 26-SEP-2000; 2000US-0234984P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239935P.  
PR 13-OCT-2000; 2000US-0239937P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241787P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 20-OCT-2000; 2000US-0241826P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.

PR	08-NOV-2000;	2000US-0246613P.	QY	121	SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDFKDFLASHAHGFSAGGAPSLLL	180
PR	17-NOV-2000;	2000US-0249207P.	Db	127	SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDFKDFLASHAHGFSAGGAPSLLL	186
PR	17-NOV-2000;	2000US-0249208P.				
PR	17-NOV-2000;	2000US-0249209P.				
PR	17-NOV-2000;	2000US-0249210P.	QY	181	LLPCALLHRLRLPDAPAHPRSLVPSVLORRRPCGRPLGHRL	223
PR	17-NOV-2000;	2000US-0249211P.	Db	187	LLPCALLHRLRLPDAPAHPRSLVPSVLORRRPCGRPLGHRL	229
PR	17-NOV-2000;	2000US-0249212P.				
PR	17-NOV-2000;	2000US-0249213P.				
PR	17-NOV-2000;	2000US-0249214P.				
PR	17-NOV-2000;	2000US-0249215P.				
PR	17-NOV-2000;	2000US-0249216P.				
PR	17-NOV-2000;	2000US-0249217P.				
PR	17-NOV-2000;	2000US-0249218P.				
PR	17-NOV-2000;	2000US-0249244P.				
PR	17-NOV-2000;	2000US-0249245P.				
PR	17-NOV-2000;	2000US-0249264P.				
PR	17-NOV-2000;	2000US-0249285P.				
PR	17-NOV-2000;	2000US-0249297P.				
PR	17-NOV-2000;	2000US-0249299P.				
PR	17-NOV-2000;	2000US-0249300P.				
PR	01-DEC-2000;	2000US-0250160P.				
PR	01-DEC-2000;	2000US-0250391P.				
PR	05-DEC-2000;	2000US-0251030P.				
PR	05-DEC-2000;	2000US-0251988P.				
PR	05-DEC-2000;	2000US-0256719P.				
PR	06-DEC-2000;	2000US-0251479P.				
PR	08-DEC-2000;	2000US-0251856P.				
PR	08-DEC-2000;	2000US-0251868P.				
PR	08-DEC-2000;	2000US-0251869P.				
PR	08-DEC-2000;	2000US-0251899P.				
PR	08-DEC-2000;	2000US-0251990P.				
PR	11-DEC-2000;	2000US-0254097P.				
PR	05-JAN-2001;	2001US-0259678P.				
XX						
PA	(HUMA-) HUMAN GENOME SCI INC.					
XX						
PI	Rosen CA, Barash SC, Ruben SM;					
XX						
XX						
DR	WPI; 2001-488777/53.					
DR	N-PSDB; AAS28964.					
XX						
PT	New nucleic acid molecules encoding 49 human secreted proteins for					
PT	diagnosing, preventing, treating or ameliorating medical conditions and					
PT	used as food additives or preservatives.					
XX						
FS	Claim 11; SEQ ID NO 98; 524pp; English.					
XX						
CC	The present invention relates to the isolation of novel human uterine					
CC	motility-association polypeptides, and cDNA (AAS28936-AAS28994) and					
CC	genomic sequences encoding for these polypeptides. The sequences of the					
CC	invention are useful in the diagnosis, treatment, prevention and/or					
CC	prognosis of diseases associated with uterine motility such as pregnancy					
CC	and labour, and menstrual disorders. The polynucleotide sequences of the					
CC	invention are also useful in gene therapy. AAU18094-AAU18152 represent					
CC	novel human uterine motility-association polypeptides. Note: The sequence					
CC	data for this patent did not form part of the printed specification, but					
CC	was obtained in electronic format directly from WIPO at					
CC	ftp.wipo.int/pub/published_pct_sequences					
XX						
SQ	Sequence 229 AA;					
	Query Match 100.0%; Score 1249; DB 4; Length 229;					
	Best Local Similarity 100.0%; Pred. No. 2.1e-95;					
	Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
QY	1 MTWRHHVRLFTVSLALQIINLNSYQREKHNGRGEVTKVATQKHRSPLNWTSSHFGE 60					
Db						
	7 MTWRHHVRLFTVSLALQIINLNSYQREKHNGRGEVTKVATQKHRSPLNWTSSHFGE 66					
QY	61 VTGSAEGMGPEEPLPYSAFGEASAPRCRCRNGTCTVLGSFCVCPAHTGTRYCEHQR 120					
Db						
	67 VTGSAEGMGPEEPLPYSAFGEASAPRCRCRNGTCTVLGSFCVCPAHTGTRYCEHQR 126					

PR 01-SEP-2000; 2000US-0229287P.  
 PR 01-SEP-2000; 2000US-0229343P.  
 PR 01-SEP-2000; 2000US-0229344P.  
 PR 01-SEP-2000; 2000US-0229345P.  
 PR 05-SEP-2000; 2000US-0229509P.  
 PR 05-SEP-2000; 2000US-0229513P.  
 PR 06-SEP-2000; 2000US-0230437P.  
 PR 08-SEP-2000; 2000US-0230438P.  
 PR 08-SEP-2000; 2000US-0231242P.  
 PR 08-SEP-2000; 2000US-0231243P.  
 PR 08-SEP-2000; 2000US-0231244P.  
 PR 08-SEP-2000; 2000US-0231413P.  
 PR 08-SEP-2000; 2000US-0231414P.  
 PR 08-SEP-2000; 2000US-0232080P.  
 PR 08-SEP-2000; 2000US-0232081P.  
 PR 12-SEP-2000; 2000US-0231968P.  
 PR 14-SEP-2000; 2000US-0232337P.  
 PR 14-SEP-2000; 2000US-0232338P.  
 PR 14-SEP-2000; 2000US-0232339P.  
 PR 14-SEP-2000; 2000US-0232400P.  
 PR 14-SEP-2000; 2000US-0232401P.  
 PR 14-SEP-2000; 2000US-0233063P.  
 PR 14-SEP-2000; 2000US-0233064P.  
 PR 14-SEP-2000; 2000US-0233065P.  
 PR 21-SEP-2000; 2000US-0234223P.  
 PR 21-SEP-2000; 2000US-0234274P.  
 PR 25-SEP-2000; 2000US-0234997P.  
 PR 25-SEP-2000; 2000US-0234998P.  
 PR 26-SEP-2000; 2000US-0235484P.  
 PR 27-SEP-2000; 2000US-0235834P.  
 PR 27-SEP-2000; 2000US-0235836P.  
 PR 29-SEP-2000; 2000US-0236327P.  
 PR 29-SEP-2000; 2000US-0236367P.  
 PR 29-SEP-2000; 2000US-0236368P.  
 PR 29-SEP-2000; 2000US-0236369P.  
 PR 29-SEP-2000; 2000US-0236370P.  
 PR 02-OCT-2000; 2000US-0236802P.  
 PR 02-OCT-2000; 2000US-0237037P.  
 PR 02-OCT-2000; 2000US-0237038P.  
 PR 02-OCT-2000; 2000US-0237039P.  
 PR 02-OCT-2000; 2000US-0237040P.  
 PR 13-OCT-2000; 2000US-0239935P.  
 PR 13-OCT-2000; 2000US-0239937P.  
 PR 20-OCT-2000; 2000US-0240960P.  
 PR 20-OCT-2000; 2000US-0241221P.  
 PR 20-OCT-2000; 2000US-0241785P.  
 PR 20-OCT-2000; 2000US-0241786P.  
 PR 20-OCT-2000; 2000US-0241787P.  
 PR 20-OCT-2000; 2000US-0241808P.  
 PR 20-OCT-2000; 2000US-0241809P.  
 PR 20-OCT-2000; 2000US-0241826P.  
 PR 01-NOV-2000; 2000US-0244617P.  
 PR 08-NOV-2000; 2000US-0246474P.  
 PR 08-NOV-2000; 2000US-0246475P.  
 PR 08-NOV-2000; 2000US-0246476P.  
 PR 08-NOV-2000; 2000US-0246477P.  
 PR 08-NOV-2000; 2000US-0246478P.  
 PR 08-NOV-2000; 2000US-0246523P.  
 PR 08-NOV-2000; 2000US-0246524P.  
 PR 08-NOV-2000; 2000US-0246525P.  
 PR 08-NOV-2000; 2000US-0246526P.  
 PR 08-NOV-2000; 2000US-0246527P.  
 PR 08-NOV-2000; 2000US-0246528P.  
 PR 08-NOV-2000; 2000US-0246532P.  
 PR 08-NOV-2000; 2000US-0246609P.  
 PR 08-NOV-2000; 2000US-0246610P.  
 PR 08-NOV-2000; 2000US-0246611P.  
 PR 08-NOV-2000; 2000US-0246613P.  
 PR 17-NOV-2000; 2000US-0249207P.  
 PR 17-NOV-2000; 2000US-0249208P.  
 PR 17-NOV-2000; 2000US-0249209P.  
 PR 17-NOV-2000; 2000US-0249210P.  
 PR 17-NOV-2000; 2000US-0249211P.  
 PR 17-NOV-2000; 2000US-0249212P.

PR 17-NOV-2000; 2000US-0249212P.  
 PR 17-NOV-2000; 2000US-0249213P.  
 PR 17-NOV-2000; 2000US-0249214P.  
 PR 17-NOV-2000; 2000US-0249215P.  
 PR 17-NOV-2000; 2000US-0249216P.  
 PR 17-NOV-2000; 2000US-0249217P.  
 PR 17-NOV-2000; 2000US-0249218P.  
 PR 17-NOV-2000; 2000US-0249244P.  
 PR 17-NOV-2000; 2000US-0249245P.  
 PR 17-NOV-2000; 2000US-0249264P.  
 PR 17-NOV-2000; 2000US-0249265P.  
 PR 17-NOV-2000; 2000US-0249297P.  
 PR 17-NOV-2000; 2000US-0249299P.  
 PR 17-NOV-2000; 2000US-0249300P.  
 PR 01-DEC-2000; 2000US-0250160P.  
 PR 01-DEC-2000; 2000US-0250391P.  
 PR 05-DEC-2000; 2000US-0251030P.  
 PR 05-DEC-2000; 2000US-0251988P.  
 PR 05-DEC-2000; 2000US-0256719P.  
 PR 06-DEC-2000; 2000US-0251479P.  
 PR 08-DEC-2000; 2000US-0251856P.  
 PR 08-DEC-2000; 2000US-0251868P.  
 PR 08-DEC-2000; 2000US-0251869P.  
 PR 08-DEC-2000; 2000US-0251989P.  
 PR 08-DEC-2000; 2000US-0251990P.  
 PR 11-DEC-2000; 2000US-0254097P.  
 PR 05-JAN-2001; 2001US-02559678P.  
 XX  
 (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 Rosen CA, Barash SC, Ruben SM;  
 PI  
 WPI; 2001-476222/51.  
 DR N-PSDB; AAS26933.  
 XX

Novel polypeptides and polynucleotides useful as diagnostic reagents to  
 diagnose diseases or disorders associated with aberrant expression or  
 activity of polypeptides, for treating blood clotting disorder,  
 hemophilia.  
 XX

Claim 11; SEQ ID NO 269; 601pp; English.

The invention relates to isolated nucleic acid molecules and their  
 encoded secreted proteins. The nucleic acids and proteins are used to  
 prevent, treat or ameliorate a medical condition in e.g. humans, mice,  
 rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used  
 in diagnosing a pathological condition or susceptibility to a  
 pathological condition. Antibodies to the proteins can also be used in  
 alleviating symptoms associated with the disorders and in diagnostic  
 immunoassays e.g. radioimmunoassays or enzyme linked immunosorbant assays  
 (ELISA). Disorders which are diagnosed or treated include autoimmune  
 diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.  
 neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac  
 arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,  
 nervous system disorders e.g. Alzheimer's disease, infections caused by  
 bacteria, viruses and fungi and ocular disorders e.g. corneal infection,  
 and many other disorders listed in the specification. The polypeptides  
 can also be used to aid wound healing and epithelial cell proliferation,  
 to prevent skin aging due to sunburn, to maintain organs before  
 transplantation, for supporting cell culture of primary tissues, to  
 regenerate tissues and in chemotaxis. The polypeptides can also be used  
 as a food additive or preservative to increase or decrease storage  
 capabilities, fat content, lipid, protein, carbohydrate, vitamins,  
 minerals, cofactors and other nutritional components. The present  
 sequence represents a novel secreted protein of the invention. Note: The

Query Match 100.0%; Score 1249; DB 4; Length 229;  
 Best Local Similarity 100.0%; Pred. No. 2.1e-95;  
 Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTWRHHVRLFTVSLALQIINLGNYSQREKHNGRGCEVTKVATQKHQSPLNWTSFHFGE 60  
 |||||  
 DB 7 MTWRHHVRLFTVSLALQIINLGNYSQREKHNGRGCEVTKVATQKHQSPLNWTSFHFGE 66  
 |||||

```
Qy 61 VTGSAECGWPEELPYSGAFEGASARPRCCRNGGTCVLGSCFVCPAHTGTRYCEHDQRR 120
    |||||
Db 67 VTGSAECGWPEELPYSGAFEGASARPRCCRNGGTCVLGSCFVCPAHTGTRYCEHDQRR 126
    |||||
Qy 121 SECCALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180
    |||||
Db 127 SECCALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 186
    |||||
Qy 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGREGLGHRL 223
    |||||
Db 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGREGLGHRL 229
    |||||

RESULT 4
ABBI0300
ID ABB10300 standard; protein; 229 AA.
XX AC ABB10300;
XX DT 10-JAN-2002 (first entry)
XX DE Human cDNA SEQ ID NO: 608.
XX KW Human; gene therapy; neural disorder; immune system disorder;
KW muscular disorder; reproductive disorder; gastrointestinal disorder;
KW pulmonary disorder; cardiovascular disorder; renal disorder;
KW proliferative disorder; inflammation.
XX OS Homo sapiens.
XX PN WC200154474-A2.
XX PD 02-AUG-2001.
XX PF 17-JAN-2001; 2001WO-US0001349.
XX 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 11-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 14-JUL-2000; 2000US-0217496P.
PR 26-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 14-AUG-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234224P.
PR 25-SEP-2000; 2000US-0234977P.
PR 25-SEP-2000; 2000US-0234978P.
PR 25-SEP-2000; 2000US-0234988P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
```

```
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249219P.
PR 17-NOV-2000; 2000US-0249220P.
PR 17-NOV-2000; 2000US-0249221P.
PR 17-NOV-2000; 2000US-0249222P.
PR 17-NOV-2000; 2000US-0249223P.
PR 17-NOV-2000; 2000US-0249224P.
PR 17-NOV-2000; 2000US-0249225P.
PR 17-NOV-2000; 2000US-0249226P.
PR 17-NOV-2000; 2000US-0249227P.
PR 17-NOV-2000; 2000US-0249228P.
PR 17-NOV-2000; 2000US-0249229P.
PR 17-NOV-2000; 2000US-0249230P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 06-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254037P.
PR 05-JAN-2001; 2001US-0255967P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX Reen CA, Baraeh SC, Ruben SM;
XX
XX WPI; 2001-476161/51.
XX N-PSDB; ABA06522.
XX
XX Isolated nucleic acid molecule encoding an inflammation-associated
XX polypeptide is used in preventing, treating or ameliorating a medical
XX condition.
XX
XX Claim 11; SEQ ID NO 608; 859pp + Sequence Listing; English.
XX
XX The present invention provides human cDNAs, proteins and related genomic
XX DNAs. These can be used in the treatment of neural, immune system,
XX muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
XX renal and proliferative disorders and inflammation. The present sequence
XX is a protein of the invention
XX
XX Sequence 229 AA;
XX
XX Query Match 100.0%; Score 1249; DB 4; Length 229;
XX Best Local Similarity 100.0%; Pred. No. 2.1e-95;
XX Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 MTRHHVRLFTVSLALQIINLGSYQREKHNGRGVTKVATQKHRSPLNWTSSHFG 60
Db 7 MTRHHVRLFTVSLALQIINLGSYQREKHNGRGVTKVATQKHRSPLNWTSSHFG 66
Qy 61 VTSAEGWGPEEPLPYSRATGEGASAPRCRNGGTCVLGSCFVCPAFTGRYCEHDQRR 120
Db 67 VTSAEGWGPEEPLPYSRATGEGASAPRCRNGGTCVLGSCFVCPAFTGRYCEHDQRR 126
Qy 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180
Db 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186
Qy 181 LLPCALLHRLLRDAPAHPSLPVSLQRRRCGRPLGHLRL 223
Db 187 LLPCALLHRLLRDAPAHPSLPVSLQRRRCGRPLGHLRL 229
XX
XX RESULT 5
XX AAU19904
XX ID AAU19904 standard; protein; 229 AA.
```

```
XX
AC AAU19904;
XX
XX 06-DEC-2001 (first entry)
XX
XX Novel human calcium-binding protein #13.
XX
XX Human; calcium-binding protein; calcium flux; neurological disease;
XX immune dysfunction; digestive disorder; neoplastic disease;
XX blood disorder; infectious disease; gene therapy; immunosuppressive;
XX antiarthritic; cytostatic; vasotropic; antibacterial; nootropic;
XX virucide.
XX
XX Homo sapiens.
XX
XX WO200155304-A2.
XX
XX 02-AUG-2001.
XX
XX 17-JAN-2001; 2001WO-US001302.
XX
XX 31-JAN-2000; 2000US-0179065P.
XX 04-FEB-2000; 2000US-0180628P.
XX 24-FEB-2000; 2000US-0184664P.
XX 02-MAR-2000; 2000US-0186350P.
XX 16-MAR-2000; 2000US-0189874P.
XX 17-MAR-2000; 2000US-0190076P.
XX 18-APR-2000; 2000US-0198123P.
XX 19-MAY-2000; 2000US-0205515P.
XX 07-JUN-2000; 2000US-0209467P.
XX 28-JUN-2000; 2000US-0214886P.
XX 30-JUN-2000; 2000US-0215135P.
XX 07-JUL-2000; 2000US-0216647P.
XX 07-JUL-2000; 2000US-0216880P.
XX 11-JUL-2000; 2000US-0217487P.
XX 11-JUL-2000; 2000US-0217496P.
XX 14-JUL-2000; 2000US-0218290P.
XX 26-JUL-2000; 2000US-0220963P.
XX 26-JUL-2000; 2000US-0220964P.
XX 14-AUG-2000; 2000US-0224518P.
XX 14-AUG-2000; 2000US-0224519P.
XX 14-AUG-2000; 2000US-0225213P.
XX 14-AUG-2000; 2000US-0225214P.
XX 14-AUG-2000; 2000US-0225266P.
XX 14-AUG-2000; 2000US-0225267P.
XX 14-AUG-2000; 2000US-0225268P.
XX 14-AUG-2000; 2000US-0225270P.
XX 14-AUG-2000; 2000US-0225447P.
XX 14-AUG-2000; 2000US-0225757P.
XX 14-AUG-2000; 2000US-0225758P.
XX 14-AUG-2000; 2000US-0225759P.
XX 18-AUG-2000; 2000US-0226279P.
XX 22-AUG-2000; 2000US-0226681P.
XX 22-AUG-2000; 2000US-0226686P.
XX 22-AUG-2000; 2000US-0227182P.
XX 23-AUG-2000; 2000US-0227009P.
XX 30-AUG-2000; 2000US-0228924P.
XX 01-SEP-2000; 2000US-0229287P.
XX 01-SEP-2000; 2000US-0229343P.
XX 01-SEP-2000; 2000US-0229344P.
XX 01-SEP-2000; 2000US-0229345P.
XX 05-SEP-2000; 2000US-0229509P.
XX 05-SEP-2000; 2000US-0229513P.
XX 06-SEP-2000; 2000US-0230437P.
XX 06-SEP-2000; 2000US-0230438P.
XX 08-SEP-2000; 2000US-0231242P.
XX 08-SEP-2000; 2000US-0231243P.
XX 08-SEP-2000; 2000US-0231244P.
XX 08-SEP-2000; 2000US-0231413P.
XX 08-SEP-2000; 2000US-0231414P.
XX 08-SEP-2000; 2000US-0232080P.
XX 08-SEP-2000; 2000US-0232081P.
XX 12-SEP-2000; 2000US-0231968P.
```

PR 14-SEP-2000; 2000US-02323397P.  
PR 14-SEP-2000; 2000US-02323398P.  
PR 14-SEP-2000; 2000US-02323399P.  
PR 14-SEP-2000; 2000US-0232400P.  
PR 14-SEP-2000; 2000US-0232401P.  
PR 14-SEP-2000; 2000US-0233063P.  
PR 14-SEP-2000; 2000US-0233064P.  
PR 14-SEP-2000; 2000US-0233065P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 25-SEP-2000; 2000US-0234998P.  
PR 26-SEP-2000; 2000US-0235484P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 27-SEP-2000; 2000US-0235836P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239315P.  
PR 13-OCT-2000; 2000US-0239317P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241221P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241786P.  
PR 20-OCT-2000; 2000US-0241787P.  
PR 20-OCT-2000; 2000US-0241808P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 20-OCT-2000; 2000US-0241826P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 08-NOV-2000; 2000US-0246474P.  
PR 08-NOV-2000; 2000US-0246475P.  
PR 08-NOV-2000; 2000US-0246476P.  
PR 08-NOV-2000; 2000US-0246477P.  
PR 08-NOV-2000; 2000US-0246478P.  
PR 08-NOV-2000; 2000US-0246523P.  
PR 08-NOV-2000; 2000US-0246524P.  
PR 08-NOV-2000; 2000US-0246525P.  
PR 08-NOV-2000; 2000US-0246526P.  
PR 08-NOV-2000; 2000US-0246527P.  
PR 08-NOV-2000; 2000US-0246528P.  
PR 08-NOV-2000; 2000US-0246532P.  
PR 08-NOV-2000; 2000US-0246609P.  
PR 08-NOV-2000; 2000US-0246610P.  
PR 08-NOV-2000; 2000US-0246611P.  
PR 08-NOV-2000; 2000US-0246613P.  
PR 17-NOV-2000; 2000US-0249207P.  
PR 17-NOV-2000; 2000US-0249208P.  
PR 17-NOV-2000; 2000US-0249209P.  
PR 17-NOV-2000; 2000US-0249210P.  
PR 17-NOV-2000; 2000US-0249211P.  
PR 17-NOV-2000; 2000US-0249212P.  
PR 17-NOV-2000; 2000US-0249213P.  
PR 17-NOV-2000; 2000US-0249214P.  
PR 17-NOV-2000; 2000US-0249215P.  
PR 17-NOV-2000; 2000US-0249216P.  
PR 17-NOV-2000; 2000US-0249217P.  
PR 17-NOV-2000; 2000US-0249218P.  
PR 17-NOV-2000; 2000US-0249244P.  
PR 17-NOV-2000; 2000US-0249245P.  
PR 17-NOV-2000; 2000US-0249246P.  
PR 17-NOV-2000; 2000US-0249255P.  
PR 17-NOV-2000; 2000US-0249297P.  
PR 17-NOV-2000; 2000US-0249300P.  
PR 01-DEC-2000; 2000US-0250160P.  
PR 01-DEC-2000; 2000US-0250391P.

PR 05-DEC-2000; 2000US-0251030P.  
PR 05-DEC-2000; 2000US-0251988P.  
PR 05-DEC-2000; 2000US-0256719P.  
PR 06-DEC-2000; 2000US-0251479P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
PR 08-DEC-2000; 2000US-0251989P.  
PR 08-DEC-2000; 2000US-0251990P.  
PR 11-DEC-2000; 2000US-0254097P.  
PR 05-JAN-2001; 2001US-0259678P.  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
XX  
XX Rosen CA, Barash SC, Ruben SM;  
PI  
XX  
XX WPI; 2001-465568/50.  
DR N-PSDB; AAS31589.  
XX  
XX Isolated nucleic acid molecule encoding a calcium-binding protein is used  
PT in preventing, treating or ameliorating a medical condition.  
XX  
XX Claim 11; SEQ ID NO 101; 542pp; English.  
XX  
XX The present invention relates to the isolation of novel human calcium-binding proteins, and cDNA (AAS31577-AAS31654) and genomic sequences encoding for these proteins. The sequences of the invention are useful in the diagnosis, prevention and/or prognosis of diseases associated with aberrant calcium flux. Such disorders include neurological diseases (e.g. amyotrophic lateral sclerosis, ALS), immune dysfunction (e.g. severe combined immunodeficiency, SCID), digestive disorders (e.g. irritable bowel syndrome, IBS), neoplastic disease (e.g. cancer), blood disorders (e.g. haemophilia), and/or infectious disease (e.g. acquired immunodeficiency syndrome, AIDS). The novel calcium-binding proteins are also useful as screening tools to identify antagonists and/or agonists that may enhance or inhibit activities mediated by calcium-binding proteins. The polynucleotides of the invention are also useful in gene therapy. AAU19892-AAU19969 represent the novel human calcium-binding proteins. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 229 AA;  
Query Match 100.0%; Score 1249; DB 4; Length 229;  
Best Local Similarity 100.0%; Pred. No. 2.1e-95;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTWRHVRLLFTVSLALQIINLGNYSQREKHNGRGGEVTKVATQKHRSPLNWTSSHFGE 60  
DB 7 MTWRHVRLLFTVSLALQIINLGNYSQREKHNGRGGEVTKVATQKHRSPLNWTSSHFGE 66  
QY 61 VTGSAGWGPEEPLYSRAFEGASARPCRCRNGGTCVLGSPVCVPAHFTGRVCEHDQRR 120  
DB 67 VTGSAGWGPEEPLYSRAFEGASARPCRCRNGGTCVLGSPVCVPAHFTGRVCEHDQRR 126  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 186  
QY 181 LLPCALLHRLLRDPAPAHPRSLVPSVLQRRRRCGRFGLGHLRL 223  
DB 187 LLPCALLHRLLRDPAPAHPRSLVPSVLQRRRRCGRFGLGHLRL 229

RESULT 6  
ABJ05749  
ID ABJ05749 standard; protein; 229 AA.  
XX ABJ05749;  
XX  
DT 14-NOV-2002 (first entry)  
XX



XX Human; neurotropic; cytostatic; dermatological; virucide;  
KW immunosuppressive; antiinflammatory; anti-HIV; antibacterial; vulnery;  
KW antiparkinsonian; antitickling; antianaemic; antiarthritic; cancer;  
KW antirheumatic; hepatotropic; cerebroprotective; antiinflammatory;  
KW antiallergic; antidiabetic; antitumor; anticonvulsant; antifungal;  
KW antiparasitic; cardiant; immune disorder; cardiovascular disorder;  
KW neurological disease; infection; neurotropic; gene therapy; vaccine.  
XX  
OS Homo sapiens.  
XX  
XX US2002090672-A1.  
PN  
XX 11-JUL-2002.  
XX  
XX 17-JAN-2001; 2001US-00764853.  
XX  
PR 31-JAN-2000; 2000US-0179065P.  
PR 04-FEB-2000; 2000US-0180628P.  
PR 28-JUN-2000; 2000US-0214886P.  
PR 07-JUL-2000; 2000US-0216647P.  
PR 07-JUL-2000; 2000US-0216980P.  
PR 11-JUL-2000; 2000US-0217487P.  
PR 11-JUL-2000; 2000US-0217496P.  
PR 14-JUL-2000; 2000US-0218290P.  
PR 26-JUL-2000; 2000US-0220963P.  
PR 26-JUL-2000; 2000US-0220964P.  
PR 14-AUG-2000; 2000US-0224518P.  
PR 14-AUG-2000; 2000US-0224519P.  
PR 14-AUG-2000; 2000US-0225267P.  
PR 14-AUG-2000; 2000US-0225268P.  
PR 14-AUG-2000; 2000US-0225270P.  
PR 14-AUG-2000; 2000US-0225447P.  
PR 14-AUG-2000; 2000US-0225757P.  
PR 14-AUG-2000; 2000US-0225758P.  
PR 22-AUG-2000; 2000US-0226868P.  
PR 30-AUG-2000; 2000US-0228924P.  
PR 01-SEP-2000; 2000US-0229287P.  
PR 01-SEP-2000; 2000US-0229343P.  
PR 01-SEP-2000; 2000US-0229344P.  
PR 01-SEP-2000; 2000US-0229345P.  
PR 05-SEP-2000; 2000US-0229509P.  
PR 05-SEP-2000; 2000US-0229513P.  
PR 08-SEP-2000; 2000US-0231413P.  
PR 21-SEP-2000; 2000US-0234223P.  
PR 21-SEP-2000; 2000US-0234274P.  
PR 25-SEP-2000; 2000US-0234997P.  
PR 27-SEP-2000; 2000US-0235834P.  
PR 29-SEP-2000; 2000US-0236327P.  
PR 29-SEP-2000; 2000US-0236367P.  
PR 29-SEP-2000; 2000US-0236368P.  
PR 29-SEP-2000; 2000US-0236369P.  
PR 29-SEP-2000; 2000US-0236370P.  
PR 02-OCT-2000; 2000US-0236802P.  
PR 02-OCT-2000; 2000US-0237037P.  
PR 02-OCT-2000; 2000US-0237038P.  
PR 02-OCT-2000; 2000US-0237039P.  
PR 02-OCT-2000; 2000US-0237040P.  
PR 13-OCT-2000; 2000US-0239355P.  
PR 20-OCT-2000; 2000US-0240960P.  
PR 20-OCT-2000; 2000US-0241785P.  
PR 20-OCT-2000; 2000US-0241809P.  
PR 01-NOV-2000; 2000US-0244617P.  
PR 11-NOV-2000; 2000US-0249299P.  
PR 08-DEC-2000; 2000US-0251856P.  
PR 08-DEC-2000; 2000US-0251868P.  
PR 08-DEC-2000; 2000US-0251869P.  
XX  
XX (ROSE/) ROSEN C A.  
PA (RUBE/) RUBEN S M.  
PA (BARA/) BARASH S C.  
XX  
XX Rosen CA, Ruben SM, Barash SC;  
PI

XX WPI; 2002-681727/73.  
DR N-PSDB; ABV83859.  
XX  
PT Novel polypeptide useful for diagnosis, prognosis, prevention, and  
PT treatment of immune, hyperproliferative, renal, respiratory,  
PT cardiovascular, reproductive, endocrine, gastrointestinal and  
PT neurological disorders.  
XX  
PS Claim 11; SEQ ID NO 608; 369pp + Sequence Listing; English.  
XX  
XX The invention relates to novel genes (ABV83682-ABV84101) and proteins  
CC (ABP66710-ABP67129) useful for preventing, treating or ameliorating  
CC medical conditions e.g. by protein or gene therapy. The genes are  
CC isolated from a range of human tissues disclosed in the specification.  
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in  
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and  
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,  
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune  
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic  
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,  
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)  
CC cardiovascular disorders such as myocardial ischaemias; (d) wound healing  
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)  
CC infectious diseases such as viral, bacterial, fungal and parasitic  
CC infections. Note: The sequence data for this patent did not form part of  
CC the printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 229 AA;  
Query Match 100.0%; Score 1249; DB 5; Length 229;  
Best Local Similarity 100.0%; Pred. No. 2.1e-95;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTRRHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKIQRSPLNWTSSHFGE 60  
DB 7 MTRRHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKIQRSPLNWTSSHFGE 66  
QY 61 VTGSAEGMGPEEPLPYSRAPGEGASARPRCCRNNGTCTVLGSCVCPAHFTGRYCEHDQRR 120  
DB 67 VTGSAEGMGPEEPLPYSRAPGEGASARPRCCRNNGTCTVLGSCVCPAHFTGRYCEHDQRR 126  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGAPSLLL 186  
QY 181 LLPCALLHLLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGRL 223  
DB 187 LLPCALLHLLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGRL 229  
RESULT 8  
AAU16957  
ID AAU16957 standard; protein; 231 AA.  
XX  
XX AAU16957;  
AC  
XX  
DT 07-NOV-2001 (first entry)  
XX  
DE Human novel secreted protein, SEQ ID 198.  
XX  
XX Human; immunosuppressive; antiarthritic; antirheumatic; cytostatic;  
KW cardiant; vasotropic; cerebroprotective; neurotropic; neuroprotective;  
KW antibacterial; virucide; fungicide; ophthalmological; vulnerary;  
KW secreted protein; rheumatoid arthritis; hyperproliferative disorder;  
KW cardiovascular disorder; cardiac arrest; cerebrovascular disorder;  
KW cerebral ischaemia; angiogenesis; nervous system disorder;  
KW Alzheimer's disease; infection; ocular disorder; corneal infection;  
KW wound healing; epithelial cell proliferation; skin ageing; food additive;  
KW preservative; antiproliferative.  
XX  
XX Homo sapiens.

```

XX PN WO200155441-A2.
XX PD 02-AUG-2001.
XX PF 17-JAN-2001; 2001WO-US001320.
XX 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216980P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220563P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225113P.
PR 14-AUG-2000; 2000US-0225114P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225477P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 18-AUG-2000; 2000US-0225759P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226686P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 08-SEP-2000; 2000US-0231142P.
PR 08-SEP-2000; 2000US-0231143P.
PR 08-SEP-2000; 2000US-0231144P.
PR 08-SEP-2000; 2000US-0231145P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234957P.
PR 25-SEP-2000; 2000US-0234958P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 13-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241828P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249266P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 06-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX (HUMA-) HUMAN GENOME SCI INC.
XX PA
XX

```

```
PI Rosen CA, Barash SC, Ruben SM;
XX WPI: 2001-476222/51.
DR N-PSDB; AAS26862.
XX
XX Novel polypeptides and polynucleotides useful as diagnostic reagents to
PT diagnose diseases or disorders associated with aberrant expression or
PT activity of polypeptides, for treating blood clotting disorder,
PT hemophilia.
XX
XX Claim 11; SEQ ID NO 198; 601pp; English.
PS
XX The invention relates to isolated nucleic acid molecules and their
XX encoded secreted proteins. The nucleic acids and proteins are used to
CC prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. Antibodies to the proteins can also be used in
CC alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbant assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiodenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection,
CC and many other disorders listed in the specification. The polypeptides
CC can also be used to aid wound healing and epithelial cell proliferation,
CC to prevent skin aging due to sunburn, to maintain organs before
CC transplantation, for supporting cell culture of primary tissues, to
CC regenerate tissues and in chemotaxis. The polypeptides can also be used
CC as a food additive or preservative to increase or decrease storage
CC capabilities, fat content, lipid, protein, carbohydrate, vitamins,
CC minerals, cofactors and other nutritional components. The present
CC sequence represents a novel secreted protein of the invention. Note: The
Query Match 99.4%; Score 1242; DB 4; Length 231;
Best Local Similarity 99.6%; Pred. No. 8e-95;
Matches 222; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MTRHHVRLFTVSLALQIINLGNVQREKHNGRGVEVTKVATQKHRSPLNWTSSHFG 60
DB 9 MTRHHVRLFTVSLALQIINLGNVQREKHNGRGVEVTKVATQKHRSPLNWTSSHFG 68
QY 61 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120
DB 69 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 128
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180
DB 129 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 188
QY 181 LLPCALLHRLRLDPADPAHPRLSPVSLQRRRRCGRPLGHRL 223
DB 189 LLPCALLHRLRLDPADPAHPRLSPVSLQRRRRCGRPLGHRL 231
RESULT 9
ABB90336
ID ABB90336 standard; protein; 223 AA.
XX
AC ABB90336;
XX
XX Human polypeptide SEQ ID NO 2712.
DE
XX
XX Cytostatic; immunosuppressive; nootropic; neuroprotective; antiviral;
KW anti-allergic; hepatotropic; antidiabetic; antiinflammatory; antiulcer;
KW vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic;
KW cardiant; gene therapy; cancer; immune disorder; cardiovascular disorder;
KW neurological disease; infection; human; secreted protein.
XX
```

```
OS Homo sapiens.
XX
XX WO200190304-A2.
XX
XX 29-NOV-2001.
XX
XX 18-MAY-2001; 2001WO-US016450.
XX
XX 19-MAY-2000; 2000US-0205515P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Birse CE, Rosen CA;
XX
XX WPI: 2002-122018/16.
XX N-PSDB; ABL90745.
XX
XX Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
PT prevention of neural, immune system, muscular, reproductive,
PT gastrointestinal, pulmonary, cardiovascular, renal and proliferative
PT disorders.
XX
XX Claim 11; SEQ ID NO 2712; 2081pp + Sequence Listing; English.
PS
XX The invention relates to novel genes (ABL9449-ABL90853) and proteins
CC (ABB9040-ABB90444) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful in
CC the diagnosis, treatment and prevention of: (a) cancer, e.g. breast and
CC ovarian cancer and other cancers of the adrenal gland, bone, bone marrow,
CC breast, gastrointestinal tract, liver, lung, or urogenital; (b) immune
CC disorders e.g. Addison's disease, allergies, autoimmune haemolytic
CC anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's disease,
CC multiple sclerosis, rheumatoid arthritis and ulcerative colitis; (c)
CC cardiovascular disorders such as myocardial ischaemia; (d) wound healing
CC ; (e) neurological diseases e.g. cerebral anoxia and epilepsy; and (f)
CC infectious diseases such as viral, bacterial, fungal and parasitic
CC infections. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at fcp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 223 AA;
Query Match 99.4%; Score 1241; DB 5; Length 223;
Best Local Similarity 99.6%; Pred. No. 9.3e-95;
Matches 222; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 MTRHHVRLFTVSLALQIINLGNVQREKHNGRGVEVTKVATQKHRSPLNWTSSHFG 60
DB 1 MTRHHVRLFTVSLALQIINLGNVQREKHNGRGVEVTKVATQKHRSPLNWTSSHFG 60
QY 61 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120
DB 61 VTGSAGWGPEEPLPYSRAFEGEGASARPCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180
DB 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180
QY 181 LLPCALLHRLRLDPADPAHPRLSPVSLQRRRRCGRPLGHRL 223
DB 181 LLPCALLHRLRLDPADPAHPRLSPVSLQRRRRCGRPLGHRL 223
RESULT 10
ABU56711
ID ABU56711 standard; protein; 223 AA.
XX
AC ABU56711;
XX
XX 02-APR-2003 (first entry)
XX
```

DE Lung cancer-associated polypeptide #304.

XX Lung cancer-associated polypeptide; cytostatic; emphysema;

KW antiinflammatory; antiasthmatic; non-small cell lung cancer; atelectasis;

KW small cell lung cancer; benign lesion; precancerous lesion; bronchitis;

KW chronic obstructive pulmonary disease; hypersensitivity pneumonitis;

KW interstitial pulmonary fibrosis; fibrosis; asthma; bronchiectasis.

XX Unidentified.

OS

XX WO200286443-A2.

PN

XX 31-OCT-2002.

PD

XX 18-APR-2002; 2002WO-US012476.

PF

XX 18-APR-2001; 2001US-0284770P.

PR

XX 10-MAY-2001; 2001US-0290492P.

PR

XX 09-NOV-2001; 2001US-0339245P.

PR

XX 13-NOV-2001; 2001US-0350666P.

PR

XX 29-NOV-2001; 2001US-0334370P.

PR

XX 12-APR-2002; 2002US-0372246P.

PR

XX (EOSB-) EOS BIOTECHNOLOGY INC.

PA

XX Aziz N, Murray R;

PI

XX WPI; 2003-093161/08.

DR

XX N-PSDB; ABX76440.

DR

XX Detecting a lung cancer-associated transcript in a cell from a patient

PT for treating lung cancer, by contacting a biological sample from the

PT patient with a polynucleotide that exhibits increased or decreased

PT expression in lung cancer.

PT

XX Claim 27; Page 426; 453pp; English.

PS

XX The invention relates to a method for detecting a lung cancer-associated

CC transcript in a cell from a patient, comprising contacting a biological

CC sample from the patient with a polynucleotide that selectively hybridizes

CC to a sequence that is at least 80 % identical to a gene that exhibits

CC increased or decreased expression in lung cancer samples. Lung cancer-

CC associated polynucleotides and polypeptides are used for identifying a

CC compound that modulates a lung cancer-associated polypeptide, for

CC inhibiting proliferation of a lung cancer-associated cell to treat lung

CC cancer in a patient and for treating a mammal having lung cancer by

CC administering a modulatory compound identified. The methods are useful

CC for treating lung cancer, such as small cell lung cancer, non-small cell

CC lung cancer or other benign or precancerous lesions, e.g. atelectasis,

CC emphysema, bronchitis, chronic obstructive pulmonary disease, fibrosis,

CC hypersensitivity pneumonitis, interstitial pulmonary fibrosis, asthma and

CC bronchiectasis. The genes, polynucleotides and polypeptides are useful

CC for diagnostic purposes and as targets for screening for therapeutic.

CC compounds that modulate lung cancer, such as antibodies. Sequences

CC ABU56408-ABU56745 represent lung cancer-associated polypeptides of the

CC invention

XX

SQ Sequence 223 AA;

Query Match 99.4%; Score 1241; DB 6; Length 223;

Best Local Similarity 99.8%; Pred. No. 9.3e-95;

Matches 222; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1 MTRHHVRLFTVSLAQIINLGNYSQREKHNGRGREVTKVATQKHQSPLNWTSFHGE 60

DB 1 MTRHHVRLFTVSLAQIINLGNYSQREKHNGRGREVTKVATQKHQSPLNWTSFHGE 60

OY 61 VTGAEGWGPEEPLPYSAFEGEGASAPRCRRNGGTCVLGSPFCVPAHFTGRVCEHDQRR 120

DB 61 VTGAEGWGPEEPLPYSAFEGEGASAPRCRRNGGTCVLGSPFCVPAHFTGRVCEHDQRR 120

OY 121 SEGGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGGAPSLLL 180

Db 121 SEGGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGGAPSLLL 180

OY 181 LLPCALIHLRLRPDAPAHPRSLVPSVLQRRPCCGRPGIGHRL 223

DB 181 LLPCALIHLRLRPDAPAHPRSLVPSVLQRRPCCGRPGIGHRL 223

RESULT 11

ADN39104

ID ADN39104 standard; protein; 223 AA.

XX

AC ADN39104;

XX

DT 17-JUN-2004 (first entry)

XX

DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:422.

XX

KW Human; differential expression; cancer; angiogenic disorder;

KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;

KW inflammatory disease; autoimmune disease;

KW retinal neovascularization syndrome; scarring; uterine fibroid;

KW detection; diagnosis; prognosis; drug screening; drug targeting;

KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;

KW vulneryary; gene therapy; vaccine.

XX

OS Homo sapiens.

XX

PN WO2003042661-A2.

XX

PD 22-MAY-2003.

XX

XX 13-NOV-2002; 2002WO-US036810.

PF

XX 13-NOV-2001; 2001US-0350666P.

PR

XX 21-NOV-2001; 2001US-0332464P.

PR

XX 29-NOV-2001; 2001US-0334393P.

PR

XX 03-DEC-2001; 2001US-0335394P.

PR

XX 14-DEC-2001; 2001US-0340376P.

PR

XX 08-JAN-2002; 2002US-0347211P.

PR

XX 10-JAN-2002; 2002US-0347349P.

PR

XX 08-FEB-2002; 2002US-0355250P.

PR

XX 13-FEB-2002; 2002US-0356714P.

PR

XX 20-FEB-2002; 2002US-0359077P.

PR

XX 29-MAR-2002; 2002US-0368809P.

PR

XX 04-APR-2002; 2002US-0370110P.

PR

XX 12-APR-2002; 2002US-0372246P.

PR

XX 05-JUN-2002; 2002US-0386614P.

PR

XX 16-JUL-2002; 2002US-0396839P.

PR

XX 22-JUL-2002; 2002US-039775P.

PR

XX 22-JUL-2002; 2002US-0397845P.

PR

XX 09-SEP-2002; 2002US-0409450P.

XX

PA (EOSB-) EOS BIOTECHNOLOGY INC.

XX

XX Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;

PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;

XX

XX WPI; 2003-468649/44.

DR

XX N-PSDB; ADN39103.

DR

XX Determining the presence or absence of a pathological cell in a patient,

PT useful for diagnosing, prognosing or treating cancer, comprises detecting

PT a nucleic acid in a biological sample.

PT

XX Claim 12; SEQ ID NO 422; 1385pp; English.

PS

XX The invention relates to nucleic acids and proteins (ADN38683-ADN40064)

CC whose expression is upregulated or downregulated in specific cancers or

CC whose diseases such as angiogenic or fibrotic disorders, and to methods

CC of determining the presence or absence of a pathological cell in a

CC patient by detecting a nucleic acid at least 80% identical to those of

CC the invention or by detecting a polypeptide of the invention. The

CC invention also relates to expression vectors and host cells comprising a

CC nucleic acid of the invention; antibodies which specifically bind a  
CC polypeptide of the invention; use of such antibodies for drug targeting;  
CC and methods of screening for modulators of activity or expression of the  
CC polypeptides and nucleic acids. The nucleic acids, polypeptides, and  
CC antibodies and methods are useful for diagnosing, prognosing and treating  
CC cancer and other conditions such as psoriasis, ischaemia, heart disease,  
CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal  
CC neovascularisation syndromes, scarring and uterine fibroids. They may  
CC also be useful in wound healing and in contraception. The present  
CC sequence represents a polypeptide of the invention.  
XX  
SQ Sequence 223 AA;  
Query Match 99.4%; Score 1241; DB 7; Length 223;  
Best Local Similarity 99.6%; Pred. No. 9.3e-95;  
Matches 222; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKHRSPLNWTSSHFGE 60  
DB 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKHRSPLNWTSSHFGE 60  
QY 61 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNNGTCTVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 61 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNNGTCTVLGSCFVCPAHFTGRYCEHDQRR 120  
QY 121 SEGCALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180  
DB 121 SEGCALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180  
QY 181 LLPCALLHRLRPDAPAHPSRLVPSVLQRRRRCGRPLGHLRL 223  
DB 181 LLPCALLHRLRPDAPAHPSRLVPSVLQRRRRCGRPLGHLRL 223  
RESULT 12  
ADN39975  
ID ADN39975 standard; protein; 223 AA.  
XX  
AC ADN39975;  
XX  
DT 17-JUN-2004 (first entry)  
XX  
DE Cancer/angiogenesis/fibrosis-related polypeptide, SEQ ID NO:C345.  
XX  
KW Human; differential expression; cancer; angiogenic disorder;  
KW fibrotic disorder; psoriasis; ischaemia; heart disease; atherosclerosis;  
KW inflammatory disease; autoimmune disease;  
KW retinal neovascularisation syndrome; scarring; uterine fibroid;  
KW detection; diagnosis; prognosis; drug screening; drug targeting;  
KW wound healing; contraception; cytostatic; cardiant; immunomodulatory;  
KW vulnery; gene therapy; vaccine.  
XX  
OS Homo sapiens.  
XX  
PN W02003042661-A2.  
XX  
PD 22-MAY-2003.  
XX  
PF 13-NOV-2002; 2002WO-US036810.  
XX  
PR 13-NOV-2001; 2001US-0350666P.  
PR 21-NOV-2001; 2001US-0332464P.  
PR 23-NOV-2001; 2001US-0334393P.  
PR 03-DEC-2001; 2001US-0335394P.  
PR 14-DEC-2001; 2001US-0340376P.  
PR 08-JAN-2002; 2002US-0347211P.  
PR 10-JAN-2002; 2002US-0347349P.  
PR 08-FEB-2002; 2002US-035250P.  
PR 13-FEB-2002; 2002US-0356714P.  
PR 20-FEB-2002; 2002US-0359077P.  
PR 29-MAR-2002; 2002US-036809P.  
PR 04-APR-2002; 2002US-0370110P.  
PR 12-APR-2002; 2002US-0372246P.

PR 05-JUN-2002; 2002US-0386614P.  
PR 16-JUL-2002; 2002US-0396839P.  
PR 22-JUL-2002; 2002US-039775P.  
PR 22-JUL-2002; 2002US-0397845P.  
PR 09-SEP-2002; 2002US-0409450P.  
XX  
PA (SOSB-) EOS BIOTECHNOLOGY INC.  
XX  
XX Afar D, Aziz N, Ginsburg WM, Gish KC, Glynn R, Hevezi PA;  
PI Mack DH, Murray R, Watson SR, Wilson KE, Zlotnik A;  
XX  
DR WPI; 2003-468649/44.  
DR N-PSDB; ADN39758.  
XX  
PT Determining the presence or absence of a pathological cell in a patient,  
PT useful for diagnosing, prognosing or treating cancer, comprises detecting  
PT a nucleic acid in a biological sample.  
XX  
PS Claim 12; SEQ ID NO C345; 1385pp; English.  
XX  
CC The invention relates to nucleic acids and proteins (ADN38683-ADN40064)  
CC whose expression is upregulated or downregulated in specific cancers or  
CC other diseases such as angiogenic or fibrotic disorders, and to methods  
CC of determining the presence or absence of a pathological cell in a  
CC patient by detecting a nucleic acid at least 80% identical to those of  
CC the invention or by detecting a polypeptide of the invention. The  
CC invention also relates to expression vectors and host cells comprising a  
CC nucleic acid of the invention; antibodies which specifically bind a  
CC polypeptide of the invention; use of such antibodies for drug targeting;  
CC and methods of screening for modulators of activity or expression of the  
CC polypeptides and nucleic acids. The nucleic acids, polypeptides,  
CC antibodies and methods are useful for diagnosing, prognosing and treating  
CC cancer and other conditions such as psoriasis, ischaemia, heart disease,  
CC atherosclerosis, inflammatory diseases, autoimmune diseases, retinal  
CC neovascularisation syndromes, scarring and uterine fibroids. They may  
CC also be useful in wound healing and in contraception. The present  
CC sequence represents a polypeptide of the invention.  
XX  
SQ Sequence 223 AA;  
Query Match 99.4%; Score 1241; DB 7; Length 223;  
Best Local Similarity 99.6%; Pred. No. 9.3e-95;  
Matches 222; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKHRSPLNWTSSHFGE 60  
DB 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGEVTKVATQKHRSPLNWTSSHFGE 60  
QY 61 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNNGTCTVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 61 VTGSAEGWGPEEPLPYSRAFEGASARPRCCRNNGTCTVLGSCFVCPAHFTGRYCEHDQRR 120  
QY 121 SEGCALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180  
DB 121 SEGCALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180  
QY 181 LLPCALLHRLRPDAPAHPSRLVPSVLQRRRRCGRPLGHLRL 223  
DB 181 LLPCALLHRLRPDAPAHPSRLVPSVLQRRRRCGRPLGHLRL 223  
RESULT 13  
ADY85963  
ID ADY85963 standard; protein; 223 AA.  
XX  
AC ADY85963;  
XX  
DT 16-JUN-2005 (first entry)  
XX  
DE Human Cripitic protein, a member of the EGF-CFC family Seq 4.  
XX  
KW cell signaling; oncogenesis; antisense therapy; cytostatic; mutagenesis;  
KW protein interaction; oncoprotein.

XX OS Homo sapiens.  
XX PN WO2005028433-A2.  
XX PD 31-MAR-2005.  
XX PF 14-SEP-2004; 2004WO-US029967.  
XX PR 15-SEP-2003; 2003US-0503046P.  
XX PA (RERE-) RES DEV FOUND.  
XX PI Vale W, Gray FC, Harrison CA;  
XX PD WPI; 2005-242562/25.  
XX PT Augmenting signaling of a ligand of receptor serine kinase in a cell  
PT comprises inhibiting the formation of complexes between Cripto and the  
PT ligand on the surface of the cell.  
XX PS Disclosure; SEQ ID NO 4; 60pp; English.  
XX CC This invention relates to a novel method for augmenting signaling of a  
CC ligand of a receptor serine kinase within a cell by inhibiting the  
CC formation of complexes between Cripto and this ligand on the surface of  
CC the cell. Specifically, it refers to TGF-beta and activin which are the  
CC ligands of serine kinase receptors and which regulate tissue homeostasis  
CC by activating the Smad2/3 intracellular signaling pathway; disruption of  
CC this signaling pathway is associated with oncogenesis and tumorigenesis.  
CC As such, the present invention describes a method for augmenting Smad2/3  
CC signaling in a cell by administering a mutant ligand that retains  
CC signaling activity but is unable to bind to Cripto, and thus bypasses  
CC antagonism by Cripto. Note that augmentation of signaling increases  
CC phosphorylation and activation of Smad2 and Smad3 in the cell, such that  
CC it decreases the proliferative rate of the cell. The receptor serine  
CC kinase is a type I activin receptor-like kinases-4 or -5 (ALK-4 or ALK-5)  
CC and the formation of complexes is inhibited by suppressing expression of  
CC Cripto using antisense oligonucleotides (siRNA) directed against Cripto,  
CC and also mutating at least one allele of Cripto by homologous  
CC recombination. Accordingly, pharmaceutical compositions derived thereof  
CC exhibit cytostatic activity. This polypeptide sequence is the human  
CC Criptic protein, a member of the EGF-CFC (Epidermal Growth Factor-Cripto,  
CC FRL-1, Criptic) family of proteins of the invention.  
XX SQ Sequence 223 AA;  
Query Match 99.4%; Score 1241; DB 9; Length 223;  
Best Local Similarity 99.6%; Pred. No. 9.3e-95;  
Matches 222; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1 MTWRHHVRLFTVSLALQIINLNSYQREKHNGRGREVTKVATQKHQSPLNWTSHFGE 60  
DB 1 MTWRHHVRLFTVSLALQIINLNSYQREKHNGRGREVTKVATQKHQSPLNWTSHFGE 60  
QY 61 VTGSAGWGPEEPLPYSRAPFEGASARPCRCRNGGTCVLGSCFCVCPAHTGTYCEHDQRR 120  
DB 61 VTGSAGWGPEEPLPYSRAPFEGASARPCRCRNGGTCVLGSCFCVCPAHTGTYCEHDQRR 120  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLOTDPDRCDPKDFLASHAHGFSAGGAPSLLL 180  
DB 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLOTDPDRCDPKDFLASHAHGFSAGGAPSLLL 180  
QY 181 LLPCALLHRLRLPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223  
DB 181 LLPCALLHRLRLPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223  
RESULT 14  
AAG77914  
ID AAG77914 standard; protein; 223 AA.  
XX AC AAG77914;

XX DT 23-JAN-2002 (first entry)  
XX DE Human cryptic-like polypeptide.  
XX KW Cryptic; human; cytostatic; cardiant; nootropic; neuroleptic; cancer;  
KW antiasthmatic; anti-angiogenic; gene therapy; lung cancer; asthma; activity;  
KW respiratory disease; epilepsy; schizophrenia; depression; hyperactivity;  
KW heart hypertrophy; heart failure; cardiomyopathy; angiogenesis;  
XX OS Homo sapiens.  
XX PN WO200177322-A1.  
XX PD 18-OCT-2001.  
XX PF 06-APR-2001; 2001WO-EP003965.  
XX PR 10-APR-2000; 2000EP-00107142.  
XX PA (MERE ) MERCK PATENT GMBH.  
XX PI Duecker K;  
XX DR WPI; 2002-017462/02.  
XX DR N-PSDB; AAH77168.  
XX PT Novel cryptic-like secreted polypeptide found in various tumors and  
PT organs is useful to treat diseases including cancer, particularly lung  
PT cancer, asthma and heart disease.  
XX PS Claim 1; Page 33-34; 37pp; English.  
XX CC The sequence represents the novel human cryptic-like secreted protein of  
CC the invention. The polypeptide of the invention has cytostatic, cardiant,  
CC nootropic, neuroleptic, antiasthmatic, and anti-angiogenic activity, and  
CC has a use in gene therapy. The polypeptide and polynucleotide of the  
CC invention may be used to treat cancer, particularly lung cancer,  
CC respiratory diseases, asthma, epilepsy, schizophrenia, depression,  
CC hyperactivity, heart hypertrophy, heart failure, cardiomyopathies,  
CC aberrant angiogenesis and vasculogenesis  
XX SQ Sequence 223 AA;  
Query Match 98.7%; Score 1233; DB 5; Length 223;  
Best Local Similarity 99.1%; Pred. No. 4.3e-94;  
Matches 221; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 MTWRHHVRLFTVSLALQIINLNSYQREKHNGRGREVTKVATQKHQSPLNWTSHFGE 60  
DB 1 MTWRHHVRLFTVSLALQIINLNSYQREKHNGRGREVTKVATQKHQSPLNWTSHFGE 60  
QY 61 VTGSAGWGPEEPLPYSRAPFEGASARPCRCRNGGTCVLGSCFCVCPAHTGTYCEHDQRR 120  
DB 61 VTGSAGWGPEEPLPYSRAPFEGASARPCRCRNGGTCVLGSCFCVCPAHTGTYCEHDQRR 120  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLOTDPDRCDPKDFLASHAHGFSAGGAPSLLL 180  
DB 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLOTDPDRCDPKDFLASHAHGFSAGGAPSLLL 180  
QY 181 LLPCALLHRLRLPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223  
DB 181 LLPCALLHRLRLPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223  
RESULT 15  
AAW09111  
ID AAW09111 standard; protein; 230 AA.  
XX AC AAW09111;  
XX DT 16-APR-1997 (first entry)

XX Human criptin growth factor.  
DE  
XX  
XX Criptin growth factor; CGF; angiogenesis; wound healing; vulnerary;  
KW muscle wastage; osteoporosis; implant fixation; tissue regeneration;  
KW pancreas cancer; diagnosis; gene therapy.  
XX  
XX Homo sapiens.  
OS  
XX  
XX  
XX Key Location/Qualifiers  
FT Peptide 1. .23  
FT /label= Sig\_peptide  
XX  
XX WO9639420-A1.  
XX  
XX  
XX 12-DEC-1996.  
PD  
XX  
XX 05-JUN-1995; 95WO-US007087.  
PF  
XX  
XX 05-JUN-1995; 95WO-US007087.  
PR  
XX  
XX (HUMA-) HUMAN GENOME SCI INC.  
PA  
XX  
XX Meissner PS, Coleman TA;  
PI  
XX  
XX WPI; 1997-043055/04.  
DR N-PSDB; AAT51058.  
DR  
XX  
XX New isolated human Criptin Growth Factor polypeptide - which can be used  
PT to stimulate angiogenesis and develop products for use in diagnosis and  
PT therapy.  
PT  
XX  
XX Claim 12; Fig 1; 52pp; English.  
PS  
XX  
XX Human criptin growth factor (CGF) (AAM09111) is a novel polypeptide  
CC structurally related to human cripto growth factor. It is overexpressed  
CC and secreted by certain types of cancer cells, e.g. pancreatic cancers.  
CC Recombinant CGF can be produced in host cells utilising vectors  
CC incorporating a CGF cDNA clone (AAT51058) isolated from a human  
CC pancreatic cancer tissue cDNA library. CGF can be used to treat e.g.  
CC muscle wasting diseases, osteoporosis, to aid implant fixation, to  
CC stimulate tissue regeneration and wound healing, to promote angiogenesis  
CC and to stimulate proliferation of vascular smooth muscle and endothelial  
CC cell prodn. It can also be used as a marker for cancer diagnosis  
XX  
XX Sequence 230 AA;  
Query Match 83.6%; Score 1044; DB 2; Length 230;  
Best Local Similarity 91.4%; Pred. No. 2e-78;  
Matches 191; Conservative 1; Mismatches 5; Indels 12; Gaps 2;  
Qy 1 MTRHHVRLFTVSLALQIINLNGSYOREKHNGRGEVTKVATQKHQSPINWTSSHFG 60  
Db 1 MTRHHVRLFTVSLALQIINLNGSYOREKHNGRGEVTKVATQKHQSPINWTSSHFG 60  
Qy 61 VTGSAEGWGPEEPYPYRAFEGEGASAPRCRNGGTGVLGSCFVCPAHFTGRYCEHDQRR 120  
Db 61 VTGSAEGWGPEEPYPYRAFEGEGASAPRCRNGGTGVLGSCFVCPAHFTGRYCEHDQRR 120  
Qy 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGGAPSLLL 180  
Db 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGGAPSLLL 180  
Qy 181 LLPCALLHRLRPDAPA-----HPRSLVP 204  
Db 181 LLPCA-----TPAPASCARMRPRTLGP 202

Search completed: September 7, 2006, 11:54:01  
Job time : 198 secs

**This Page Blank (uspto)**

GenCore version 5.1.9  
Copyright (c) 1993 - 2006 Bioceleration Ltd.  
OM protein - protein search, using sw model  
Run on: September 7, 2006, 12:35:51 ; Search time 174 Seconds  
(without alignments)  
593.660 Million cell updates/sec  
Title: US-10-665-602-2  
Perfect score: 223  
Sequence: 1 MTRWHVRLFTVSLALQII.....PSVLQRERRPCGRPLGHLRL 223  
Scoring table: OLIGO  
Gapop 60.0 , Gapext 60.0  
Searched: 2097797 seqs, 463214858 residues  
Word size : 30  
Total number of hits satisfying chosen parameters: 14  
Minimum DB seq length: 0  
Maximum DB seq length: 200000000  
Post-processing: Listing first 45 summaries  
Database : Published Applications AA Main:  
1: /EMC\_Celerra\_SID33/ptodata/2/pubpaa/US07\_PUBCOMB.pap.\*  
2: /EMC\_Celerra\_SID33/ptodata/2/pubpaa/US08\_PUBCOMB.pap.\*  
3: /EMC\_Celerra\_SID33/ptodata/2/pubpaa/US09\_PUBCOMB.pap.\*  
4: /EMC\_Celerra\_SID33/ptodata/2/pubpaa/US10\_PUBCOMB.pap.\*  
5: /EMC\_Celerra\_SID33/ptodata/2/pubpaa/US10\_PUBCOMB.pap.\*  
6: /EMC\_Celerra\_SID33/ptodata/2/pubpaa/US11\_PUBCOMB.pap.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES					Description
Result No.	Score	Query Match	Length	ID	
1	223	100.0	223	4	US-10-665-602-2
2	223	100.0	229	3	US-09-764-893-98
3	223	100.0	229	3	US-09-764-881-101
4	223	100.0	229	3	US-09-764-853-608
5	223	100.0	229	3	US-09-764-898-269
6	223	100.0	229	3	US-09-764-881-101
7	223	100.0	229	4	US-10-073-865-98
8	223	100.0	229	4	US-10-242-747-101
9	187	83.9	223	4	US-10-295-027-422
10	187	83.9	223	4	US-10-295-027-1293
11	187	83.9	223	4	US-10-264-237-2712
12	187	83.9	223	5	US-10-940-431-4
13	187	83.9	231	3	US-09-764-898-198
14	145	65.0	223	4	US-10-257-113-2

ALIGNMENTS

RESULT 1  
US-10-665-602-2  
; Sequence 2, Application US/10665602  
; Publication No. US20040086967A1  
; GENERAL INFORMATION:  
; APPLICANT: Meisner, Paul S.  
; Coleman, Timothy A.  
; TITLE OF INVENTION: Human Cripitin Growth Factor

NUMBER OF SEQUENCES: 7  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Human Genome Sciences, Inc.  
STREET: 9410 Key West Avenue  
CITY: Rockville  
STATE: MD  
COUNTRY: USA  
ZIP: 20850  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patentin Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/665,602  
FILING DATE: 22-Sep-2003  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/09/393,023A  
FILING DATE: 09-SEP-1999  
APPLICATION NUMBER: US 08/471,371  
FILING DATE: 06-JUN-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Marks, Michelle S.  
REGISTRATION NUMBER: 41,971  
REFERENCE/DOCKET NUMBER: PF200D1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 301-309-8504  
TELEFAX: 301-309-8439  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 223 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
US-10-665-602-2  
Query Match 100.0%; Score 223; DB 4; Length 223;  
Best Local Similarity 100.0%; Pred. No. 1.4e-196; Indels 0; Gaps 0;  
Matches 223; Conservative 0; Mismatches 0  
Qy 1 MTRWHVRLFTVSLALQIIINLGNSTYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFG 60  
Db 1 MTRWHVRLFTVSLALQIIINLGNSTYQREKHNGRGVEVTKVATQKHRSPLNWTSSHFG 60  
Qy 61 VTGSAEGWGPEEPLYSRAFEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
Db 61 VTGSAEGWGPEEPLYSRAFEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
Qy 121 SEGGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180  
Db 121 SEGGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGFSAGAPSLLL 180  
Qy 181 LLPCALLHRLLRDPAHAHPRSLVPSVLQRRRRCGRPLGHLRL 223  
Db 181 LLPCALLHRLLRDPAHAHPRSLVPSVLQRRRRCGRPLGHLRL 223  
RESULT 2  
US-09-764-893-98  
; Sequence 98, Application US/09764893  
; Publication No. US20020086330A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: P209  
; CURRENT APPLICATION NUMBER: US/09/764,893  
; CURRENT FILING DATE: 2001-01-19  
; Prior application data removed - consult PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 154  
; SOFTWARE: Patentin Ver. 2.0  
; SEQ ID NO 98

; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-893-98

Query Match 100.0%; Score 223; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-196;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVTKVATQKHQSPLNWTSSTHSGE 60  
DB 7 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVTKVATQKHQSPLNWTSSTHSGE 66  
QY 61 VTGSAEGWGPEEPLPYSRAFEGEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 67 VTGSAEGWGPEEPLPYSRAFEGEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGAPSLLL 186  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGHLR 223  
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGHLR 229

## RESULT 3

US-09-764-881-101  
; Sequence 101, Application US/09764881  
; Publication No. US20020086821A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: PT207  
; CURRENT APPLICATION NUMBER: US/09/764,881  
; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - refer to PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 192  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 101  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-881-101

Query Match 100.0%; Score 223; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-196;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVTKVATQKHQSPLNWTSSTHSGE 60  
DB 7 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVTKVATQKHQSPLNWTSSTHSGE 66  
QY 61 VTGSAEGWGPEEPLPYSRAFEGEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 67 VTGSAEGWGPEEPLPYSRAFEGEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGAPSLLL 180

DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGAPSLLL 186  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGHLR 223  
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGHLR 229

## RESULT 4

US-09-764-853-608  
; Sequence 608, Application US/09764853  
; Patent No. US20020090672A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: PJZ06  
; CURRENT APPLICATION NUMBER: US/09/764,853  
; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - consult PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 939  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 608  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-853-608

Query Match 100.0%; Score 223; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-196;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVTKVATQKHQSPLNWTSSTHSGE 60  
DB 7 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVTKVATQKHQSPLNWTSSTHSGE 66  
QY 61 VTGSAEGWGPEEPLPYSRAFEGEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 67 VTGSAEGWGPEEPLPYSRAFEGEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126  
QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGAPSLLL 186  
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGHLR 223  
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGGLGHLR 229

## RESULT 5

US-09-764-898-269  
; Sequence 269, Application US/09764898  
; Patent No. US20020090673A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: PJZ01  
; CURRENT APPLICATION NUMBER: US/09/764,898  
; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - consult PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 311  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 269  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE

LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-898-269

Query Match 100.0%; Score 223; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-196;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVKVATQKHQPSPLNWTSSHFGE 60  
DB 7 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVKVATQKHQPSPLNWTSSHFGE 66

QY 61 VTGSAEGWGPEEPLPYSAFEGEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 67 VTGSAEGWGPEEPLPYSAFEGEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126

QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186

QY 181 LLPCALLHRLRPDAPAHPSLSVPSVLQRRRRCGRPGLGHRL 223  
DB 187 LLPCALLHRLRPDAPAHPSLSVPSVLQRRRRCGRPGLGHRL 229

RESULT 6  
US-09-764-881-101  
; Sequence 101, Application US/09764881  
; Publication No. US20030125246A9  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: PTZ07  
; CURRENT APPLICATION NUMBER: US/09/764,881  
; CURRENT FILING DATE: 2001-01-17  
; Prior application data removed - refer to PALM or file wrapper  
; NUMBER OF SEQ ID NOS: 192  
; SOFTWARE: Patentin Ver. 2.0  
; SEQ ID NO 101  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: SITE  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: SITE  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-09-764-881-101

Query Match 100.0%; Score 223; DB 3; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-196;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVKVATQKHQPSPLNWTSSHFGE 60  
DB 7 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVKVATQKHQPSPLNWTSSHFGE 66

QY 61 VTGSAEGWGPEEPLPYSAFEGEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 67 VTGSAEGWGPEEPLPYSAFEGEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126

QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186

QY 181 LLPCALLHRLRPDAPAHPSLSVPSVLQRRRRCGRPGLGHRL 223  
DB 187 LLPCALLHRLRPDAPAHPSLSVPSVLQRRRRCGRPGLGHRL 229

RESULT 7  
US-10-073-865-98  
; Sequence 98, Application US/10073865  
; Publication No. US20030044904A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: PJZ09C1  
; CURRENT APPLICATION NUMBER: US/10/073,865  
; CURRENT FILING DATE: 2002-02-14  
; Prior Application removed - See file Wrapper or Palm  
; NUMBER OF SEQ ID NOS: 154  
; SOFTWARE: Patentin Ver. 2.0  
; SEQ ID NO 98  
; LENGTH: 229  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (2)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
; NAME/KEY: misc feature  
; LOCATION: (3)  
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids  
US-10-073-865-98

Query Match 100.0%; Score 223; DB 4; Length 229;  
Best Local Similarity 100.0%; Pred. No. 1.5e-196;  
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVKVATQKHQPSPLNWTSSHFGE 60  
DB 7 MTRHHVRLFTVSLALQIINLGNYSQREKHNGRGVEVKVATQKHQPSPLNWTSSHFGE 66

QY 61 VTGSAEGWGPEEPLPYSAFEGEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120  
DB 67 VTGSAEGWGPEEPLPYSAFEGEGASAPRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126

QY 121 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 180  
DB 127 SECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPSAGAPSLLL 186

QY 181 LLPCALLHRLRPDAPAHPSLSVPSVLQRRRRCGRPGLGHRL 223  
DB 187 LLPCALLHRLRPDAPAHPSLSVPSVLQRRRRCGRPGLGHRL 229

RESULT 8  
US-10-242-747-101  
; Sequence 101, Application US/10242747  
; Publication No. US20040005577A1  
; GENERAL INFORMATION:  
; APPLICANT: Rosen et al.  
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies  
; FILE REFERENCE: PTZ07C1  
; CURRENT APPLICATION NUMBER: US/10/242,747  
; CURRENT FILING DATE: 2002-09-13  
; Prior Application Number: 09/764,881  
; Prior Filing Date: 2001-01-17  
; Prior Application Number: 60/179,065  
; Prior Filing Date: 2000-01-31  
; Prior Application Number: 60/180,628  
; Prior Filing Date: 2000-02-04  
; Prior Application Number: 60/214,886  
; Prior Filing Date: 2000-06-28  
; Prior Application Number: 60/217,487  
; Prior Filing Date: 2000-07-11  
; Prior Application Number: 60/225,758  
; Prior Filing Date: 2000-08-14  
; Prior Application Number: 60/220,963  
; Prior Filing Date: 2000-07-26

```
; PRIOR APPLICATION NUMBER: 60/217,496
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/225,447
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/218,290
; PRIOR FILING DATE: 2000-07-14
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 101
; LENGTH: 229
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-10-242-747-101

Query Match      100.0%; Score 223; DB 4; Length 229;
Best Local Similarity 100.0%; Pred. No. 1.5e-196;
Matches 223; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTRHHVRLFTVSLAQIINLGNVQREKHNGRGVEVTKVATQKIRQSPLNWTSSTHFG 60
DB 7 MTRHHVRLFTVSLAQIINLGNVQREKHNGRGVEVTKVATQKIRQSPLNWTSSTHFG 66
QY 61 VTGSAEGWGPEEPLPYSAFEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 120
DB 67 VTGSAEGWGPEEPLPYSAFEGASAPRCRCRNGGTCVLGSCFVCPAHFTGRYCEHDQRR 126
QY 121 SECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAGPSAGAPSL 180
DB 127 SECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAGPSAGAPSL 186
QY 181 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 223
DB 187 LLPCALLHRLRPDAPAHPRSLVPSVLQRRRRCGRPGLGHRL 229

RESULT 9
US-10-295-027-422
; Sequence 422, Application US/10295027
; Publication No. US2003023350A1
; GENERAL INFORMATION:
; APPLICANT: Afar, Daniel
; APPLICANT: Aziz, Natasha
; APPLICANT: Ginsberg, Wendy M.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Glynn, Richard
; APPLICANT: Hevezi, Peter A.
; APPLICANT: Murray, Richard
; APPLICANT: Watson, Susan R.
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and
; FILE REFERENCE: 018501-012500US
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US/10/295,027
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/335,394
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/332,464
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: US 60/334,393
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
```

```
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: US 60/347,211
; PRIOR FILING DATE: 2002-01-08
; PRIOR APPLICATION NUMBER: US 60/347,349
; PRIOR FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/355,250
; PRIOR FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/356,714
; PRIOR FILING DATE: 2002-02-13
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1386
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 422
; LENGTH: 223
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-295-027-422

Query Match      83.9%; Score 187; DB 4; Length 223;
Best Local Similarity 100.0%; Pred. No. 1.8e-163;
Matches 187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 EYTKVATQKROSPLNWTSSTHFGVTSAGWGPEEPLPYSAFEGASAPRCRCRNGGT 96
DB 37 EYTKVATQKROSPLNWTSSTHFGVTSAGWGPEEPLPYSAFEGASAPRCRCRNGGT 96
QY 97 CVLGSCFVCPAHFTGRYCEHDQRRSECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDR 156
DB 97 CVLGSCFVCPAHFTGRYCEHDQRRSECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDR 156
QY 157 CDPKDFLASHAGPSAGAPSLLLLPALLHRLRPDAPAHPRSLVPSVLQRRRRCGR 216
DB 157 CDPKDFLASHAGPSAGAPSLLLLPALLHRLRPDAPAHPRSLVPSVLQRRRRCGR 216
QY 217 PGLGHRL 223
DB 217 PGLGHRL 223

RESULT 10
US-10-295-027-1293
; Sequence 1293, Application US/10295027
; Publication No. US2003023350A1
; GENERAL INFORMATION:
; APPLICANT: Afar, Daniel
; APPLICANT: Aziz, Natasha
; APPLICANT: Ginsberg, Wendy M.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Glynn, Richard
; APPLICANT: Hevezi, Peter A.
; APPLICANT: Mack, David H.
; APPLICANT: Murray, Richard
; APPLICANT: Watson, Susan R.
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and
; FILE REFERENCE: 018501-012500US
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US/10/295,027
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US 09/663,733
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/335,394
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/332,464
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: US 60/334,393
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
```

```

; PRIOR APPLICATION NUMBER: US 60/347,211
; PRIOR FILING DATE: 2002-01-08
; PRIOR APPLICATION NUMBER: US 60/347,349
; PRIOR FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/355,250
; PRIOR FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/356,714
; PRIOR FILING DATE: 2002-02-13
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1386
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1293
; LENGTH: 223
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-295-027-1293

Query Match      83.9%; Score 187; DB 4; Length 223;
Best Local Similarity 100.0%; Pred. No. 1.8e-163;
Matches 187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 EVTKVATQKHRSQPLNWTSSHFGEVGTGSAEGWGPEEPLPYSRAFGEGASARPRCCRNNGT 96
DB 37 EVTKVATQKHRSQPLNWTSSHFGEVGTGSAEGWGPEEPLPYSRAFGEGASARPRCCRNNGT 96

QY 97 CVLGSCFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156
DB 97 CVLGSCFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156

QY 157 CDPKDFLASHAHGPSAGGAPSLLLLPALLHLLRPDPAHPRSLVPSVLQRRRPPCGR 216
DB 157 CDPKDFLASHAHGPSAGGAPSLLLLPALLHLLRPDPAHPRSLVPSVLQRRRPPCGR 216

QY 217 PGLGHRLL 223
DB 217 PGLGHRLL 223

US-10-264-237-2712
; Sequence 2712, Application US/10264237
; Publication No. US20040009491A1
; GENERAL INFORMATION:
; APPLICANT: Birse et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: P131P1
; CURRENT APPLICATION NUMBER: US/10/264,237
; PRIOR FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/16450
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/205,515
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 2876
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 2712
; LENGTH: 223
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-264-237-2712

Query Match      83.9%; Score 187; DB 4; Length 223;
Best Local Similarity 100.0%; Pred. No. 1.8e-163;
Matches 187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 EVTKVATQKHRSQPLNWTSSHFGEVGTGSAEGWGPEEPLPYSRAFGEGASARPRCCRNNGT 96
DB 37 EVTKVATQKHRSQPLNWTSSHFGEVGTGSAEGWGPEEPLPYSRAFGEGASARPRCCRNNGT 96

QY 97 CVLGSCFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156
DB 97 CVLGSCFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156

QY 157 CDPKDFLASHAHGPSAGGAPSLLLLPALLHLLRPDPAHPRSLVPSVLQRRRPPCGR 216
DB 157 CDPKDFLASHAHGPSAGGAPSLLLLPALLHLLRPDPAHPRSLVPSVLQRRRPPCGR 216

QY 217 PGLGHRLL 223
DB 217 PGLGHRLL 223

US-10-940-431-4
; Sequence 4, Application US/10940431
; Publication No. US20050208045A1
; GENERAL INFORMATION:
; APPLICANT: Vale, Wylie
; APPLICANT: Harrison, Craig A.
; APPLICANT: Gray, Peter C.
; TITLE OF INVENTION: Cripto Antagonism of Activin and TGF-
; FILE REFERENCE: D6525
; CURRENT APPLICATION NUMBER: US/10/940,431
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: 60/503,046
; PRIOR FILING DATE: 2003-09-15
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: Macintosh OS 10
; SEQ ID NO 4
; LENGTH: 223
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: amino acid sequence of human Criptic protein
US-10-940-431-4

Query Match      83.9%; Score 187; DB 5; Length 223;
Best Local Similarity 100.0%; Pred. No. 1.8e-163;
Matches 187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 EVTKVATQKHRSQPLNWTSSHFGEVGTGSAEGWGPEEPLPYSRAFGEGASARPRCCRNNGT 96
DB 37 EVTKVATQKHRSQPLNWTSSHFGEVGTGSAEGWGPEEPLPYSRAFGEGASARPRCCRNNGT 96

QY 97 CVLGSCFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156
DB 97 CVLGSCFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156

QY 157 CDPKDFLASHAHGPSAGGAPSLLLLPALLHLLRPDPAHPRSLVPSVLQRRRPPCGR 216
DB 157 CDPKDFLASHAHGPSAGGAPSLLLLPALLHLLRPDPAHPRSLVPSVLQRRRPPCGR 216

QY 217 PGLGHRLL 223
DB 217 PGLGHRLL 223

US-09-764-898-1398
; Sequence 198, Application US/09764898
; Patent No. US20020090673A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PJ201
; CURRENT APPLICATION NUMBER: US/09/764,898
; CURRENT FILING DATE: 2001-01-17
; Prior application data removed - consult PALM or file wrapper
; NUMBER OF SEQ ID NOS: 311
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 198
; LENGTH: 231
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: SITE

```

```
; LOCATION: (44)
; OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-898-198

Query Match      83.9%; Score 187; DB 3; Length 231;
Best Local Similarity 100.0%; Pred. No. 1.9e-163; Indels 0; Gaps 0;
Matches 187; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 EVTKVATQKHRQSLNWTSSHFGEVTSAGWGMPPEPLPYSRAFGEGASARPRCCRNNGT 96
Db 45 EVTKVATQKHRQSLNWTSSHFGEVTSAGWGMPPEPLPYSRAFGEGASARPRCCRNNGT 104

QY 97 CVLGSCFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 156
Db 105 CVLGSCFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDR 164

QY 157 CDPKDFLASHAHGPSAGGAPSLLLLLPCALLHRLLRDPAPAHPRSLVPSVLQRRERPCGR 216
Db 165 CDPKDFLASHAHGPSAGGAPSLLLLLPCALLHRLLRDPAPAHPRSLVPSVLQRRERPCGR 224

QY 217 PGLGHRL 223
Db 225 PGLGHRL 231

RESULT 14
US-10-257-113-2
; Sequence 2, Application US/10257113
; Publication No. US20030207293A1
; GENERAL INFORMATION:
; APPLICANT: DUCKER, KLAUS
; TITLE OF INVENTION: CRYPTIC-LIKE SECRETED PROTEIN
; FILE REFERENCE: MERCK-2519
; CURRENT APPLICATION NUMBER: US/10/257,113
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: EP 00107142.2
; PRIOR FILING DATE: 2000-04-10
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 223
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-257-113-2

Query Match      65.0%; Score 145; DB 4; Length 223;
Best Local Similarity 100.0%; Pred. No. 7.7e-125; Indels 0; Gaps 0;
Matches 145; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 79 AFEGASARPRCCRNNGTCVLGSFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHL 138
Db 79 AFEGASARPRCCRNNGTCVLGSFCVCPAHTGTRYCEHDQRRSECGALEHGAWTLRACHL 138

QY 139 CRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLLLLPCALLHRLLRDPAPAH 198
Db 139 CRCIFGALHCLPLQTPDRCDPKDFLASHAHGPSAGGAPSLLLLLPCALLHRLLRDPAPAH 198

QY 199 PRSLVPSVLQRRERPCGRPGLGHRL 223
Db 199 PRSLVPSVLQRRERPCGRPGLGHRL 223

Search completed: September 7, 2006, 12:39:18
Job time : 175 secs
```



QY 61 VTGSAEGWGPEEPLPYSRAGGASARPRCCRRNGGTCVLGSCVCPAHFTGRYCEHDQRR 120  
Db 61 VTGSAEGWGPEEPLPYSRAGGASARPRCCRRNGGTCVLGSCVCPAHFTGRYCEHDQRR 120  
QY 121 SEGGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGGAPSLLL 180  
Db 121 SEGGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCDPKDFLASHAHGSPAGGAPSLLL 180  
QY 181 LLPCALLHRLLRDAPA-----HPRSIVP 204  
Db 181 LLPCA-----TPAPASCARMRPTLGP 202  
RESULT 2  
US-08-441-629-7  
; Sequence 7, Application US/08441629  
; Patent No. 5766923  
; GENERAL INFORMATION:  
; APPLICANT: Kirschner, Marc W.  
; APPLICANT: Kinoshita, No. 5766923iyuki  
; TITLE OF INVENTION: RECEPTOR-LIGAND ASSAY  
; NUMBER OF SEQUENCES: 17  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.  
; STREET: Two Militia Drive  
; CITY: Lexington  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02173  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/441,629  
; FILING DATE: 15-MAY-1995  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/279,217  
; FILING DATE: 22-JUL-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Granahan, Patricia  
; REGISTRATION NUMBER: 32,227  
; REFERENCE/DOCKET NUMBER: HU95-01A  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 861-6240  
; TELEFAX: (617) 861-9540  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 160 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; US-08-441-629-7

Query Match 21.1%; Score 264; DB 1; Length 160;  
Best Local Similarity 43.5%; Pred. No. 1.7e-19;  
Matches 50; Conservative 7; Mismatches 44; Indels 14; Gaps 2;  
QY 58 FGEVGTG-----SAEGWGPEEPLPYSRAF-----GEGASARPRCCRRNGGTCVLGSGFC 103  
Db 20 FGPVAGRDLAIRDNSIWDQKEPAVRDRSFQFVPSVGIQNSKSLNKTCCLLNGGTCILGSGFC 79  
QY 104 VCPAHFTGRYCEHDQRRSECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCD 158  
Db 80 ACPPSPFYGRNCEHDVHKEHCGSILHGTWLPKKCSLCRCWHGQJHCLPQTFLPGCD 134

RESULT 3  
US-08-776-207-7  
; Sequence 7, Application US/08776207A

; Patent No. 6080718  
; GENERAL INFORMATION:  
; APPLICANT: Kirschner, Marc W.  
; APPLICANT: Kinoshita, No. 6080718iyuki  
; TITLE OF INVENTION: Receptor-Ligand Assay  
; FILE REFERENCE: HU95-01A2  
; CURRENT APPLICATION NUMBER: US/08/776,207A  
; CURRENT FILING DATE: 1997-06-23  
; EARLIER APPLICATION NUMBER: PCT/US95/09172  
; EARLIER FILING DATE: 1995-07-19  
; EARLIER APPLICATION NUMBER: 08/441,629  
; EARLIER FILING DATE: 1995-05-15  
; EARLIER APPLICATION NUMBER: 08/279,217  
; EARLIER FILING DATE: 1994-07-22  
; NUMBER OF SEQ ID NOS: 18  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 7  
; LENGTH: 160  
; TYPE: PRT  
; ORGANISM: Mus musculus  
; US-08-776-207-7  
Query Match 21.1%; Score 264; DB 2; Length 160;  
Best Local Similarity 43.5%; Pred. No. 1.7e-19;  
Matches 50; Conservative 7; Mismatches 44; Indels 14; Gaps 2;  
QY 58 FGEVGTG-----SAEGWGPEEPLPYSRAF-----GEGASARPRCCRRNGGTCVLGSGFC 103  
Db 20 FGPVAGRDLAIRDNSIWDQKEPAVRDRSFQFVPSVGIQNSKSLNKTCCLLNGGTCILGSGFC 79  
QY 104 VCPAHFTGRYCEHDQRRSECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCD 158  
Db 80 ACPPSPFYGRNCEHDVHKEHCGSILHGTWLPKKCSLCRCWHGQJHCLPQTFLPGCD 134

RESULT 4  
US-09-507-773-7  
; Sequence 7, Application US/09507773  
; Patent No. 6399386  
; GENERAL INFORMATION:  
; APPLICANT: Kirschner, Marc W.  
; APPLICANT: Kinoshita, No. 6399386iyuki  
; TITLE OF INVENTION: Receptor-Ligand Assay  
; FILE REFERENCE: HU95-01A2  
; CURRENT APPLICATION NUMBER: US/09/507,773  
; CURRENT FILING DATE: 2000-02-18  
; PRIOR APPLICATION NUMBER: 08/776,207  
; PRIOR FILING DATE: 1997-06-23  
; PRIOR APPLICATION NUMBER: 08/441,629  
; PRIOR FILING DATE: 1995-05-15  
; PRIOR APPLICATION NUMBER: 08/279,217  
; PRIOR FILING DATE: 1994-07-22  
; NUMBER OF SEQ ID NOS: 18  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 7  
; LENGTH: 160  
; TYPE: PRT  
; ORGANISM: Mus musculus  
; US-09-507-773-7

Query Match 21.1%; Score 264; DB 2; Length 160;  
Best Local Similarity 43.5%; Pred. No. 1.7e-19;  
Matches 50; Conservative 7; Mismatches 44; Indels 14; Gaps 2;  
QY 58 FGEVGTG-----SAEGWGPEEPLPYSRAF-----GEGASARPRCCRRNGGTCVLGSGFC 103  
Db 20 FGPVAGRDLAIRDNSIWDQKEPAVRDRSFQFVPSVGIQNSKSLNKTCCLLNGGTCILGSGFC 79  
QY 104 VCPAHFTGRYCEHDQRRSECGALEHGAWTIRACHLCRCIFGALHCLPLQTPDRCD 158  
Db 80 ACPPSPFYGRNCEHDVHKEHCGSILHGTWLPKKCSLCRCWHGQJHCLPQTFLPGCD 134

```
RESULT 5
US-10-016-447-7
; Sequence 7, Application US/10016447
; Patent No. 6844193
; GENERAL INFORMATION:
; APPLICANT: Kirschner, Marc W.
; APPLICANT: Kinoshita, No. 6844193iyuki
; TITLE OF INVENTION: Receptor-Ligand Assay
; FILE REFERENCE: HU95-01A2
; CURRENT APPLICATION NUMBER: US/10/016,447
; CURRENT FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/08/776,207
; PRIOR FILING DATE: EARLIER FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 08/441,629
; PRIOR FILING DATE: EARLIER FILING DATE: 1995-05-15
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 08/279,217
; PRIOR FILING DATE: EARLIER FILING DATE: 1994-07-22
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-016-447-7

Query Match      21.1%; Score 264; DB 2; Length 160;
Best Local Similarity 43.5%; Pred. No. 1.7e-19;
Matches 50; Conservative 7; Mismatches 44; Indels 14; Gaps 2;

QY 58 FGEVTG-----SAEGWGPEEPLPYGRAF-----GEGASARPCRCRNGGTCVLGSGFC 103
Db 20 FGPVAGRDIAIRDNSIWQKEPAVRDRSFQFVPSVGIQNSKSLNKTCCLLGGTICILGSGFC 79

QY 104 VCPAHTGTRYCEHDDRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCD 158
Db 80 ACPPSFYGRNCEHDVRKEHCGSILHGTWLPKKSCLRCWHGQLHCLPQTPLPGCD 134

RESULT 6
PCT-US95-09172-7
; Sequence 7, Application PC/TUS9509172
; GENERAL INFORMATION:
; APPLICANT: Kirschner, Marc W.
; APPLICANT: Kinoshita, Noriyuki
; TITLE OF INVENTION: RECEPTOR-LIGAND ASSAY
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 15-MAY-1995
; APPLICATION NUMBER: PCT/US95/09172
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/279,217
; FILING DATE: 22-JUL-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/441,629
; FILING DATE: 15-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: HU95-01A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-9540
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 190 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-441-629-4

Query Match      19.9%; Score 248.5; DB 1; Length 190;
Best Local Similarity 52.9%; Pred. No. 8.4e-18;
Matches 37; Conservative 13; Mismatches 19; Indels 1; Gaps 1;

QY 89 RCRNGGTCVLGSGFCVCPAHTGTRYCEHDDRRSECGALEHGAWTLRACHLCRCIFGALHCL 148
```

```
TELEPHONE: (617) 861-6240
TELEFAX: (617) 861-9540
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 160 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
PCT-US95-09172-7

Query Match      21.1%; Score 264; DB 5; Length 160;
Best Local Similarity 43.5%; Pred. No. 1.7e-19;
Matches 50; Conservative 7; Mismatches 44; Indels 14; Gaps 2;

QY 58 FGEVTG-----SAEGWGPEEPLPYGRAF-----GEGASARPCRCRNGGTCVLGSGFC 103
Db 20 FGPVAGRDIAIRDNSIWQKEPAVRDRSFQFVPSVGIQNSKSLNKTCCLLGGTICILGSGFC 79

QY 104 VCPAHTGTRYCEHDDRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCD 158
Db 80 ACPPSFYGRNCEHDVRKEHCGSILHGTWLPKKSCLRCWHGQLHCLPQTPLPGCD 134

RESULT 7
US-08-441-629-4
; Sequence 4, Application US/08441629
; Patent No. 5766923
; GENERAL INFORMATION:
; APPLICANT: Kirschner, Marc W.
; APPLICANT: Kinoshita, No. 5766923iyuki
; TITLE OF INVENTION: RECEPTOR-LIGAND ASSAY
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 15-MAY-1995
; APPLICATION NUMBER: US/08/441,629
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/279,217
; FILING DATE: 22-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: HU95-01A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-9540
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 190 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-441-629-4

Query Match      19.9%; Score 248.5; DB 1; Length 190;
Best Local Similarity 52.9%; Pred. No. 8.4e-18;
Matches 37; Conservative 13; Mismatches 19; Indels 1; Gaps 1;

QY 89 RCRNGGTCVLGSGFCVCPAHTGTRYCEHDDRRSECGALEHGAWTLRACHLCRCIFGALHCL 148
```

Accession	Protein	Length	Score	E-value	Ident	Positives	Negatives
82	KCCQNGGTFLGTCFCIPKQFTGRHCEHRRPASGVPHGDMTRQGCLLCRCVSGVLHC	141	10.0	1.0e-05	100	100	0
149	LPLQTFDRCD	158	10.0	1.0e-05	100	100	0
142	FKPESED-CD	150	10.0	1.0e-05	100	100	0

```

RESULT 8
US-08-776-207-4
; Sequence 4, Application US/08776207A
; Patent No. 6080718
; GENERAL INFORMATION:
; APPLICANT: Kirschner, Marc W.
; APPLICANT: Kinoshita, No. 6080718iyuki
; TITLE OF INVENTION: Receptor-Ligand Assay
; FILE REFERENCE: HU95-01A2
; CURRENT APPLICATION NUMBER: US/08/776,207A
; CURRENT FILING DATE: 1997-06-23
; EARLIER APPLICATION NUMBER: PCT/US95/09172
; EARLIER FILING DATE: 1995-07-19
; EARLIER APPLICATION NUMBER: 08/441,629
; EARLIER FILING DATE: 1995-05-15
; EARLIER APPLICATION NUMBER: 08/279,217
; EARLIER FILING DATE: 1994-07-22
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 190
; TYPE: PRT
; ORGANISM: Xenopus laevis
US-08-776-207-4

```

	Query Match	19.9%; Score 248.5; DB 2;	Length 190;
	Best Local Similarity	52.9%; Pred.No.	8.4e-18;
Matches	37; Conservative	13; Mismatches	19; Indels
	Gaps	1; Gaps	1;
Qy	89 RCRNGGTCVLGGFCVCPAHFTGRYCEHDDRRSECGALEHGAWTLRACHLCRCIFGALHC	148	
Dd	82 KCCQNGETCFLGTGCICPKQTGRCHCBERRPASCSCGVPHGDWTROGCCLLCRCVSGLVC	141	
Qy	149 LPLQTPDRCD	158	
Dd	142 FKPESED-CD	150	

```

RESULT 9
US-09-507-773-4
; Sequence 4, Application US/09507773
; Patent No. 639386
; GENERAL INFORMATION:
; APPLICANT: Kirschner, Marc W.
; APPLICANT: Kinoshita, No. 639386iyuki
; TITLE OF INVENTION: Receptor-Ligand Assay
; FILE REFERENCE: HU95-01A2
; CURRENT APPLICATION NUMBER: US/09/507,773
; CURRENT FILING DATE: 2000-02-18
; PRIOR APPLICATION NUMBER: 08/776,207
; PRIOR FILING DATE: 1997-06-23
; PRIOR APPLICATION NUMBER: 08/441,629
; PRIOR FILING DATE: 1995-05-15
; PRIOR APPLICATION NUMBER: 08/279,217
; PRIOR FILING DATE: 1994-07-22
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 190
; TYPE: PRT
; ORGANISM: Xenopus laevis
; US-09-507-773-4

```

Query Match 19.9%; Score 248.5; DB 2; Length 190;  
Best Local Similarity 52.9%; Pred. No. 8.4e-18;

	Matches	37;	Conservative	13;	Mismatches	19;	Indels	1;	Gaps	1;
Qy	89	RCCRN	GGTCVLSGFCVC	PAHFTGRYCEH	DORSECGALEHGAWTLRACHLCRCIFGALHC	148				
		:: :	:: :	:: :	:: :	:: :	:	:	:: :	:: :
Db	82	KCCQN	GGTFLGTFCICPKQF	TGRCH	EEHRFPASCVGVPHGDWIRGGCLLRCVSGVLHC	141				
		:: :	:: :	:: :	:: :	:: :	:	:	:: :	:: :
Qy	149	LPLQT	PDRCD	158						
		:	:	:						
Db	142	FKPESD-CD	150							

```

RESULT 10
US-10-016-447-4
; Sequence 4, Application US/10016447
; Patent No. 6844193
; GENERAL INFORMATION:
; APPLICANT: Kirschner, Marc W
; APPLICANT: Kinoshita, No. 6844193iyuki
; TITLE OF INVENTION: Receptor-Ligand Assay
; FILE REFERENCE: HU95-01A2
; CURRENT APPLICATION NUMBER: US/10/016,447
; CURRENT FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION
; PRIOR FILING DATE: EARLIER FILING DATE: 1
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION
; PRIOR FILING DATE: EARLIER FILING DATE: 1
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION
; PRIOR FILING DATE: EARLIER FILING DATE: 1
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 190
; TYPE: PRT
; ORGANISM: Xenopus laevis
; US-10-016-447-4
US-10-016-447-4

```

	Query Match	19.9%;	Score 248.5;	DB 2;	Length 190;
	Best Local Similarity	52.9%;	Pred. No. 8.4e-18;		
Matches	37; Conservative	13; Mismatches	19; Indels	1; Gaps	1;
Qy	89	RCCNRGGTCVLGSGFCVCPAHFTGRYCEHDPORSECGALEHGAWTLRACHLCRCIFGALHC	148		
	:	: ::   :: :	:: :: :: :	:	:: :: :
Dd	82	KCQNGGTCFLGTFCLFCFQKQFTGRCHHERRRPASCSGVPHGDWIRGCCLLCRCVSGVLHC	141		
	:	: ::   :: :	:: :: :: :	:	:: :: :
Qy	149	LPLQTDRCD	158		
	:	: ::			
Dd	142	FKPESRD-CD	150		

```

RESULT 11
PCT-US95-09172-4
; Sequence 4, Application PC/TUS9509172
; GENERAL INFORMATION:
; APPLICANT: Kirschner, Marc W.
; APPLICANT: Kinoshita, Noriyuki
; TITLE OF INVENTION: RECEPTOR-LIGAND ASSAY
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/09172
; FILING DATE:
; CLASSIFICATION:

```

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/279,217  
;; FILING DATE: 22-JUL-1994  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/441,629  
;; FILING DATE: 15-MAY-1995  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Granahan, Patricia  
;; REGISTRATION NUMBER: 32,227  
;; REFERENCE/DOCKET NUMBER: HU95-01A PCT  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (617) 861-6240  
;; TELEFAX: (617) 861-9540  
;; INFORMATION FOR SEQ ID NO: 4:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 190 amino acids  
;; TYPE: amino acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: peptide  
PCT-US95-09172-4  
  
Query Match 19.9%; Score 248.5; DB 5; Length 190;  
Best Local Similarity 52.9%; Pred. No. 8.4e-18;  
Matches 37; Conservative 13; Mismatches 19; Indels 1; Gaps 1;  
  
Qy 89 RCRNGTGVLSGFCVCPAHTGRCYCHDORRSECGALEHGWTLRACHLCRCIFGALHC 148  
Db 82 KCCQNGTCTGLFTGFCPCPKQFTGRHCEHRRPASCVGPHGDWIRGCLLCRCVGLHC 141  
  
Qy 149 LPLQTPDRCD 158  
Db 142 FKPESED-CD 150  
  
RESULT 12  
5256643-3  
;; Patent No. 5256643  
;; APPLICANT: Persico, Maria G.; Salomon, David S.  
;; TITLE OF INVENTION: HUMAN CRYPTO PROTEIN  
;; NUMBER OF SEQUENCES: 18  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/07/530,165  
;; FILING DATE: 29-MAY-1990  
;; SEQ ID NO: 3:  
;; LENGTH: 174  
5256643-3  
  
Query Match 18.7%; Score 233; DB 7; Length 174;  
Best Local Similarity 39.1%; Pred. No. 3.1e-16;  
Matches 43; Conservative 7; Mismatches 30; Indels 30; Gaps 2;  
  
Qy 68 WGPEEPLPYSRAGFEGASARPR-----CCRNGTGVLSGFCVCPAH 108  
Db 38 WPQEEP-----AIRPRSSQVRPPMGIQHSKELNRTCCCLNGTCLMGSCFACPPS 86  
  
Qy 109 FTGRYCEHDDORRSECGALEHGWTLRACHLCRCIFGALHCLPLQTPDRCD 158  
Db 87 FYGRNCEHVDKRCNCGSVPHDTWLPKKCSLCKCWHGQLRCFPOAFLPGCD 136  
  
RESULT 13  
US-07-749-001-3  
;; Sequence 3, Application US/07749001  
;; Patent No. 5264557  
;; GENERAL INFORMATION:  
;; APPLICANT: Salomon, David S.  
;; APPLICANT: Persico, Maria G.  
;; TITLE OF INVENTION: A HUMAN CRYPTO-RELATED GENE  
;; NUMBER OF SEQUENCES: 4  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: CUSHMAN, DARBY & CUSHMAN  
;; STREET: 1615 L Street, N.W.

;; CITY: Washington  
;; STATE: D.C.  
;; COUNTRY: USA  
;; ZIP: 20036  
;; COMPUTER READABLE FORM: disk  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patent In Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/07/749,001  
;; FILING DATE: 19910823  
;; CLASSIFICATION: 435  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Scott, Watson T.  
;; REGISTRATION NUMBER: 26,581  
;; REFERENCE/DOCKET NUMBER: WTS/5683/91630/SRL  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (202) 861-3000  
;; TELEFAX: (202) 822-0944  
;; TELEX: 248453 CUSH  
;; INFORMATION FOR SEQ ID NO: 3:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 188 amino acids  
;; TYPE: AMINO ACID  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: protein  
US-07-749-001-3  
  
Query Match 18.7%; Score 233; DB 1; Length 188;  
Best Local Similarity 39.1%; Pred. No. 3.4e-16;  
Matches 43; Conservative 7; Mismatches 30; Indels 30; Gaps 2;  
  
Qy 68 WGPEEPLPYSRAGFEGASARPR-----CCRNGTGVLSGFCVCPAH 108  
Db 52 WPQEEP-----AIRPRSSQVRPPMGIQHSKELNRTCCCLNGTCLMGSCFACPPS 100  
  
Qy 109 FTGRYCEHDDORRSECGALEHGWTLRACHLCRCIFGALHCLPLQTPDRCD 158  
Db 101 FYGRNCEHVDKRCNCGSVPHDTWLPKKCSLCKCWHGQLRCFPOAFLPGCD 150  
  
RESULT 14  
US-08-154-198-3  
;; Sequence 3, Application US/08154198  
;; Patent No. 5620866  
;; GENERAL INFORMATION:  
;; APPLICANT: SALOMON, David S.  
;; APPLICANT: PERSICO, Maria G.  
;; TITLE OF INVENTION: A HUMAN CRYPTO-RELATED GENE  
;; NUMBER OF SEQUENCES: 5  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Townsend and Townsend Kourie and Crew  
;; STREET: Steuart Street Tower, One Market Plaza  
;; CITY: San Francisco  
;; STATE: California  
;; COUNTRY: US  
;; ZIP: 94105-1493  
;; COMPUTER READABLE FORM: disk  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patent In Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/154,198  
;; FILING DATE: 17-NOV-1993  
;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/749,001  
;; FILING DATE: 23-AUG-1991  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Bastian, Kevin L.  
;; REGISTRATION NUMBER: 34,774

REFERENCE/DOCKET NUMBER: 15280-63-1  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (415) 543-9600  
TELEFAX: (415) 543-5043  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 188 amino acids  
TYPE: amino acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: protein  
US-08-154-198-3

Query Match 18.7%; Score 233; DB 1; Length 188;  
Best Local Similarity 39.1%; Pred. No. 3.4e-16;  
Matches 43; Conservative 7; Mismatches 30; Indels 30; Gaps 2;  
QY 68 WGPEEPLPYSRAFEGEGASARPR-----CCRNGGTCVLGSGFCVCPAH 108  
DB 52 WPOEEP-----AIRPRSSQVRPPMGIOHSHKELNRTCCCLNGGTCMLGSGFCACPPS 100  
QY 109 FTGRYCEHDDRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCD 158  
DB 101 FYGRNCEHDVRKENCOSVPHDTWLPKKCSLCKCMHGLRCFFQAFPLPGCD 150

RESULT 15  
US-08-463-335-3  
Sequence 3, Application US/08463335  
Patent No. 5650285  
GENERAL INFORMATION:  
APPLICANT: Salomon, David S.  
APPLICANT: Persico, Maria G.  
TITLE OF INVENTION: A HUMAN CRYPTO-RELATED GENE  
NUMBER OF SEQUENCES: 5  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: CUSHMAN, DABBY & CUSHMAN  
STREET: 1615 L Street, N.W.  
CITY: Washington  
STATE: D.C.  
COUNTRY: USA  
ZIP: 20036

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
FILING DATE: 05-JUN-1995  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/749,001  
FILING DATE: 23-AUG-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Scott, Watson T.  
REGISTRATION NUMBER: 26,581  
REFERENCE/DOCKET NUMBER: WTS/5683/91630/SRL  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 861-3000  
TELEFAX: (202) 822-0944  
TELEX: 248453 CUSH  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 188 amino acids  
TYPE: amino acid  
TOPOLOGY: linear  
MOLECULE TYPE: protein  
US-08-463-335-3

Query Match 18.7%; Score 233; DB 1; Length 188;  
Best Local Similarity 39.1%; Pred. No. 3.4e-16;  
Matches 43; Conservative 7; Mismatches 30; Indels 30; Gaps 2;

QY 68 WGPEEPLPYSRAFEGEGASARPR-----CCRNGGTCVLGSGFCVCPAH 108  
DB 52 WPOEEP-----AIRPRSSQVRPPMGIOHSHKELNRTCCCLNGGTCMLGSGFCACPPS 100  
QY 109 FTGRYCEHDDRRSECGALEHGAWTLRACHLCRCIFGALHCLPLQTPDRCD 158  
DB 101 FYGRNCEHDVRKENCOSVPHDTWLPKKCSLCKCMHGLRCFFQAFPLPGCD 150  
Search completed: September 7, 2006, 12:00:45  
Job time : 50 secs